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Abstract 
 
 
 
QUANTITATIVE ANALYSIS OF TOBACCO SPECIFIC NITROSAMINE IN 
HUMAN URINE USING MOLECULARLY IMPRINTED POLYMERS AS A 
POTENTIAL TOOL FOR CANCER RISK ASSESSMENT 
By Kumar A. Shah, M.Tech. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009. 
 
Major Director:  H. Thomas Karnes, Ph.D. 
Professor, Department of Pharmaceutics 
 
 
 
 
Measuring urinary tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL) and its glucuronide conjugate may provide the best 
biomarker of tobacco smoke lung carcinogen metabolism. Existence of differences in the 
extent of NNAL metabolism rates may be potentially related to an individuals’ lung 
cancer susceptibility. Low concentrations of NNAL in smokers urine (<1 ng/mL) require 
sensitive and selective methods for analysis. Traditionally, this involves extensive, time-
consuming sample preparation that limits throughput and adds to measurement 
variability. Molecularly imprinted polymers (MIPs) have been developed for the analysis 
of urinary NNAL by offline cartridge extraction combined with LC-MS/MS. This 
   
 xxiv 
method when reproduced demonstrated problems with matrix effects. In the first part of 
this work, investigation of matrix effects and related problems with sensitivity for the 
published offline extraction method has been conducted. In order to address the need to 
improve throughput and other analytical figures of merit for the original method, the 
second part of this work deals with development of a high-throughput online microfluidic 
method using capillary-columns packed with MIP beads for the analysis of urinary 
NNAL. The method was validated as per the FDA guidance, and enabled low volume, 
rapid analysis of urinary NNAL by direct injection on a microfluidic column packed with 
NNAL specific MIP beads. The method was used for analysis of urinary NNAL and 
NNAL-Gluc in smokers. Chemometric methods were used with this data to develop a 
potential cancer-risk-assessment tool based on pattern recognition in the concentrations 
of these compounds in urine. In the last part, method comparison approaches for the 
online and the offline sample extraction techniques were investigated. A ‘fixed’ range 
acceptance criterion based on combined considerations of method precision and 
accuracy, and the FDA bioanalytical guidance limits on precision and accuracy was 
proposed. Data simulations studies to evaluate the probabilities of successful transfers 
using the proposed criteria were performed. Various experimental designs were evaluated 
and a design comprised of 3 runs with 3 replicates each with an acceptance range of 
±20% was found appropriate. The off-line and the on-line sample extraction methods for 
NNAL analysis were found comparable using the proposed fixed range acceptance 
criteria. 
 
 1 
 
 
 
 
CHAPTER 1 Quantitative Bioanalysis of Tobacco Specific Nitrosamines 
Drawn from manuscript accepted for publication in Crit. Rev. Toxicol. 
 
 
1.1. Introduction – Why Study Tobacco Specific Nitrosamines? 
Cancer Facts and Figures published by the American Cancer Society, 2009 
estimated that between the years 2000 to 2004, smoking accounted for loss of more than 5 
million years of potential life in men and women combined. Different types of cancers 
such as cancers of the nasopharynx, nasal cavity and paranasal sinuses, lip, oral cavity, 
pharynx, larynx, lung, esophagus, pancreas, uterine cervix, kidney, bladder, stomach, along 
with acute myeloid leukemia have all been associated with smoking (US Department of 
Health and Human Services, 2004). Use of smokeless tobacco can also lead to a variety of 
health ill-effects such as pre-cancerous oral lesions, pancreatic and oral cancer as well as 
cardiovascular diseases (Hecht et al., 1986; International Agency for Research on Cancer, 
1985; International Agency for Research on Cancer, 2007). Tobacco products contain 
nicotine which is addictive and toxic, but it is not carcinogenic. This addiction, however, 
causes people to continually use tobacco products and these products contain many 
carcinogenic compounds. Thus, carcinogens form the devastating link between nicotine 
addiction and cancer. A scheme linking nicotine addiction to cancer via carcinogens is 
shown in Figure 1.  
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Figure 1: Scheme linking nicotine addiction to cancer via carcinogens (Adopted from Hecht, 1999).
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Tobacco smoke contains almost 5000 different chemical compounds (Rodgman 
and Perfetti, 2009). Of these, there are more than 16 carcinogens in smokeless tobacco and 
more than 60 in tobacco smoke (Hecht, 2003). These carcinogenic compounds belong to a 
variety of chemical classes including polycyclic aromatic hydrocarbons (PAHs), 
nitrosamines, aromatic amines, aldehydes, phenols, volatile hydrocarbons, nitro 
compounds and other organic and inorganic compounds (Hecht, 1998a; Hoffmann et al., 
1987; Hoffmann et al., 1995; Hoffmann et al., 2001; International Agency for Research on 
Cancer, 2002; Swauger et al., 2002). Tobacco and tobacco smoke contain three types of N-
nitrosamines. These include volatile nitrosamines, nitrosamines derived from residues of 
agricultural chemicals on tobacco and tobacco specific nitrosamines (TSNA) 
(Spiegelhalder and Bartsch, 1996). TSNAs have emerged as a leading class of carcinogens 
in tobacco products (Hecht and Hoffmann, 1988; International Agency for Research on 
Cancer, 2007). Extensive research has indicated the role of TSNAs in cancer induction by 
tobacco products (Hecht, 1998b; Hecht, 1999). Thus far, seven TSNAs have been 
identified in cigarettes (Djordjevic et al., 1991; Fischer et al., 1989; Hoffmann et al., 1994; 
Tricker et al., 1991; Tricker et al., 1993) as well as in smokeless tobacco products in even 
greater concentrations (Hoffmann et al., 1994; Hoffmann et al., 1995; International Agency 
for Research on Cancer, 1995; Prokopczyk et al., 1995). These include NNK, NNN, NAB, 
NAT, NNAL, iso-NNAL and iso-NNAC.  
The study of TSNA uptake will provide very useful insight into the mechanistic 
and epidemiologic role of these compounds in human cancer, especially since their origin 
is specific to tobacco (Hecht, 2003). A major challenge in this area is the ability to 
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quantitatively measure the amounts of these compounds and their metabolites in complex 
biological matrices, as a measure of exposure to these tobacco specific carcinogens.  
 
1.2. Metabolism of Tobacco Specific Nitrosamines 
Of all the TSNAs identified, NNK and NNN are the most prevalent strong 
carcinogens in tobacco products as documented by Hecht and Hoffmann, 1988, 
Spiegelhalder and Bartsch, 1996 and Hoffmann et al., 1995. Moreover, the International 
Agency for Research on Cancer, 2007 classifies NNK and NNN as the only TSNAs 
carcinogenic to humans. Thus, the discussion on the metabolism of TSNAs will be mainly 
focused on these two compounds. 
 The main routes of NNK and NNN metabolism are shown in Figure 2. NNK is 
rapidly metabolized in animals and humans via three main routes: carbonyl reduction, 
pyridine oxidation and α-hydroxylation (Hecht, 1998b). In humans, carbonyl reduction of 
NNK forms NNAL which is also a potent lung carcinogen having similar carcinogenicity 
and metabolic pathway as NNK. A major mode of metabolism of NNAL in vivo is UGT 
catalyzed glucuronidation, which is the most important detoxification pathway for 
NNK/NNAL metabolism (Chen et al., 2008b). The pyridine-N-oxidation pathway results 
in the formation of NNK-N-oxide and NNAL-N-oxide. Metabolic activation of NNK and 
NNAL to DNA adducts proceeds via α-hydroxylation pathways. The end products of this 
pathway are keto acid and hydroxy acid. NNN metabolism is similar to NNK metabolism 
(Hecht, 1998b) and is depicted in Figure 2. 
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Figure 2: Metabolism of NNK and NNN (Adopted from Carmella et al., 1997) 
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1.3. Biomarkers for Human Uptake and Metabolic Activation of TSNAs 
Many types of TSNA related biomarkers have been discussed in the literature. An 
ideal biomarker would be able to provide a measure of the carcinogen dose in people who 
use tobacco products as well as in nonsmokers exposed to secondhand smoke. Apart from 
this, it should potentially identify differences and patterns in the uptake, metabolic 
activation, and detoxification of tobacco carcinogens. These data might ultimately lead to 
the prediction of the cancer risk that a tobacco user might be susceptible to. The two main 
types of TSNA biomarkers are TSNA-DNA/protein adducts found in lungs and urinary 
compounds (Hecht, 1998b). A description of the advantages and limitations in the 
measurement of these biomarkers is discussed below. 
 
1.3.1. TSNA-DNA and Protein Adducts 
Adducts of carcinogenic compounds with DNA might provide the most direct 
relationship to cancer risk as suggested by Phillips, 1996, Bartsch, 1996 and Poirier and 
Weston, 1996. Foiles et al., 1991 have successfully analyzed TSNA-DNA adducts in 
smokers and non-smokers. However, challenges such as the limited availability of sample 
tissues as well as low levels of their occurrence (example: 1 per 106 to 108 normal human 
bases, De Bont and van Larebeke, 2004) can often make their quantification extremely 
difficult and at times impractical. Measuring protein-adducts of TSNAs has also been 
proposed as an approach to understanding metabolic activation of these carcinogens. 
However, results from the studies by Schaffler et al., 1993 and Falter et al., 1994 have 
revealed the absence of any group-specific differences in the concentrations of 
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hemoglobin-TSNA adducts determined in smokers and non-smokers. Moreover, highly 
sensitive techniques such as 32P-postlabelling and immunoassays used in most of the 
studies involving DNA- and protein-carcinogen adducts measurements often lack chemical 
specificity. For immunoassays, antibodies raised against a particular DNA adduct often 
cross-react with other adducts of the same class. Moreover, the accuracy of quantification 
using both these techniques is uncertain. This difficulty is encountered particularly in the 
case of 32P-postlabelling as discussed by Poirier et al., 2000, Phillips, 1996 and Wild and 
Pisani, 1998. Besides, identification of adducts detected using 32P-postlabelling has seldom 
been achieved. Moreover, unknown adducts may become 5´-phosphorylated with varying 
efficiencies using the 32P-postlabelling technique, resulting in underestimation of adduct 
concentrations in a human samples. 
 
1.3.2. Compounds Excreted in Urine 
Considering the pitfalls that one might encounter in the measurement of DNA and 
protein adducts, measurement of urinary biomarkers of tobacco carcinogen uptake presents 
a more practical option (Hecht, 2002). Urine is very easy to obtain in sufficient quantities 
and this can allow for quantification of even trace amounts of TSNA compounds and their 
metabolites excreted in urine. Although measurement of urinary compounds may not 
provide the most direct link with the type and risk of a particular cancer, they can provide 
information on the carcinogen dose and as well as the ability of an individual to activate or 
detoxify these compounds. Moreover, Hecht et al., 2002 have shown that some of these 
TSNA compounds have long terminal half-lives. This, along with the fact that tobacco 
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products are habitually used, provides consistent concentrations of TSNA compounds for 
measurement in urine.  
Measurement of urinary keto and hydroxy acids might be expected to be more 
appropriate since these are the end products of the DNA-adduct forming α-hydroxylation 
pathway of NNK and NNN metabolism. However, as described by Hecht, 2002, these 
compounds cannot be used to measure the extent of α-hydroxylation because they are 
formed from nicotine as well, which is a primary constituent of tobacco products. Recently 
nevertheless, Stepanov et al., 2008 have suggested the use of [pyridine-D4]NNK as a 
biomarker to measure the deuterium-labeled keto and hydroxyl acid specifically formed 
from NNK. Biomarker strategies using stable isotope labeled compounds can be expensive 
and challenging however.  
As depicted earlier in Figure 2, conversion of NNK to NNAL is an important 
metabolic pathway in humans with NNAL having similar carcinogenicity as NNK 
(Castonguay et al., 1983a, Hecht, 1998b). A characteristic feature of NNAL metabolism is 
the formation of the NNAL glucuronide conjugate (NNAL-Gluc), which is the most 
important detoxification product of the NNK-NNAL metabolic pathway in humans and 
animals as described by Hecht, 1998b, Hecht et al., 1993b and Morse et al., 1990. 
Additionally, NNAL and its glucuronide have a longer half-life (at least 10-15 days in 
smokers, and about 40-45 days in users of oral tobacco) in humans when compared with 
most other urinary metabolites. (Hecht, 2003, Hecht et al., 2002, Carmella et al., 2009). It 
has been hypothesized that the difference in half-lives of NNAL and its glucuronides in 
smokers and non-smokers arises from NNK/NNAL being sequestered in the lungs, 
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possibly in β2-adrenergic receptors found in the smooth muscle of the lungs (Hecht et al., 
2002). Since the initial dose of NNK to lungs is greater in smokers compared to oral 
tobacco users, it results in a shorter half-life among smokers because the lung acts in part 
as a first-pass uptake tissue in smokers (Hecht et al., 2002). Existence of a receptor 
mediated role has also been hypothesized for NNK/NNAL metabolism. After binding to 
the β-adrenergic receptors of the lungs, NNAL is released from these receptors, and is 
converted to the corresponding glucuronide forms. NNAL is a β-adrenergic agonist and 
stimulates DNA synthesis in cells via receptor-mediated release of arachidonic acid. 
Increased release of arachidonic acid could lead to increased production of prostaglandin 
E2, which is implicated in lung tumorigenesis (Hecht et al., 2002).  
NNN has a similar metabolic pathway to NNK as depicted in Figure 2. However, a 
problem from an analytical viewpoint is that the concentrations of NNN and its metabolites 
detected in urine of smokers is less than 15% of the total NNAL concentrations (Stepanov 
and Hecht, 2005), making its measurement much more difficult. Considering all of this, 
measuring urinary NNAL and NNAL-Gluc have evolved as one of the most prominently 
studied TSNA biomarkers.  
 
1.3.3. Other TSNA Biomarkers 
In addition to NNAL and NNAL-Gluc, other TSNAs such as NNN, NAB, and 
NAT along with their metabolites have also been studied (Gorrod and Jacob, 1999). These 
compounds have been detected and quantified in urine and saliva of tobacco users. More 
recently, TSNAs have been quantified in plasma, which is one of the most commonly 
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analyzed biological fluids in clinical studies. To further study the prevalence, etiology and 
mechanism of tobacco carcinogenesis, measurement of TSNAs has also been extended to 
amniotic fluid, cervical mucus, pancreatic juice, and toenails. Details of these studies along 
with appropriate references have been tabulated later in Table 1 and Table 2. 
 
1.4. Predominant Analytical Methodologies in TSNA Bioanalysis 
As described earlier, the study of TSNA uptake can be related to the mechanistic 
and epidemiologic role of these compounds in cancer. In fact, recent studies published by 
Yuan et al., 2009 and Church et al., 2009 have demonstrated the relationship of NNAL to 
lung cancer. It thus becomes essential to accurately and reproducibly quantify these 
compounds in biological matrices. It is highly desirable to develop a sensitive, selective 
and practical bioanalytical method to measure the levels of TSNAs in clinical studies.  
A significant amount of research investigating in vivo disposition and excretion of 
TSNAs in laboratory animals such as rats, hamsters, mice, monkeys, etc. as well as 
humans has been carried out. Most animal studies use some form of radioactivity 
measurement to study the extent of metabolite formation in radioactive samples. 
Radioactivity is usually measured by liquid scintillation counting, autoradiography or 
radioflow detection (Brittebo and Tjalve, 1980; Brittebo and Tjalve, 1981; Castonguay et 
al., 1983b, Castonguay et al., 1984; Castonguay et al., 1985; Meger et al., 1999; Richter et 
al., 2009). The extent of TSNA metabolite formation is different in animals compared to 
humans as reviewed by Hecht, 1998b. For this reason, discussion in this dissertation will 
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be focused on the bioanalytical measurement of TSNA compounds and their metabolites 
(mainly urinary NNAL and its glucuronide metabolite) in humans. 
Depending on the mode of exposure to tobacco products (direct user versus 
secondary exposure), human uptake of these compounds may vary significantly. Thus, 
different situations would demand different levels of assay sensitivity, different selectivity 
and validation. Three main aspects for consideration of a bioanalytical method include 
sample preparation, compound detection and throughput (Evans, 2004; Venn, 2000). 
Sample preparation involves extraction of the compound from the biological tissue, usually 
involving a concentration step to enhance assay sensitivity. Detection of the compound 
usually follows chromatographic separation from other components of the biological 
extract. The two most predominant techniques for TSNA bioanalysis are gas 
chromatography coupled with thermal energy analysis and liquid chromatography coupled 
with mass spectrometry employing various sample preparation techniques. The following 
two sections will discuss the progress and development in the analysis of TSNAs using 
both these techniques along with the most important analytical challenges. 
 
1.4.1. Thermal Energy Analysis (TEA) Detection 
   1.4.1.1. Principle of Operation 
Chemiluminescence detectors are one of the most selective of GC detectors 
available. One version of this detector which was originally manufactured by Thermedics 
Corporation (Chelmsford, MA, USA) is referred to as the thermal energy analyzer (TEA) 
which is a registered trademark (Beveridge, 1998). The TEA detection technique for N-
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nitroso compounds was first reported more than three decades ago (Fine et al., 1973; Fine 
et al., 1974; Fine et al., 1975b). Subsequently, the technique was utilized for the analysis of 
seven TSNA compounds in tobacco and tobacco smoke (Adams et al., 1983; Brunnemann 
et al., 1987; Brunnemann and Hoffmann, 1981; Djordjevic et al., 1989; Hoffmann et al., 
1979). The principle of the TEA detector has been discussed by Fine et al., 1975a. Briefly, 
the sample peak elutes from a GC column into a pyrolyzer in the TEA maintained at a 
temperature in excess of 275 ˚ C  which ruptures the compounds containing nitro or nitroso 
group to release the nitrosyl (NO˚) radical. Other organic compounds, solvents, and 
fragmentation products are removed using a cold trap. Nitrosyl radicals are then oxidized 
with ozone (formed by high voltage electric discharge of 7.5 kilo volts across a 1-mm glass 
dielectric in oxygen) in a reaction chamber to produce electronically excited NO2*. The 
NO2* decays back to the ground state emitting light in the near infrared region of the 
spectrum through the process of chemiluminescence. A photomultiplier then counts the 
corresponding photons which are proportional to the amount of NO moieties present.  
 
   1.4.1.2. TSNA Analysis Using TEA Detection 
Some of the first reports of the occurrence of TSNAs in human biological matrices 
utilized either GC or LC hyphenated with TEA for analysis (Hoffmann and Adams, 1981; 
Nair et al., 1985). These methods measured the concentrations of NNN, NAB, NAT and 
NNK in the saliva of betel quid chewers and snuff dippers. Pioneering work that 
demonstrated the presence of metabolites of TSNAs in the urine of smokers also used GC 
coupled with TEA (Carmella et al., 1993). This study quantified the levels of NNAL and 
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its glucuronide in 24-hour urine samples of smokers. The concentrations of these 
metabolites were detected in quantities of 0.23-1.0 and 0.57-6.5 μg/24 hr respectively. 
Subsequently, the first report of the presence of NNAL and its glucuronide in the urine of 
non-smokers exposed to sidestream cigarette smoke was published (Hecht et al., 1993a). 
Both these methods were based on a modification of a previously published method for the 
analysis of TSNA in indoor air using GC coupled with TEA (Brunnemann et al., 1992). An 
outline of the sample preparation procedure for quantitation of NNAL and NNAL-Gluc 
that was first developed (Carmella et al., 1993) is depicted in Figure 3. As seen in Figure 3, 
the sample preparation was extensive, and required extraction of large volumes of urine 
(100 mL) with ethyl acetate. Artifactual nitrosamine formation was prevented by the 
addition of either ammonium sulfamate or sodium hydroxide to urine at the time of 
collection. Fraction 1 contained unconjugated NNAL. The aqueous portion of urine was 
then subjected to incubation with β-glucuronidase for 16 hour at 37 ˚C to convert NNAL -
Gluc to free NNAL. The NNAL released was further enriched by subsequent extraction 
steps. The procedure involved two liquid chromatographic steps for purification of the 
extracts. The secondary hydroxyl group was then transformed to a trimethylsilyl ether 
derivative. Silylation is commonly done to increase the volatility of the analytes and 
therefore improve their GC properties for more efficient separation (Blau and Halket, 
1993). This derivative was finally subjected to GC analysis with TEA detection. For more 
than a decade following its publication, almost every study quantifying urinary TSNAs, 
mainly metabolites of NNK, i.e. NNAL and NNAL-Gluc utilized this method. Most of 
these studies were based on minor modifications of the method described above by 
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Carmella et al., 1993 and Hecht et al., 1993a. Some of these changes included a modified 
internal standard, decreased volume of urine analyzed, morning versus 24-hr urine 
samples, etc. The use of iso-NNAL instead of [5-3H]NNAL or [5-3H]NNAL-Gluc as the 
internal standard enabled quantification of both analyte and internal standard in the same 
chromatogram and eliminated the need for scintillation counting. Carmella et al., 1995 
showed the absence of any significant difference in results in the quantification of NNAL 
and its glucuronide conjugate for different urine collection protocols (e.g. morning versus 
24 hour samples). 
 Carmella et al., 1995 also attempted to use normal and reverse phase solid phase 
extraction cartridges to replace the HPLC purification steps. However, these attempts were 
unsuccessful because the GC-TEA chromatograms obtained on these samples had 
unacceptably high background. In a work published by Parsons et al., 1998, the sensitivity 
of the GC-TEA for urinary NNAL was improved nearly 20 fold through the use of 
capillary GC. Consequently, the urine aliquot size required for analysis was reduced to 50 
mL. Anderson et al., 2001 were able to carry out the GC-TEA assay with an even reduced 
aliquot size of 20 mL for non-smokers and 5 mL for smokers for the analysis of urinary 
NNAL and NNAL-Gluc in women exposed to environmental tobacco smoke (ETS). 
Carmella et al., 2002 were successfully able to separately analyze NNAL-O-Gluc and 
NNAL-N-Gluc. However, the procedure was very time consuming and complex. 
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Figure 3: First developed extraction protocol for analysis of urinary NNAL and its glucuronide conjugate using GC-TEA 
(Adopted from Carmella et al., 1993b) 
24 hr urine sample + ammonium 
sulfamate
FRACTION 1
ethyl acetate
aqueous
[5-3H]NNAL
HPLC
Silylation
GC-TEA
Neutralize, 
[5-3H]NNAL-Gluc
Extract with ethyl acetate
β-glucuronidase
Acidify (pH 2)
Extract with ethyl acetate
ethyl acetateaqueous
Neutralize
Extract with dichloromethane
FRACTION 2
dichloromethane
HPLC
Silylation
GC-TEA
aqueous
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The extensive sample preparation procedure for analysis of NNAL using GC with 
TEA detection was finally simplified by Carmella et al., 2003. The method was 
streamlined by introducing an acid partitioning step and omission of one of the HPLC 
purification steps. The pyridine ring on NNAL was protonated by adjusting the pH to 2-3. 
This allowed it to remain in the aqueous phase whereas relatively non-polar neutral and 
acidic organic compounds were extracted into CH2Cl2 and discarded. The traditional 
method for analysis of NNAL using GC-TEA published by Carmella et al., 1995 typically 
analyzed ten urine samples in an analytical run. Considering the extensive sample 
preparation, 24 hour enzyme hydrolysis and derivatization, followed by chromatographic 
run times of 20 minutes meant that the entire assay followed by data analysis could take up 
to a week to complete. In the simplified procedure developed by Carmella et al., 2003 
described above, the authors reported that the speed of analysis was almost two fold faster 
than the traditional method. However, a disadvantage of the method was that NNAL and 
NNAL-Gluc were not distinguished in this assay. This was because the partition step using 
ethyl acetate to separate free and conjugated NNAL was omitted. Rather, the sample was 
directly hydrolyzed using β-glucuronidase. Free and conjugated NNAL can however be 
easily determined with this method by carrying out the analysis with and without the β-
glucuronidase enzyme hydrolysis step, then determining NNAL-Gluc by the difference 
between total and free NNAL concentrations. 
In order to study the tumorigenic contributions of the two enantiomers of NNAL, 
viz. (R)-NNAL and (S)-NNAL, Carmella et al., 1999 had used chiral stationary phase 
(CSP) GC-TEA for analysis. The assay procedure was similar to the traditional assay for 
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GC-TEA analysis of NNAL, except that GC column was replaced by a β-cyclodextrin 
chiral selector GC column. Using CSP-GC-TEA, baseline resolution of (S)- and (R)-
NNAL-TMS standards, as well as (S)- and (R)-iso-NNAL internal standard, was achieved. 
The chromatographic run time of the assay was a long 100 minutes however. This 
procedure was successfully used by Hecht et al., 2002 to study the stereoselective receptor 
binding of NNAL.  
Apart from urine, NNAL and NNK have also been quantified in other biological 
matrices such as plasma using GC combined with TEA analysis as suggested by Hecht et 
al., 1999. Analysis was done starting with a large volume of blood (5-10 mL). After 
alkalizing plasma with 0.1 N NaOH, it was neutralized and extracted three times with 
CH2Cl2. Further analysis of NNAL and NNK followed a similar procedure to the 
traditional urine method. A sample preparation technique using supercritical fluid 
extraction for determining NNK in cervical mucus and NNN, NNK and NNAL in 
pancreatic juice was published by Prokopczyk et al., 1997 and Prokopczyk et al., 2002 
respectively. The method involved extraction using carbon dioxide containing 10% 
methanol followed by GC separation and nitrosamine selective detection using TEA. 
However, extraction of liquid samples (particularly biological fluids such as urine, blood 
and saliva) is often reported to be very difficult or impossible using supercritical fluid 
extraction (Zougagh et al., 2004).  
A listing of the literature compiling the studies which analyzed NNAL and its 
metabolites along with other TSNA compounds in biological matrices using nitrosamine 
specific TEA detection and quantitation is provided in Table 1.   
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Table 1: Compilation of studies analyzing and quantifying TSNA compounds in biological matrices using TEA detection  
TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
NNN, 
NAT, 
NNK 
Snuff dippers 
(4F) 
Saliva HPLC-TEA  5.0-125.0 ng/g (NNN); 
2.1-201.0 ng/g (NNK); 
6.6-147.0 ng/g (NAT) 
 ~0.8 to 1.6 g saliva collected for 
analysis. 
 No further assay description provided. 
Hoffmann 
and Adams, 
1981 
NNN, 
NAT, 
NAB, 
NNK 
Snuff dippers Saliva GC-TEA Concentrations of 
TSNAs measured 
ranged from 20-890 
μg/kg 
 Assay description not provided 
 
Hoffmann 
et al., 1982 
NNN, 
NAT, 
NNK 
Betel quid chewers 
 
Saliva GC-TEA 1.6-59.7 ng/g (NNN); 
1.0-51.7 ng/g (NNK); 
0.0-2.3 ng/g (NAT) 
 Assay description not provided Nair et al., 
1985 
NNAL, 
NNAL-
Gluc 
11 Smokers (9F) 
7 Non-smokers 
 
Urine GC-TEA 0.23-1.0 μg/24 hrs 
(NNAL); 0.57-6.5 
μg/24 hrs (NNAL-
Gluc). 
NNAL not detected in 
non-smokers . 
NNK not detected in 
urine. 
 100 mL aliquot size.  
 Purification of extracts using two 
preparative HPLC steps, followed by 
derivatization of 2˚  OH group of NNAL 
to trimethylsilyl ether, followed by GC-
TEA analysis.  
 Internal standard was [5-3H (NNAL)]. 
 Conversion of NNAL-Gluc to the 
unconjugated form achieved by 
incubation with β-glucuronidase 
enzyme. 
Carmella et 
al., 1993 
NNAL, 
NNAL-
Gluc 
Non-Smokers 
exposed to sidestream 
cigarette smoke (5M) 
Urine GC-TEA 33.9 ±20.0 ng/24 hrs 
(NNAL+NNAL-Gluc) 
 Sample preparation was based on 
Carmella et al., 1993 with a modified 
internal standard (iso-NNAL).  
Hecht et 
al., 1993a 
NNK, 
NNAL, 
NNAL-
Gluc 
Sudanese snuff-
dippers (7M) 
Urine GC-TEA 0.39 ±0.14 nmol/ml 
NNAL; 0.88±0.5 
nmol/ml NNAL-Gluc 
 Method was based on Carmella et al., 
1993,  with minor modifications.   
Murphy et 
al., 1994 
NNAL, 
NNAL-
O-Gluc 
Smokers (30M, 31F). 
Study to investigate 
intra- and 
interindividual 
differences in 
Urine GC-TEA 0.08-7.2 pmol/mg 
creatinine NNAL. 0.16-
19.0 pmol/mg 
creatinine NNAL-Gluc 
 Method was based on Carmella et al., 
1993, with minor modifications.  
 50-100 mL aliquot size.  
 Internal standard was iso-NNAL.  
 Attempts to use normal and reverse 
Carmella et 
al., 1995 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
metabolites of NNK phase SPE instead of HPLC for sample 
cleanup were unsuccessful.  
 Assay results demonstrated 6 month 
stability for NNAL and NNAL-Gluc 
stored at -20 ˚C  
 No significant difference was found in 
urine collection protocols. (E.g. morning 
sample versus 24-hrs collection) 
 Detection limit of assay was reported as 
1 ng per urine sample.  
NNAL, 
NNAL-
Gluc 
Smokers (5M, 6F). 
Study to investigate 
the effect of 
watercress 
consumption on 
metabolism of 
TSNAs 
Urine GC-TEA Average baseline 
concentrations of 
NNAL+NNAL-Gluc 
were 3.28±1.88 
nmol/24 hr; Average 
concentrations on the 
days of watercress 
consumption were 
4.21±2.58 nmol/24 hrs 
 Method was based on Carmella et al., 
1995 with minor modifications.  
Hecht et 
al., 1995 
NNAL, 
NNAL-
Gluc 
Non-tobacco users 
(8M). Non-smokers 
but smokeless 
tobacco users (39M). 
Study to investigate  
relations between 
urinary biomarkers 
and oral leukoplakia 
in smokeless tobacco 
users. 
Urine GC-TEA 0.02-8.73 pmol/mg 
creatinine (NNAL); 
0.14-30.3 pmol/mg 
creatinine (NNAL-
Gluc)  
 Method was based on Carmella et al., 
1995 with minor modifications 
Kresty et 
al., 1996 
NNK-N-
Oxide, 
NNAL-
N-Oxide 
Smokers (18); 
Smokeless tobacco 
users (11) 
Urine i.  GC-TEA 
ii. LC/ESI-
MS/MS for 
analysis of 
NNAL-N-
Oxide directly 
NNK-N-Oxide not 
detected in urine; 
Concentrations of 
NNAL-N-oxide were 
0.06-1.41pmol/mg 
creatinine in smokers 
 i. 20 to 45 mL aliquot size.  
 Method involved solvent extraction and 
purification by HPLC to separate 
NNAL-N-Oxide and NNK-N-Oxide 
from endogenous NNAL and NNK.  
 NNAL-N-Oxide and NNK-N-Oxide 
Carmella et 
al., 1997 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
in urine (for 
identity 
confirmation) 
and 0.02-1.20 pmol/mg 
creatinine in smokeless 
tobacco users. 
being thermally unstable were not 
amenable to direct GC-TEA analysis.  
Thus, they were reduced to free NNAL 
and NNK respectively using Proteus 
mirabilis.  
 NNAL and NNK were then analyzed by 
method suggested by Carmella et al., 
1995. 
 iso-NNAL-N-Oxide was used as the 
internal standard 
 ii. For LC-ESI-MS/MS, 500 mL urine 
aliquot size was used.  
 Following solvent extraction and HPLC 
purification, the samples were 
concentrated and analyzed using reverse 
phase LC-ESI-MS/MS. 
  
NNK Smokers (15F), Non-
smokers (10F). Study 
to identify NNK in 
cervical mucus. 
Cervical 
mucus 
Supercritical 
fluid 
extraction 
followed by: 
i. GC-TEA  
ii.Capillary 
GC-MS/MS 
(for identity 
confirmation) 
Mean concentrations of 
NNK in cervical mucus 
of smokers 46.9±32.5 
ng/g; 
Mean concentrations of 
NNK in cervical mucus 
of non-smokers 
13.0±9.3 ng/g; 
 
 Supercritical fluid extraction of cervical 
mucus (31-615 mg) with the use of 
carbon-dioxide that contained 10% 
methanol.  
 This was followed by analysis by GC-
TEA and GC-MS/MS.  
 d3-NNK was used as the internal 
standard. 
Prokopczyk 
et al., 1997 
NNAL, 
NNAL-
Gluc 
Smokers (13F) Study 
to investigate 
concentrations of 
NNK metabolites 
before and after 
indole-3-carbinol 
(I3C) treatment. 
Urine GC-TEA Mean difference in 
NNAL+NNAL-Gluc 
concentrations before 
and after I3C treatment 
was -0.43±0.16 
pmol/mg creatinine. 
 Method was based on Carmella et al., 
1995 
Taioli et 
al., 1997 
NNAL, 
NNAL-
Smokers (34 black 
and 24 white). Study 
Urine GC-TEA Black smokers: 
1.22±1.44 pmol/mg 
 Method based on Carmella et al., 1995 Richie et 
al., 1997 
   
 21 
TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
Gluc to investigate 
differences in NNK 
metabolites in black 
and white smokers. 
creatinine (NNAL), 
4.24±4.56 pmol/mg 
creatinine (NNAL-
Gluc); White smokers: 
0.603±0.345 pmol/mg 
creatinine (NNAL), 
3.13±2.44 pmol/mg 
creatinine 
NNAL-
Gluc 
Non-smokers (5M, 
4F). Study to analyze 
concentrations of 
urinary NNAL-Gluc 
in non-smokers 
exposed to 
environmental 
tobacco smoke. 
Urine i. GC-TEA 
ii. GC-MS/MS 
(for identity 
confirmation). 
Mean NNAL-Gluc 
concentrations 
0.059±0.028 pmol/mL 
(23 pg/mL urine) 
 50 mL aliquot size  
 GC-TEA Method was based on 
Carmella et al., 1995 with minor 
modifications.  
 Use of capillary GC improved 
sensitivity 20 fold (LOD 4 fmol/mL).  
  
 iso-NNAL was used as internal standard. 
Parsons et 
al., 1998 
NNAL, 
NNAL-
Gluc 
27 Subjects 
(smokers) 
participating in a 
smoking cessation 
study 
NNAL 
and 
NNAL-
Gluc in 
urine, 
NNK and 
NNAL in 
plasma 
i. GC-TEA 
ii. GC-MS/MS 
(for identity 
confirmation) 
Urinary concentrations: 
Baseline levels - 
0.6±0.366 pmol/mL 
(NNAL), 1.35±0.738 
pmol/mL (NNAL-
Gluc).  
6 weeks after cessation, 
7.6% of original 
NAL+NNAL-Gluc 
remained. 
Plasma concentrations: 
NNK was not detected 
in any of the samples. 
NNAL was detected in 
CH2Cl2 extracts of 
unhydrolyzed plasma 
from three of the four 
smokers analyzed.  
Concentrations of 
 Method to deternine urinary NNAL and 
NNAL-Gluc was based on minor 
modifications of Carmella et al., 1995 
and Parsons et al., 1998.  
 For plasma analysis, 5-10 mL blood 
aliquots were drawn.  
 RBC and plasma were separated. The 
RBC pellet was lysed with water, and 
extracted twice with hexane. The hexane 
extract was discarded and the aqueous 
phase was extracted thrice with CH2Cl2, 
and the combined extracts were analyzed 
for unconjugated NNAL and NNK as 
described for urine.  
 The plasma phase treated with 0.1 N 
NaOH, with sonication for 1 hr at room 
temperature. After neutralization, it was 
extracted three times with equal volumes 
of CH2Cl2 and then analyzed for NNAL 
Hecht et 
al., 1999 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
NNAL were 0.052, 
0.086, and 0.114 
pmol/ml plasma.  
NNAL was not detected 
in CH2Cl2 extracts of 
RBCs, or in the base or 
acid hydrolysates of 
RBC or plasma.  
and NNK as for the urine method. 
NNAL, 
NNAL-
Gluc 
Newborns (31from 
newborns whose 
mothers smoked and 
17 from newborns 
whose mothers did 
not smoke) 
Urine i. GC-TEA 
ii. GC-MS/MS 
(for identity 
confirmation) 
Mean concentration of 
0.14 pmol/mL 
(NNAL+NNAL-Gluc) 
in newborns whose 
mothers smoked. Not 
detected in newborns 
whose mothers did not 
smoke. 
 Method was based on Carmella et al., 
1993 and Parsons et al., 1998 with minor 
modifications 
Lackmann 
et al., 1999 
NNAL, 
NNAL-
Gluc 
Pregnant mothers (21 
smokers, 30 non-
smokers) 
Amniotic 
fluid (AF) 
i. GC-TEA 
ii. GC-MS/MS 
(for identity 
confirmation) 
Mean concentrations in 
AF of mothers who 
smoked: 0.025±0.029 
pmol/mL (NNAL), 
0.0032±0.01 pmol/mL 
(NNAL-Gluc); 
Mean concentrations in 
AF of non-smoker 
mothers: 
0.0018±0.0074 
pmol/mL (NNAL), 
0.0069±0.03 pmol/mL 
(NNAL-Gluc); 
 
 Method based on Lackmann et al., 1999 
with certain modifications. Further assay 
details were not provided. 
Milunsky 
et al., 2000 
NNAL, 
NNAL-
Gluc 
Heavy smokers (13F, 
10 M). Study to 
determine effects of 
smoking cessation 
Urine GC-TEA Average 25% reduction 
in total NNAL 
concentration observed 
at week 24 after 
smoking cessation 
 Method was based on Carmella et al., 
1993 and Carmella et al., 1995 
Hurt et al., 
2000 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
NNAL, 
NNAL-
Gluc 
Non-smoker (23F 
whose partners 
smoked, 22F whose 
partners did not 
smoke). Study to 
measure 
environmental TSNA 
in women exposed to 
ETS 
Urine i. GC-TEA 
ii. GC-MS/MS 
(for identity 
confirmation) 
Geometric means in 
women whose husbands 
smoked: 0.013 pg/mg 
creatinine (NNAL), 
0.027 pg/mg creatinine 
(NNAL-Gluc); 
Geometric means in 
women whose husbands 
did not smoked: 0.004 
pg/mg creatinine 
(NNAL), 0.004 pg/mg 
creatinine (NNAL-
Gluc) 
 Method based on Carmella et al., 1993; 
Hecht et al., 1993a and Parsons et al., 
1998 with some modifications.  
 20 mL urine aliquots from non-smokers 
and 5 mL aliquots from smokers were 
sufficient for analysis. 
Anderson 
et al., 2001 
NNAL, 
NNAL-
Gluc 
Children (38 – 
exposure to ETS 
reported, 35 – no 
exposure to ETS 
reported) 
Urine i. GC-TEA 
ii. GC-MS/MS 
for 
confirmation 
of NNAL-
Gluc identity. 
Mean concentration in 
children who reported 
exposure: 0.04 
pmol/mL 
(NNAL+NNAL-Gluc); 
Mean concentration in 
children who did not 
report exposure: 0.008 
pmol/mL 
(NNAL+NNAL-Gluc) 
 Method was based on Hecht et al., 
1993a and Parsons et al., 1998 with 
some modifications.   
 20 mL aliquot size was sufficient for 
analysis.  
 Detection limit of NNAL+NNAL-Gluc 
was reported as 0.003 pmol/mL 
Hecht et 
al., 2001 
NNAL, 
NNAL-
Gluc 
Non-smokers, 
smokeless tobacco 
users (13M). 
Participating in 
smokeless tobacco 
use cessation study 
Urine, 
Plasma 
i. GC-TEA 
ii. GC-MS/MS 
(for identity 
confirmation) 
iii. CSP-GC-
TEA 
  Method to measure NNAL and NNAL-
Gluc in urine was based on Hecht et al., 
1999. 
 Enantiomers of NNAL and 
diastereomers of NNAL-Gluc were 
analyzed using CSP-GC-TEA. 
 For plasma analysis, 5 mL aliquot size 
was used.  
 Plasma analysis was based on method  
suggested by Hecht et al., 1999.  
 Detection limit in plasma was 0.01 
pmol/mL.  
Hecht et 
al., 2002 
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Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
 Chromatographic run time was 100 min. 
NNAL, 
NNAL-
O-Gluc, 
NNAL-
N-Gluc 
Smokers (6M, 4F); 
Snuff dippers (10M); 
Toombak users (4M) 
Urine  i. GC-TEA for 
analysis of 
smokers and 
snuff dippers 
urine 
ii. LC-ESI-
MS/MS (for 
identity 
confirmation 
of NNAL-N-
Gluc in urine 
of toombak 
users) 
Mean concentrations in 
smokers: 0.462±0.214 
pmol/mL (NNAL), 
0.322±0.161 pmol/mL 
(NNAL-N-Gluc), 
0.434±0.343 pmol/mL 
(NNAL-O-Gluc)  
Mean concentrations in 
snuff dippers: 
1.48±1.13 pmol/mL 
(NNAL), 0.59±0.60 
pmol/mL (NNAL-N-
Gluc), 2.13±2.55 
pmol/mL (NNAL-O-
Gluc) 
Mean concentrations in 
toombak users: 
354.8±187.2 pmol/mL 
(NNAL), 32.6±17.4 
pmol/mL (NNAL-N-
Gluc), 231.8±264.8 
pmol/mL (NNAL-O-
Gluc) 
 Aliquot size was 10 mL.  
 Extraction using C18 SPE.  
 NNAL-O-Gluc and NNAL-N-Gluc were 
eluted using 10% methanol, followed by 
β-glucuronidase treatment (for 
hydrolysis of  O- an N-Gluc) or base 
treatment (for specific hydrolysis of N-
Gluc).  
 NNAL was eluted using 50% methanol 
as two separate fractions. After solvent 
partition and HPLC purification, NNAL 
was quantified by GC-TEA as described 
by Hecht et al., 2001. 
  iso-NNAL used as internal standard was 
added to urine rather than ethyl acetate 
extracts as described in previous assay 
(Carmella et al., 1995) for better 
quantitation. 
 NNAL-N-Gluc in toom bak users was 
confirmed using C18-SPE followed by 
LC-ESI-MS/MS using graphite 
stationary phase for HPLC. 1 mL 
aliquots was used 
Carmella et 
al., 2002 
NNN, 
NNK, 
NNAL  
smokers (18) and 
non-smokers (9) 
Pancreatic 
juice 
i. Supercritical 
fluid 
extraction 
followed by 
GC-MS/MS 
for quantitatio 
n of NNN and 
NNK 
i. Supercritical 
fluid 
extraction 
Smokers: 0-68.1 ng/mL 
(NNN), 0-604 ng/mL 
(NNK) was detected; 
Non-Smokers: NNN 
was not detected, 0-96.8 
ng/mL (NNK); 
NNAL was identified in 
8 out of 15 smoker 
samples and 3 out of 9 
non-smoker samples. 
 Aliquot size was ~300 μL.  
 SFE with the use of carbon-dioxide that 
contained 10% methanol. This was 
followed by analysis by GC-MS/MS.  
 d4-NNK was used as the internal 
standard. 
 NNAL was identified but not quantified.  
Prokopczyk 
et al., 2002 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
followed by 
GC-MS/MS 
or GC-TEA 
(for identity 
confirmation) 
Total 
NNAL 
(i.e. sum 
of NNAL 
and 
NNAL-
Gluc) 
Smokers (41), Snuff 
dippers (55), Non 
smokers exposed to 
ETS (18) 
Urine GC-TEA Concentrations of total 
NNAL (pmol/mg 
creatinine) were 
2.60±1.30 in smokers, 
3.25±1.77 in snuff-
dippers, and 
0.042±0.020 in 
nonsmokers exposed to 
ETS 
 
 NNAL and NNAL-Gluc were not 
distinguished in this assay.  
 Urine treated with β-glucuronidase, 
followed by solvent partitioning and 
further purification on a liquid-liquid 
extraction cartridge and by high-
performance liquid chromatography.  
 Total NNAL was silylated and finally 
quantified by GC-TEA.  
 Acid partitioning step produced cleaner 
samples,  
 Internal standard iso-NNAL was added 
directly to urine to improve accuracy. 
 Detection limit for the assay was 0.1 
pmol/mL starting with a 5 mL aliquot. 
Carmella et 
al., 2003 
Total 
NNAL 
(i.e. sum 
of NNAL 
and 
NNAL-
Gluc) 
Non-smokers 
exposed to ETS (13F, 
3M) 
Urine GC-TEA Mean concentrations of 
total NNAL prior to 
ETS exposure was 
0.02±0.02 pmol/mg 
creatinine. After ETS 
exposure, the mean 
Total NNAL 
concentrations 
increased by 0.018 
pmol/mg creatinine 
 Method based on Hecht et al., 1993a; 
Parsons et al., 1998 and Carmella et al., 
1993 with some modification 
Anderson 
et al., 2003 
NNAL, 
NNAL-
Gluc 
Smokers (151). Study 
to determine effects 
of cigarette cessation. 
Urine GC-TEA Subjects who reduced 
smoking by 70% 
achieved approximately 
50% reduction in total 
NNAL concentration by 
 Method based on Carmella et al., 1995 
and Hecht et al., 1999.  
 Urine aliquots used for analysis were 4.5 
mL. 
Hecht et 
al., 2004b 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
weeks 8-12. 
NNAL, 
NNAL-
Gluc 
Cigarette smokers (74 
M, 10 F). Study to 
investigate effect of 
cruciferous vegetable 
consumption on 
metabolism of NNK 
Urine GC-TEA Range of NNAL 
concentration 
determined in urine was 
0-3.62 pmol/mg 
creatinine while that of 
NNAL-Gluc was 0-5.07 
pmol/mg creatinine. 
Association was shown 
between cruciferous 
vegetable intake and 
urinary NNAL, NNAL-
Gluc and total NNAL 
concentrations 
 Based on method described by Carmella 
et al., 1995.  
Hecht et 
al., 2004a 
Total 
NNAL 
Cigarette smokers 
(38), Smokeless 
tobacco users (41). 
Investigation to study 
effects of reduced-
exposure tobacco 
products or medicinal 
nicotine on tobacco 
associated 
carcinogens 
Urine GC-TEA Mean total NNAL 
concentration of the 
“reduced risk” cigarette 
group  was 1.9 
pmol of NNAL/mg of 
creatinine, while the 
nicotine patch group 
had concentration of 1.2 
pmol of NNAL/mg of 
creatinine. 
 Method as described by Carmella et al., 
2003 
Hatsukami 
et al., 2004 
NNAL, 
NNAL-
Gluc 
46 Cigarette smokers. 
This study 
investigated the 
relationships of 
Urinary biomarkers 
of Tobacco and 
Carcinogen exposure 
in smokers 
Urine  GC-TEA The range of total 
NNAL measure was 0.9 
to 54 pmol/mL with a 
mean value of 
2.66±1.22 pmol/mL of 
urine. 
 Based on method described by Hecht et 
al., 1999 and Carmella et al., 1995 
Murphy et 
al., 2004 
NNN, 
NNN-
Gluc, 
14 Smokers and 11 
smokeless tobacco 
users. 
Urine i. GC-TEA 
ii. GC-MS/MS 
(for identity 
Mean concentrations of 
total NNN, NAT, and 
NAB in smokers were 
 Total NNN (NNN plus NNN-N-Gluc) 
was assayed using 5-methyl-NNN as 
internal standard.  
Stepanov 
and Hecht, 
2005 
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Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
NAT, 
NAT-
Gluc, 
NAB, 
NAB-
Gluc,  
First study to show 
presence of urinary 
NNN, NNN-Gluc, 
NAT, NAT-Gluc, 
NAB and NAB-Gluc 
in tobacco users. 
confir-
mation) 
(pmol/mg creatinine) 
0.18 ± 0.22, 0.19 ± 
0.20, and 0.040 ± 0.039 
respectively, whereas 
the corresponding 
amounts in the urine of 
11 smokeless tobacco 
users were 0.64 ± 0.44, 
1.43 ± 1.10, and 0.23 ± 
0.19, respectively. 
 
 36 mL aliquot size was used. 
  Urine was treated with β-glucuronidase. 
Following solvent partitioning and and 
two SPE steps, total NNN was 
determined using GC-TEA.  
 Total NAT and total NAB were 
quantified in the same samples using 
GC-TEA. 
 Separate quantitation of NNN, NNN-N-
Gluc, NAT, NAT-N-Gluc, NAB, and 
NAB-N-Gluc was accomplished by 
extraction of the urine with ethyl acetate 
before beta-glucuronidase hydrolysis. 
NNN, NAT and NAB was analyzed in 
the ethyl acetate extract. NNN, NAB and 
NAT released from the glucuronide 
conjugate was quantified in the extracted 
urine after enzyme treatment.  
  
 The detection limits of the method were 
0.032 pmol/mL urine for NNN, 0.014 
pmol/mL urine for NAT, and 0.018 
pmol/mL urine for NAB. 
NNAL, 
NNAL-
Gluc and 
total 
NNAL 
69 Black and 93 
White smokers. 
Study to investigate 
racial differences in 
exposure and 
glucuronidation of 
the NNK. 
Urine GC-TEA The geometric mean 
concentrations of 
urinary NNAL, NNAL-
Gluc and total NNAL 
(pmol/mg creatinine) 
detected were: 
i. 0.6, 1.9 and 2.6 in 
Black men and 0.45, 
1.4 and 1.9 in White 
men respectively 
ii. 0.76, 1.9 and 2.7 in 
Black women and 
0.7, 2.4 and 3.2 in 
 Based on method described by Carmella 
et al., 1995 
Muscat et 
al., 2005 
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Study Type 
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Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
White women 
respectively 
Total 
NNAL 
20 Non-smokers 
(6M, 14F). Study to 
investigate 
concentration of 
total-NNAL in non-
smokers exposed to 
smoke in restaurants 
and bars. 
Urine GC-TEA Mean difference (SD) 
in total NNAL 
concentration before 
and after exposure to 
smoke was 0.033 
(0.034) pmol/mL. 
 Based on method described by Carmella 
et al., 2003 
 Total NNAL could not be determined in 
one subject recruited in the study 
because of co-eluting peaks, suggesting 
potential selectivity problems with the 
GC-TEA method.  
Detection limit of the assay reported was 
0.01-0.07 pmol/mL based on recovery. 
Tulunay et 
al., 2005 
Total 
NNAL 
400 participants in 
study to investigate 
relationships between 
cigarette 
consumption and 
biomarkers of 
tobacco toxin 
exposure.  
Urine  GC-TEA The range of total 
NNAL measurements 
was 0 to 23.9 pmol/mg 
creatinine. 
 Based on method described by Hecht et 
al., 1999 and Carmella et al., 1995. 
Joseph et 
al., 2005 
Total 
NNAL 
144 infants between 
the ages of 3-12 
months. Study to 
investigate 
concentrations of 
total NNAL in the 
urine of infants 
exposed to ETS. 
Urine  GC-TEA Mean concentrations of 
total NNAL in the 144 
infants were 0.083 ± 
0.200 pmol/mL 
 Total NNAL was analyzed as described 
in method by Carmella et al., 2003 
except that HPLC purification step was 
replaced by purification on a mixed 
mode cation exchange SPE cartridge as 
described by Carmella et al., 2005.  
 5-(methylnitrosamino)-1-(3-pyridyl)-1-
pentanol was used as internal standard. 
 Detection limits for NNAL were 
calculated for each sample based on 
urine volume and recovery and ranged 
from 0.09-0.36pmol/mL 
Hecht et 
al., 2006 
Total 
NNAL 
80 children ages 5 
to 10 years from 
areas of Moldova. 
The study 
Urine GC-TEA Mean ± SD level of 
total NNAL was 0.09 ± 
0.077 pmol/mL 
 Analysis was based on method described 
by Hecht et al., 2001 and Hecht et al., 
1999 with some modifications.  
 C5-NNAL was used as the internal 
Stepanov et 
al., 2006b 
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investigated uptake of 
NNAL by Moldovan 
children. 
standard 
 30 
  1.4.1.3. Problems with GC-Thermal Energy Analysis 
Most of the studies conducted prior to 2003 used GC with TEA detection to 
quantify TSNAs. Although TEA has been highly instrumental in advancing our knowledge 
in the TSNA field, many laboratories cannot justify the use of such a highly specialized 
detector if they do not have a regular application. Secondly, the methods based on 
GC/TEA can require very high sample volumes. This can be a limitation, especially if 
urine or plasma is designated for multiple types of assays, and the quantity available is 
limited. Also, the sample preparation is highly complex including multiple extraction and 
purification steps, followed by 24-hour enzyme hydrolysis in the case of measuring 
conjugated compounds (note: this is a common step for LC/MS/MS based methods 
discussed later) and finally there is a derivatization step. Moreover, for most cases elution 
times are in excess of 15 minutes in order to get good separation of the target compounds. 
This significantly affects the throughput of the assays which can typically take almost a 
week to complete sample preparation, chromatography and data analysis for a batch of 
samples. It should be noted that with advancement in technology and experience over the 
years, the current state of the art has substantially improved throughput of GC-TEA based 
methods. Currently, however, there are no publications that have described validation of 
GC-TEA methods based on the widely used FDA guidelines (US Food and Drug 
Administration, 2001). The ability to validate these methods according to accepted 
standards becomes especially important with the recent legislation that gives the U.S. FDA 
authority to regulate tobacco (Curfman et al., 2009). Another major disadvantage of GC-
TEA is its inability to distinguish co-eluted nitroso compounds even though it is nitroso 
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specific as reported by Wu et al., 2008. Morcos and Wiklund, 2001 and Meulemans and 
Delsenne, 1994 have reported the presence of nitrates and nitrites in human urine which 
can be a potential sources of interference as reported by Fine et al., 1975b. In fact, in the 
study published by Tulunay et al., 2005, total NNAL could not be determined in one 
subject recruited in the study because of co-eluting peaks. This suggests potential 
selectivity problems with the GC-TEA method. Moreover, for thermally unstable 
compounds, GC-TEA might not be the best method of choice. Consequently, there has 
been a recent trend towards the use of more widely available LC/MS/MS analytical 
technique for the analysis of TSNAs. 
 
1.4.2. LC-ESI-MS/MS 
One of the chief causes that precludes complete validation of GC-TEA based 
methods for analysis of tobacco specific nitrosamines is limited throughput due to 
extensive and complex sample extraction steps. The need for high throughput quantitative 
determination of analytes in biological matrices has been largely fulfilled with the modern 
development of liquid chromatography coupled with tandem mass spectrometry. Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) is one of the most prevalent 
hyphenated techniques that have been adopted for fast and cost-effective analytical 
methods. It has led to major breakthroughs in the field of quantitative bioanalysis for 
almost two decades due to its inherent selectivity, sensitivity, and speed (Xu et al., 2007). 
A mass detector is highly selective by virtue of its ability to isolate and quantify specific 
ions. It is now generally accepted as the preferred technique for quantitative analysis of 
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small molecule drugs, metabolites, and other xenobiotics in biological matrices such as 
plasma, blood, serum, urine, and tissue.  
The basic principle of mass spectrometric analysis involves production of ions of 
the compound to be analyzed by inducing either a loss or gain of a charge from a neutral 
species. Once formed, the ions are electrostatically directed into the mass analyzer where 
they are separated and detected according to their mass-to-charge (m/z) ratio. The four 
main components of most mass spectrometers are a sample inlet, ionization source, mass 
analyzer and ion detector (Venn, 2000). Electrospray ionization (ESI) is one of the most 
widely used atmospheric pressure ionization source conducive to formation of singly 
charged small molecules as well as multiply charged large molecules. Thus far, all 
published methods for TSNA bioanalysis using LC-MS/MS have utilized an ESI source. 
ESI operates by formation of a fine spray of highly charged droplets from a liquid sample 
in the presence of an electric field. Dry gas and heat, are applied to the droplets at 
atmospheric pressure thus causing the solvent to evaporate from each droplet. As the size 
of the charged droplet decreases, the charge density on its surface increases. The mutual 
coulombic repulsion between like charges on this surface becomes so great that it exceeds 
the forces of surface tension, and ions are ejected. The ejected ions are then drawn into the 
vacuum of the mass analyzer through a series of lenses (Hoffmann and Stroobant, 2001). 
The most important advantage of the ESI source is its sensitivity, easy adaptability to 
liquid chromatography and amenability to tandem mass analyzers such as triple 
quadrupoles and ion traps. However, a common problem encountered in ESI is matrix 
effects which can affect the quantitative performance of an assay as well as compromise 
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method sensitivity (Van Eeckhaut et al., 2009). The issue of matrix effects commonly 
encountered in LC-ESI-MS/MS methods will be discussed in more detail in the following 
sections and chapters of this thesis.  
It is now standard practice to validate bioanalytical methods according to the 
bioanalytical method validation guidelines as prescribed by the FDA (US Food and Drug 
Administration, 2001). Validation of the method serves to ensure reliability and 
reproducibility of a particular method used to quantitatively measure analytes in a 
biological matrix. Validation involves documenting the performance characteristics of the 
entire method in terms of accuracy, precision, selectivity, sensitivity, reproducibility and 
stability employing thorough laboratory investigations. Considering the extensive and 
complex sample preparation procedures, method validation may not be practical in the case 
of TEA based methods. There is currently no published GC-TEA method published for 
TSNA analysis which has been fully validated according to the FDA recommended 
bioanalytical method validation guidelines. Thus an increasing number of LC/MS/MS 
based methods are being published for bioanalysis of TSNAs.  
  
   1.4.2.1. TSNA Analysis Using LC-ESI-MS/MS  
Properly employed LC-ESI-MS/MS methods possess high selectivity, sensitivity, 
and throughput. Byrd and Ogden, 2003 have published the first fully validated assay for 
the determination of NNAL in urine using LC/MS/MS and a single-step SPE. The SPE 
was performed on a mixed-mode cation exchange cartridge. d3-NNAL was used as an 
internal standard for the assay. The assay was validated according to the FDA criteria, and 
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was found to be accurate, precise and selective. The limit of quantitation of the assay was 
20 pg/mL accomplished on a Micromass Quattro Ultima triple quadrupole mass 
spectrometer operated in the positive ESI mode. This was sufficient for analysis of free and 
total NNAL in smoker’s urine using a 15 mL aliquot.  
NNAL and its glucuronide have also been quantified using LC-ESI-MS/MS in 
biological matrices other than urine such as plasma samples of smokers. Carmella et al., 
2005 used a single step mixed-mode cation exchange SPE followed by separation on a 
reverse phase C18 HPLC column and MS/MS detection. Considering the polar nature of 
NNAL, Pan et al., 2004 developed a method for determination of NNAL concentrations in 
plasma based on a simple liquid/liquid extraction and hydrophilic interaction liquid 
chromatography with tandem mass spectrometry (HILIC/MS/MS) analysis. While reverse 
phase chromatography is most widely used for analysis of polar analytes, it relies on 
separation by the analyte’s degree of hydrophobic interaction with the stationary phase. In 
reverse phase chromatography, a non-polar stationary phase and a polar mobile phase are 
used. HILIC on the other hand is useful for separation of polar compounds by eluting with 
a strong organic mobile phase against a hydrophilic stationary phase where elution is 
driven by increasing the aqueous content in the mobile phase (Hsieh, 2008). The highly 
volatile organic mobile phases such as methanol and acetonitrile used in HILIC provide 
increased ionization efficiencies for MS/MS detection. Moreover, the lower viscosities of 
these solvents lead to lower column backpressure and possibly improved column life 
(Dejaegher et al., 2008). The throughput of the method developed by Pan et al., 2004 for 
the analysis of NNAL in plasma was substantially improved with chromatographic run 
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times of just 1 minute. Both, the reverse phase chromatography based method and the 
HILIC method described above used only 1 mL of plasma compared to 5-10 mL required 
in previously published GC-TEA based methods. The recent shortage in availability and 
skyrocketing in acetonitrile prices may pose a limitation for HILIC chromatography 
(Majors, 2009). Acetonitrile with a small amount of water content is the most typical 
mobile phase for HILIC methods.  
More recently, mass spectrometry based assays have been developed by Stepanov 
and Hecht, 2008 and Stepanov et al., 2006a for analysis of NNAL and NNN in human 
toenail. Some of the advantages of biomarkers in the toenail include the potential for 
evaluation of long-term cumulative exposure to tobacco carcinogens, steady accumulation 
of biomarkers due to the slow growth rate of nails and enhanced sample stability. Toenail 
specimens are not typically collected in most epidemiological studies however.  
A listing of the literature compiling the studies analyzing and quantifying NNAL 
and its metabolites along with other TSNA compounds in biological matrices using LC-
MS/MS is provided in Table 2.  
 
   1.4.2.2. Matrix Effects - Challenge in LC-MS/MS Methods for TSNA Analysis 
An important selectivity issue which is sometimes neglected in LC-MS/MS method 
development is matrix effects. These are caused by alteration of ionization efficiency by 
the presence of co-eluting substances. These effects can often have a detrimental impact on 
the method accuracy and sensitivity (Annesley, 2003). The recovery experiments carried 
out by Byrd and Ogden, 2003 revealed an almost 50% ion suppression of the NNAL signal  
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Table 2: Compilation of studies analyzing and quantifying TSNA compounds in biological matrices using LC-MS/MS  
TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
NNAL, 
NNAL-
Gluc 
Smokers (5M, 2F) Urine  LC-MS/MS Mean concentrations in 
smokers ranged from 
126-961ng/24 hr 
(NNAL), 320-2033 
ng/24 hr 
 First fully validated determination of 
NNAL in urine using LC/MS/MS and 
single step mixed-mode cation exchange 
SPE.  
 10 mL urine aliquot used for free NNAL 
analysis and 5 mL urine aliquot used for 
NNAL-Gluc analysis.  
 
 d3-NNAL was used as internal standard. 
 Method was linear over a range of 20-
1000 pg/mL  
 HPLC Column needed rinsing after 
every 10 injections as later reported by 
Pan et al., 2004.  
Byrd and 
Ogden, 
2003 
NNAL, 
NNAL-
Gluc 
Incurred plasma 
samples (n=9) 
Plasma HILIC-
MS/MS 
Free NNAL 
concentrations in 
incurred samples ranged 
from 5.5 to 16.4 pg/mL, 
total NNAL level 
ranged from 6.02 to 
21.5 pg/mL 
 First LC-MS/MS method for analysis of 
NNAL in plasma.  
 Method comprised of liquid/liquid 
extraction of NNAL from 1 mL plasma 
aliquots, followed by analysis by HILIC-
MS/MS.  
 d4-NNAL was used as the internal 
standard  
 LLOQ was reported as 5.0 pg/mL with a 
1 minute run time. 
Pan et al., 
2004 
Total 
NNAL 
16 smokers and 5 non-
smokers. 
Plasma  LC-ESI-
MS/MS 
Concentrations of total 
NNAL averaged 42 ± 
22 (SD) and ranged 1.7 
to 88 fmol/mL plasma 
in 16 smokers; NNAL 
was not detected in the 
plasma of five non-
smokers 
 Aliquot size was 1 mL  
 [Pyridine-D4] NNAL was used as 
internal standard.  
 Samples were incubated with β-
glucuronidase enzyme and then 
subjected to mixed mode cation 
exchange solid phase extraction. This 
was followed by LC-ESI-MS/MS.  
 NNAL eluted at 16.3 minutes.  
Carmella 
et al., 
2005 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
 The limit of quantitation of the assay 
was reported as ~8 fmol total NNAL/mL 
plasma. 
 The assay was evaluated for accuracy 
and precision. Average recovery was 
28±21%. 
NNAL, 
Total-
NNAL 
41 smokers exposed to 
sidestream smoke 
Urine LC-ESI-
MS/MS 
Following exposure to 
sidestream smoke, the 
mean concentration of 
total NNAL post-
exposure was 24.1 
pg/mg of creatinine, 
with a mean difference 
of 20.6 pg/mg of 
creatinine. 
 Aliquot size was 5 mL.  
 Analysis was done using LC-ESI-
MS/MS combined with sample 
extraction using SPE on a MIP column.. 
 13C6-NNAL was used as the internal 
standard.  
 The chromatographic run time was 3 
minutes  
 The limit of detection of the assay was 
about 1.7 pg/mL and the method was 
linear upto 2 ng/mL. The method was 
validated for accuracy, precision and 
stability. 
Xia et al., 
2005 
Total 
NNAL 
16 Smokers. Assay was 
developed for combined 
analysis of r-1,t-2,3,c-4-
tetrahydroxy-,2,3,4- 
Tetrahydrophenanthrene 
and 4-
(Methylnitrosamin)-1-
(3-Pyridyl)-1-Butanol in 
Smokers’ Plasma 
Plasma LC-ESI-
MS/MS 
Concentrations of 
NNAL in plasma 
averaged 36 ± 21 
fmol/mL, which are 
~1% to 2% of the 
amounts found in urine 
 [D10]PheT and [pyridine-D4]NNAL 
were used as internal standards.  
 Plasma was treated with β-glucuronidase 
to release conjugated PheT and NNAL. 
 Analytes were enriched by SPE on a 
mixed mode cation exchange cartridge 
and the PheT fraction was further 
purified by HPLC. The appropriate 
fractions were analyzed by GC-negative 
ion chemical ionization-MS for PheT 
and LC-ESI-MS/MS for NNAL.  
 Limits of quantitation for NNAL was 3 
fmol/mL. The method was evaluated for 
accuracy and precision 
Carmella 
et al., 
2006 
NNAL 35 Smokers and six 
non-smokers. Assay 
Toenail LC-ESI-
MS/MS 
Mean NNAL in 
smokers was 
 50-80 mg toenails were used.  
 Toenails were washed with CH2Cl2, and 
Stepanov 
et al., 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
was developed to 
measure NNAL in 
human toenail. 
0.41 ± 0.67 pg/mg 
toenail. 
Samples collected from 
six nonsmokers were 
negative for NNAL. 
digested overnight in NaOH. pH was 
adjusted to 6-8, the aqueous toenail 
digest was enriched by partitioning with 
CH2Cl2 on a ChemElut liquid-liquid 
extraction cartridge . Final enrichment 
was accomplished by a mixed mode 
cation exchange extraction on an Oasis 
MCX solid- phase extraction cartridge. 
The fraction containing NNAL was then 
directly analyzed by LC-ESI-MS/MS.  
 13C6-NNAL was used as internal 
standard.  
 The detection limit of the assay for 
NNAL in toenails from smokers was 
0.02 pg/mg toenail.  
 The assay was evaluated for accuracy 
and precision.  
2006a 
NNAL, 
Total 
NNAL 
266 Smokers (99M, 
167F) This study 
investigated relations 
between machine-
derived smoke yields 
and biomarkers in 
cigarette smokers in 
Germany 
Urine LC-ESI-
MS/MS 
Mean concentrations of 
total NNAL found in 
smokers 1.53 ± 
1.71nmol/24 hrs 
 Free NNAL was determined after SPE 
on cation exchange cartridges.  
 [D3-methyl]-NNAL was used as internal 
standard.  
 Determination of total NNAL was 
carried out by hydrolysis with β-
glucuronidase prior to SPE. 
Scherer et 
al., 2007 
Total 
NNAL 
420 smokers and 182 
smokeless tobacco 
users. Study to compare 
relations between 
concentrations of 
urinary total NNAL in 
smokers versus 
smokeless tobacco 
users. 
Urine  Study was 
conducted in 
six parts. GC-
TEA was used 
for studies 1 
and 2 while 
LC-ESI-
MS/MS for 
studies 4-6 
Concentrations of total 
NNAL in smokers 
ranged from 2.03 to 
2.35 pmol/mL, while in 
smokeless tobacco 
users, concentrations of 
total NNAL ranged 
from 3.40 to 4.21 
pmol/mL 
 Studies 1 and 2 were based on method 
described by Carmella et al., 1995.  
 Studies 3-6 were based on method 
described by Carmella et al., 2003 and 
Carmella et al., 2005 
Hecht et 
al., 2007 
Total 212 smokeless tobacco Urine The study was Mean concentrations of  The analysis was based on methods Hecht et 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
NNAL users. conducted in 
three parts and 
analyses were 
either done by 
GC-TEA and 
LC-ESI-
MS/MS 
total NNAL ranged 
from 2.47 to 5.21 
pmol/mL as the 
duration of daily use of 
smokeless tobacco 
increased from 0 to 
more than 21 years 
described by Carmella et al., 2005, 
Carmella et al., 2003 and Hecht et al., 
1999. 
al., 2008 
NNN 17 Smokers. Assay was 
developed to measure 
NNN in human toenail. 
Toenail LC-ESI-
MS/MS 
Mean total NNN level 
in these samples was 
4.63 ± 6.48 fmol/mg 
toenail. 
 40-100 mg toenails were used.  
 Toenails were washed with CH2Cl2, and 
digested overnight in NaOH. The 
aqueous toenail digest was enriched by 
partitioning with CH2Cl2 on a ChemElut 
liquid-liquid extraction cartridge. Further 
enrichment was accomplished by a 
mixed mode cation exchange extraction 
on an Oasis MCX SPE cartridge.  Final 
enrichment was achieved using Bond-
Elut silica SPE cartridges. The fraction 
containing NNAL was then directly 
analyzed by LC-ESI-MS/MS.  
 13C6-NNAL was used as internal 
standard.  
 The detection limit of the assay for NNN 
in toenails from smokers was 0.02 
pg/mg toenail. 
 The assay was evaluated for accuracy 
and precision. 
Stepanov 
and 
Hecht, 
2008 
Total 
NNAL 
73 non-smokers who 
suffered from chronic 
obstructive pulmonary 
disease. The assay was 
developed 
subpicogram/mL 
determination of NNAL 
in human urine using 
Urine LC-ESI-
MS/MS 
Nonsmokers who 
suffered from chronic 
obstructive pulmonary 
disease had mean 
NNAL concentration of 
5.5 pg/mL 
 The method involves liquid-liquid 
extraction followed by conversion of 
NNAL to the hexanoate ester derivative. 
(derivatization facilitated separation 
from interfering urinary constituents).  
 LLOQ was 0.25 pg/mL for 5-mL urine 
samples. The method was evaluated for 
accuracy and precision. 
Jacob et 
al., 2008 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
LC-MS/MS 
NNAL, 
Total 
NNAL 
Incurred urine samples 
from 10 smokers. Study 
investigated influence 
of ion suppression due 
to sample matrix effect 
on the LC-MS/MS 
determination of 
NNAL. 
Urine  LC-ESI-
MS/MS 
Smokers had free 
NNAL concentrations 
ranging from below 
LOQ to 160.4 pg/mL, 
while total NNAL 
concentrations ranging 
from below LOQ to 392 
pg/mL. 
 The method was a modification of the 
assay published by Xia et al., 2005 using 
SPE on a MIP column combined with 
ESI-MS/MS.   
 LC conditions were modified to resolve 
the elution of the peak of interest from 
the region of ionization suppression.  
 A 25-fold improvement in response was 
observed with the modified method. 
Shah et 
al., 2009 
Total 
NNAL, 
Total 
NNN, 
Total 
NAB, 
Total 
NAT 
7 Smokers and 7 non-
smokers. Assay was 
developed for 
simultaneous 
determination of four 
TSNA’s in human urine 
Urine  LC-ESI-
MS/MS 
Mean concentrations of 
NNAL, NNN, NAB and 
NAT in smokers were 
152.5, 7.2, 47.0 and 
161.1 pg/mL. NNAL 
was detected in 3 out of 
7 non-smokers (mean 
level 2.68 pg/mL), 
while other TSNAs 
were not detected.  
 Aliquot size was 6 ml.  
 The method involved simultaneous 
determination of four TSNA in urine. 
Four corresponding deuterated internal 
standards were added to urine followed 
by treatment with β-glucuronidase. SPE 
was carried out on a TSNA-specific MIP 
cartridge followe by further enrichment 
by SPE on a cation-exchange resin 
followed by LC–ESI-MS/MS 
 The limits of detection (LOD) were 2.0, 
0.8, 1.1 and 0.7 pg/ml for NNAL, NNN, 
NAB and NAT, respectively.  
Kavvadias 
et al., 
2009 
Total 
NNN 
16 smokers. Assay was 
used for investigation of 
respiratory retention of 
NNN  
Urine LC-ESI-
MS/MS 
After smoking, average 
NNN concentrations 
were found to reach 4.0 
pg/mL within one day 
 20 mL aliquot size was used. 
 NNN-d4 was used as internal standard. 
 After pH adjustment urine was treated 
with β-glucuronidase. 
 Sample enrichment was achieved by 
liquid extraction on an Extrelut 
diatomaceous earth cartridge followed 
by LLE and SPE on a mixed mode 
cation exchange cartridge. 
 LC-ESI-MS/MS analysis consisted of 
two reverse phase analytical columns in 
series. Chromatographic run time was 15 
Urban et 
al., 2009 
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TSNA 
Analyzed 
Study Population/ 
Study Type 
Sample 
Matrix  
Analytical 
Method 
Concentrations 
Measured 
Sample Preparation and Remarks Reference 
minutes. 
 Method was validated. LLOQ was 2 
pg/mL with calibration line linear upto 
256 pg/mL. 
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by co-eluting species from the sample matrix when compared with samples in a simple 
water matrix.  
Matrix effects can be minimized by a modification of the sample extraction 
methodology and/or improved chromatographic separation from co-eluting substances 
(Avery, 2003). In this respect, Jacob et al., 2008 modified the sample extraction protocol to 
develop a method for sub-picogram per milliliter determination of NNAL in human urine 
that avoided matrix effects. The method relied on the derivatization of the hydroxy group 
of NNAL to a relatively non-polar hexanoate ester. This facilitated the chromatographic 
separation from potentially interfering polar urinary constituents. More efficient separation 
from other ionizable urinary species by extraction and chromatography reduced the extent 
of ion suppression which commonly occurs in ESI. Further, the hexanoate ester derivative 
of NNAL would have a larger mass than the parent compound. Sterner et al., 2000 have 
shown that larger masses are less susceptible to suppression when compared to smaller 
molecules. The authors reported a limit of quantitation of 0.25 pg/mL for a 5 mL sample 
aliquot. This is the lowest reported LOQ for NNAL quantitation published to date. The 
authors state that a typical run consisting of 46 samples plus 26 standards and quality 
control samples required 3 days to carry out the enzyme incubation, extraction and 
derivatization steps. Further LC-MS/MS analysis with long chromatographic run times (20 
minutes) means that a typical run can take a week to complete. This hinders sample 
throughput, and can be a problem economically when faster turnaround times are required.  
It is highly desirable to develop novel sample preparation techniques and/or 
sorbents capable of highly selective sample extraction and at the same time be throughput 
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efficient. Molecularly imprinted polymers are one such type of synthetic sorbent having 
predetermined selectivity for an individual analyte or a class of compounds. These are fast 
gaining wide utility in the field of TSNA bioanalysis as discussed in the next section. 
 
1.5. Molecularly Imprinted Polymers – New Sample Extraction Sorbents for TSNA 
Bioanalysis 
Solid phase extraction (SPE) techniques are one of the most useful techniques for 
extraction of TSNAs from biological matrices prior to quantitative analysis. SPE has 
significant advantages compared to traditional liquid/liquid extraction methods. The wide 
range of sorbents available makes this technique applicable to most classes of compounds. 
Typical SPE sorbents have limited selectivity, however, since they retain analytes by 
nonselective hydrophobic or polar interactions. This constitutes a problem when a selective 
extraction from a complex biological matrix needs to be performed. The analyte is retained 
together with other matrix compounds, which can hinder its final determination (e.g., 
problem of matrix effects). Because of these limitations, synthetic molecular recognition 
sorbent materials which can recognize target analytes have been developed, called 
molecularly imprinted polymers (MIPs) (Mosbach and Mosbach, 1966). 
The technique of molecular imprinting was further developed by Wulff and Sarhan, 
1972. This technique has been shown to be capable of producing materials with ‘antibody-
like’ selectivity (Andersson et al., 1995). Molecularly imprinted polymers are extensively 
cross-linked polymers containing specific recognition sites that act as artificial receptors 
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having predetermined selectivity for an analyte or class of analytes (Allender et al., 1999; 
Danielsson, 2008; Pichon, 2007; Sellergren and Andersson, 2000). The process of 
molecular imprinting consists of the following steps: (a) The imprint is obtained by 
arranging polymerisable functional monomers around a template representing the target 
molecule, and complexes are then formed through covalent or non-covalent or semi-
covalent molecular interactions between the template and monomer functional groups; (b) 
The complexes are assembled in the liquid phase and undergo polymerization by cross-
linking. (c) Subsequent removal of the template molecule through extraction or hydrolysis 
with appropriate solvents gives rise to imprints or cavities which are complementary to the 
analyte of interest both chemically and sterically. These binding sites thus offer high 
affinity for the target molecule. A schematic diagram of the imprinting process described 
above is shown in Figure 4. 
The principle of selective extraction using MIPS is similar to that of 
immunosorbents, and typically involves a conditioning step, followed by sample loading, a 
washing step, and finally desorption of the target analyte. Synthesizing MIPs having high 
affinity and selectivity for target analytes is a challenge. Xia et al., 2005 were successfully 
able to design MIPs for selective extraction of NNAL in human urine followed by LC/ESI-
MS/MS detection. These MIPs for NNAL are now commercially available. Further 
advancement in the use of MIPs for TSNA analysis came when Kavvadias et al., 2009 
developed a method for simultaneous determination of urinary NNN, NNK, NAB and 
NAT using these artificial synthetic receptors. The sample preparation involved a two step 
SPE procedure – selective extraction on a commercially available MIP cartridge specific 
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Figure 4: Schematic representation of preparation of MIPs (Adopted from Lasakova et al., 2009) 
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for TSNAs, followed by extraction on a mixed-mode cation exchange cartridge. The 
compounds were then subjected to analysis by LC-ESI-MS/MS. However, these published 
methods did not investigate the issue of matrix effects which can affect the quantitative 
performance as well as sensitivity of LC/MS-MS based assays.  
 
1.6. Conclusions: 
Considering the worldwide problem associated with tobacco use, study of TSNA 
uptake will provide very useful insights into the mechanistic and epidemiologic role of 
these compounds in human cancer, especially since their origin is specific to tobacco. 
TSNA-DNA adducts might provide the most direct relationship to cancer risk. However, 
there are significant measurement problems. Measurement of urinary NNAL and NNAL-
Gluc have evolved as one of the most prominently studied and practical TSNA biomarker. 
The nitrosamine selective GC-TEA technique had been the method of choice for 
bioanalysis of TSNAs for a long time. However, due to the extensive and complex sample 
preparation steps for GC-TEA methods, recently there has been a shift to development of 
methods for TSNA bioanalysis using the more widely available LC-MS/MS technique. 
Molecularly imprinted polymers have recently been developed for selective sample 
extraction of urinary NNAL combined with LC-MS/MS analysis. However, the important 
issue of matrix effects that can potentially affect the quantitative performance of this assay 
requires investigation. Further research that will enhance the throughput of sample 
extraction using MIPs on a miniaturized scale presents an excellent potential for reduced 
costs, fast analysis times and small sample size. 
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1.7. Dissertation Objectives: 
The first part of the dissertation will investigate the presence of matrix effects and 
related problems with sensitivity for re-establishment of the method published by Xia et 
al., 2005. In this method, urinary NNAL will be analyzed based on an offline sample 
extraction using MIPs combined with LC/MS-MS. The method will be validated and used 
for subject sample analysis.  
The second part of the dissertation will deal with the development of a high-
throughput online sample extraction method using capillary micro-columns packed with 
MIP beads combined with tandem MS for the analysis of urinary NNAL. The method will 
be optimized and matrix effects will be evaluated and avoided. The method will enable low 
volume, rapid analysis of urinary NNAL by direct injection on a microfluidic column 
packed with molecularly imprinted beads specific to NNAL. The method will be validated 
and used for the analysis of NNAL and NNAL-Gluc concentrations in smokers’ urine. The 
ratio of NNAL-Gluc to NNAL will be used to investigate the extent of NNAL metabolism. 
Chemometric methods will be examined to develop potential cancer risk assessment tools 
based on recognition of patterns in the measured concentrations of these compounds.  
In the third part of the dissertation, method comparison approaches for the online 
and the offline sample extraction techniques will be investigated. Currently there is no 
clear consensus on the most appropriate acceptance criteria or study design for transfer or 
comparison of bioanalytical methods. In this part of the dissertation, a ‘fixed’ range 
acceptance criterion based on a combined consideration of method precision and accuracy, 
and the FDA bioanalytical guidance limits on precision and accuracy will be proposed. 
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Data simulations to evaluate the probabilities of a successful transfer using the proposed 
criterion will be performed. Advantages and limitations of the proposed ‘fixed’ range 
criteria will be discussed.  
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CHAPTER 2 Modified Method to Determine Urinary NNAL by Off-Line Solid 
Phase Extraction on Molecularly Imprinted Polymeric Cartridges and LC-MS/MS 
Drawn from manuscript published in J. Chromatogr. B (2009) 877: 1575-1582 
 
2.1. Introduction  
A number of clinical studies measuring tobacco specific nitrosamine NNAL and 
the NNAL-Glucuronide conjugate (NNAL-Gluc) in human urine have been carried out as 
seen from Table 1 and Table 2 in Chapter 1. These studies indicate that free and total 
NNAL (i.e. free NNAL along with its glucuronide detoxification products) concentrations 
in urine are often in the pico-molar range. Such low concentrations of NNAL in human 
urine require very sensitive and selective methods. At the same time, it is desired that these 
methods be easy to implement. GC-TEA and LC-MS/MS are the two most commonly used 
techniques for TSNA analysis. Considering the complex sample preparation procedure and 
limited throughput of GC-TEA based assays, LC-MS/MS is becoming the method of 
choice for the analysis of TSNA compounds.  
The major disadvantage of conventional SPE sorbents, such as C18, ion-exchange 
and size-exclusion phases frequently used for sample preparation of LC-MS/MS methods 
is the lack of adequate selectivity, leading to co-extraction of matrix components with the 
target analytes. Hence additional sample preparation selectivity is usually needed before 
the final LC-MS/MS analysis. Due to the high selectivity and molecular recognition 
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ability, molecularly imprinted polymer (MIP) - solid phase extraction provides a powerful 
analytical tool which is capable of solving many problems occurring in the analysis of 
complex samples. The application of these synthetic polymers as sorbents allows not only 
pre-concentration and cleanup of the sample but also selective extraction of target analytes. 
This is important, particularly for complex biological sample matrices. MIPs are 
synthesized by two methods – covalent and non-covalent. The non-covalent approach is 
the most frequently used method of preparing MIPs. In this approach, a template molecule 
is mixed with monomers and cross-linkers in a suitable solvent prior to initiation of the 
polymerization. Frequently used functional monomers include methacrylic acid, 2- and 4-
vinylpyridines, trifluoromethylacrylic acid, acrylamide and hydroxyethylmethacrylate. 
Common cross-linkers include ethylene glycol dimethacrylate, divinylbenzene and 
trimethylolpropane trimethacrylate. Maximal efficiency of imprint formation occurs when 
the polymerisation reaction is performed using non- to moderately polar and aprotic 
solvents such as toluene, dichloromethane, chloroform, etc. (Andersson, 2000). For the 
non-covalent approach, complexes mainly rely on electrostatic, hydrogen bonding, van der 
Waal forces, π–π and hydrophobic interactions. The polar nature of these interactions 
between the templates and monomers make it difficult to apply MIPs directly to aqueous 
samples. Recently a few studies have reported the use of polar and protic media, such as 
methanol, ethanol and even water, for the synthesis of MIPs targeted for compounds able 
to develop strong electrostatic interactions (Pichon, 2007). For aqueous matrices, it 
becomes important for initial removal of analyte from the matrix and binding to the MIP 
cavity. The affinity of MIP binding sites prepared using the non-covalent approach is 
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generally weaker and heterogeneous compared to those prepared using covalent methods 
which result in more homogenous binding sites. However, the ease of preparation and 
better kinetics make non-covalent imprinting the technique of choice for MIP synthesis 
(Pichon, 2007). 
In order to improve the selectivity of solid phase extraction, Xia et al., 2005 have 
developed a method for the analysis of NNAL in urine by extraction on a molecularly 
imprinted polymeric (MIP) SPE cartridge followed by LC-MS/MS analysis. The MIPs 
were synthesized using non-covalent methodology. In order to avoid background 
interference for low-concentration analyses such as NNAL, the authors avoided the use of 
NNAL as the MIP template. Despite extensive washings, the MIPs may retain some 
template molecules, which may bleed during the extraction process causing background 
interference leading to false positive results. Instead, the authors used the commonly 
followed practice of utilizing structural analogues as MIP templates (identity of the 
structural analogue of NNAL used for MIP synthesis is not revealed in the publication, 
however). The choice of appropriate functional monomer is also essential in preparing a 
selective MIP as it provides specific non-covalent interaction complementary to particular 
chemical moieties of the functional group. It should also contain a polymerisable entity in 
its structure. Methacrylic acid which has a carboxylic acid group is capable of acting as a 
proton donor and a receiver. It is the most extensively used functional monomer in MIP 
production, and was also used by Xia et al., 2005 for the synthesis of MIPs specific to 
NNAL. It can therefore play the role of complementary group to the basic and acidic 
functional groups of the template molecule. Also, the authors used trimethylpropane 
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trimethacrylate as the cross-linking monomer. The extraction of NNAL on the MIP sorbent 
was comprised of a conditioning step, followed by loading of the urine sample, a wash step 
to remove interfering compounds and finally elution of NNAL by using a solvent capable 
of developing interactions with the sorbent to displace the analyte from the MIP bed.  
Despite the enhanced selectivity offered by MIPs in sample extraction, it has been 
reported that matrix components may still be present after sample extraction (van Hout et 
al., 2003). The selectivity of the MS step may eliminate the signals of co-eluting 
components, but their presence in the eluate may still cause ion suppression or 
enhancement, also known as matrix effects. Matrix effects are proportional errors of slope 
which affect the calibration curve of a method (Karnes et al., 1991). This may result in the 
loss of reliability and accuracy of the obtained data. Matrix effects mainly occur when 
endogenous matrix components co-elute with the analyte of interest, thus altering its 
ionization efficiency. The exact mechanism of matrix effects is uncertain, but is likely due 
to competition reactions between an analyte of interest and the co-eluting matrix 
component (Matuszewski et al., 2003, Taylor, 2005). Mechanistically, matrix effects are 
generally thought to be caused by either a physical or chemical interaction of the analyte 
with some components of the matrix. Charge transfer or proton transfer reactions between 
analyte molecules and matrix components are such common forms of interactions (Figg 
and McLeod, 2004). These interactions are as shown below: 
Charge Transfer: A+ + M  M+ + A 
Proton Transfer: AH+ + M  MH+ + A 
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where A+ and AH+ represent charged and protonated analyte species, while M+ and MH+ 
represent charged and protonated matrix components. A and M represent the 
corresponding uncharged or unprotonated forms. These reactions lead to ion suppression 
matrix effects. Such an interaction is mediated through an interaction constant which 
results in a proportional relationship of matrix effects to concentrations. Other causes of 
ion suppression with electrospray ionization involve a decrease in evaporation of the 
solution or an increase in surface tension due to high concentrations of matrix compounds 
(Fu et al., 1998; King et al., 2000). An alternative pathway is binding to and/or co-
precipitation of the analyte with nonvolatile matrix species (King et al., 2000). When ion 
suppression occurs, it can lead to decreased response of analyte measured in matrix 
compared to non matrix analysis. The sensitivity and lower limit of quantification of a 
method may in turn be adversely affected (Buhrman et al., 1996).  
Although the FDA guidance does not specify any particular test for matrix effects, 
evaluating and reducing matrix effects in LC/MS/MS methods is an important aspect in the 
development of bioanalytical method. The two main techniques used to determine the 
degree of matrix effects are post-extraction addition and post-column infusion (PCI) 
(Matuszewski et al., 2003; Bonfiglio et al., 1999). The post-extraction addition technique 
involves comparing the signal from the analyte in a neat solution with the signal of analyte 
added to an extracted matrix sample. The difference in response between the post-
extraction sample and the neat solution determines the degree of matrix effect. The main 
benefit of this technique is that it provides a quantitative assessment of matrix effects. 
However, a limitation of this technique is that it only provides information about matrix 
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effects at the point of elution of the analyte of interest, and not throughout the 
chromatographic run. On the other hand, the most important advantage of the PCI 
technique is that it enables investigation of the influence of the matrix on analyte response 
over the entire chromatographic run. The PCI technique uses an infusion pump to deliver a 
constant flow of analyte into the HPLC mobile phase at a point after the chromatographic 
column and before the mass spectrometer ionization source. A sample extract (without 
added analyte) is injected under the desired chromatographic conditions and the change in 
response from the infused analyte is recorded. Any endogenous compound that elutes from 
the column and causes a variation in ESI response of the infused analyte is seen as a 
suppression or enhancement in the response of the infused analyte. The limitation of this 
approach is that it only provides a semi-quantitative picture of the level of matrix effect 
observed for specific analytes. Another approach involves individual monitoring of 
suspected matrix components capable of causing unwanted matrix effects (Chambers et al., 
2007, Ismaiel et al., 2007). 
The use of stable isotope labeled internal standards is best suited to correct for 
matrix effects and to improve both the accuracy and precision of analytical methods 
employing LC-MS/MS. Stable isotope labeled internal standards are compounds in which 
several atoms in the analyte are replaced by their stable isotopes such as 2H (D), 13C, 15N or 
17O. These compounds typically shows identical behavior to the analyte of interest in terms 
of sample extraction, chromatography, as well as in ionization (Van Eeckhaut et al., 2009). 
Since the stable isotope labeled internal standard co-elutes with the analyte, the relative 
ionization efficiency of both the analyte and the internal standard remains unaffected. 
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Thus, matrix effects can be adequately compensated by the use of stable isotope labeled 
internal standards. However, use of internal standards may not fully solve the problems 
associated with matrix effects, especially if ion suppression significantly reduces the 
analyte or internal standard signal. In order to obtain a robust HPLC-MS/MS method, there 
is therefore a need to remove or minimize the presence of compounds that cause matrix 
effects.   
An aim of the current work was to investigate ionization suppression in the method 
to determine urinary NNAL by solid phase extraction using molecularly imprinted 
polymers combined with LC-MS/MS. This important aspect of bioanalytical method 
development which can often compromise assay performance and sensitivity was not 
investigated by Xia et al., 2005. In spite of this, the authors were able to analyze low 
pg/mL concentrations of NNAL. When we tried to reproduce the method published by Xia 
et al., 2005 in our laboratory, we found that the sensitivity of the method was much lower, 
however. This did not allow detection of low pg/mL concentrations of NNAL. This 
indicated possible matrix effects. Matrix effect can vary with different lots and/or sources 
of biofluids (Matuszewski et al., 2003). Possibly matrix effects were not a problem in the 
original publication. However, ion suppression was present when we tried to reproduce the 
published method. The original method was modified to address ion suppression in order 
to achieve improved sensitivity of the assay. Also, sample throughput of the published 
method was limited by a tedious and time consuming solid phase extraction on a vacuum 
manifold. The HPLC column used in the method could maintain a stable back pressure for 
only a limited number of injections. Thus the ruggedness of the published method needed 
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improvement. Throughput was addressed by using centrifugation in the extraction 
procedure which significantly reduced extraction time. Finally, the method was validated 
according to the FDA guidance for bioanalytical method validations and used for real 
sample analysis. 
 
2.2. Experimental 
2.2.1. Chemicals and Reagents 
NNAL (C10H15N3O2, MW =209.25) (Figure 5) and 4-(methyl-d3-nitrosamino)-1-(3-
pyridyl)-1-butanol (i.e. d3-NNAL) (C10H12D3N3O2, MW=212.16) (Figure 5) were purchased 
from Toronto Research Chemicals (Toronto, ON, Canada). High purity water was obtained 
in-house using a Nanopure Diamond water system from Barnstead International (Dubuque, 
IA, USA). High purity methanol, acetonitrile, dichloromethane and toluene were obtained 
from Burdick and Jackson (Muskegon, MI, USA). Acetic acid was procured from Curtin 
Matheson Scientific Inc. (Houston, TX, USA). Formic acid was obtained from EMD 
Chemicals Inc. (Gibbstown, NJ, USA). Blank as well as smokers human urine were 
obtained from BioChemed Services (Winchester, VA, USA), Type H1 β-glucuronidase 
and ammonium dihydrogen phosphate was obtained from Sigma Aldrich (St.Louis, MO, 
USA). 
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Figure 5: Chemical structures of (A) NNAL and (B) d3-NNAL 
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2.2.2. Materials 
Urine samples were aliquoted into 15 mL flip-top plastic centrifuge tubes obtained 
from Nalge Nunc International (Rochester, NY, USA). SupelMIP – SPE NNAL MIP 
cartridges provided by Supelco (Bellefonte, PA, USA) were used for solid phase extraction 
using an Allegra X-15R centrifuge from Beckman Coulter (Fullerton, CA, USA). Solid 
phase extraction was carried out in the centrifuge using size 16 x 125 mm borosilicate 
glass culture tubes and 16 x 114 mm borosilicate conical centrifuge tubes with snap cap 
rims obtained from VWR International (West Chester, PA, USA). Extracted samples were 
evaporated using Turbovap LC Evaporator procured from Zymark Corp. A syringe pump 
(pump # 17) from Harvard Apparatus (Holliston, MA, USA) was used for infusing NNAL 
for post-column infusion studies. 
 
2.2.3. Instrument and Analytical Conditions 
A Shimadzu (Shimadzu, Kyoto, Japan) chromatographic system was used in the 
study. The HPLC system consisted of a Shimadzu system controller SCL-10A VP, pumps 
LC-10AD VP, solvent degasser DGU14A. The auto-sampler HTS PAL from CTC 
Analytics (Zwingen, Switzerland) and a CH-30 column heater from Eppendorf (Westbury, 
NY, USA) were used. The HPLC column was a Phenomenex (Torrance, CA) Gemini C-18 
analytical column (100 mm x 2.0 mm I.D., 3.0 μm) with the adoption of an gradient 
elution mode (see Table 3) using two mobile phases, (A) 10 mM ammonium formate 
buffer (pH 6.1 adjusted with formic acid) and (B) acetonitrile. A Phenomenex C18 guard 
column (4.0 mm x 2.0 mm) was used to extend life of the analytical column. The mobile  
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Table 3: Modified gradient time-table for mobile phase 
Time (min) Mobile Phase A (%) Mobile Phase B (%) 
   
0.00 90 10 
3.00 60 40 
4.50 60 40 
4.70 90 10 
6.50 90 10 
Mobile phase A: 10 mM ammonium formate buffer (pH 6.1 adjusted with formic acid) 
Mobile phase B: Acetonitrile  
   
 60 
phase was delivered at 0.5 mL/min and the column temperature was maintained at 55 ˚C. 
The injection port was washed in between runs with 50% methanol. The mass 
spectrometer was Micromass Quattro LC triple quadrupole mass spectrometer from Waters 
Corporation (Milford, MA, USA) with data acquisition software MassLynx version 4.1 
installed on an IBM Lenovo ThinkCenter computer. The data analysis was performed 
using the QuanLynx processing software that accompanies MassLynx.  
 
2.2.4. Mass Spectrometric Conditions 
The mass spectrometer was operated in the positive electrospray ionization (ESI) 
mode with multiple reaction monitoring (MRM). The mass spectrometer parameters were 
tuned and optimized to achieve maximum sensitivity. The desolvation temperature was 
maintained at 450 ˚C, and the source block temperature was maintained at 145 ˚C. The ion 
spray voltage and multiplier voltage were fixed at 3.20 kV and 700 V, respectively. The 
mass spectrometer was equipped with an Edwards E2M30 two stage rotary vacuum pump 
(Edwards, UK). Liquid nitrogen from Airgas National Welders (Charlotte, NC, USA) was 
used as nebulizer and desolvation gas source with flow rates of 95 L/hr and 600 L/hr, 
respectively. NNAL and NNAL-d3 eluted at approximately 1.85 minutes and were assayed 
by quantifying the MRM transition of [M + H]+ ion of NNAL at m/z 210.1  180.2 and 
d3-NNAL at m/z 213.0  183.2 respectively. The transitions for the analyte and the I.S. 
were investigated for the presence of ion cross-talk. Absence of cross-talk was verified by 
infusing a 100 ng/mL methanolic solution of one compound and confirming the absence of 
the other transition, and vice versa. 
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2.2.5. Stock Solution Preparation and Stock Dilution 
A standard stock solution of 10 mg/mL of NNAL was prepared in methanol and 
stored at -20 ˚C. A series of standard working solutions was then obtained by appropriately 
diluting the standard stock solution of NNAL with water. Internal standard stock solution 
at 1 mg/mL was prepared in methanol and stored at -20 ˚C. Internal standard working 
solution was prepared at a concentration of 50 ng/mL by appropriately diluting the internal 
standard stock solution in water. Both NNAL and internal standard working solutions were 
prepared immediately prior to spiking into the urine. 
 
2.2.6. Preparation of Calibration Standards and Quality Control Samples  
Three lots of analyte-free human urine (obtained from non-smokers) were thawed 
and pooled to provide the matrix for the study. Appropriate volumes of the working 
solutions of NNAL were spiked into the urine to obtain calibration curve standards 
spanning a range of 20 to 2500 pg/mL. Calibration standards were prepared freshly before 
each analytical run. In a similar fashion, quality control samples representing limit of 
quantitation (LOQ) quality control (QC), low (LQC), medium (MQC) and high (HQC) 
quality controls were prepared at 20, 60, 400 and 2000 pg/mL, respectively. A dilution QC 
sample above the upper limit of quantitation was prepared at a concentration of 10 ng/mL. 
All of the calibration standards as well as the QC samples contained less than or equal to 
5% (v/v) of the working solution in order to simulate real samples as much as possible. 
The QC samples were divided into replicate aliquots of 5.5 mL each, and stored at -20 ˚C 
until analysis. 
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2.2.7. Sample Preparation 
The sample preparation procedure was modified from the originally published 
method (Xia et al., 2005). A scheme depicting sample preparation steps in shown in Figure 
6. Urine samples were thawed at room temperature. This method was used for the 
determination of both free and total NNAL. A 5 mL urine aliquot was required in either 
case to which 20 μL of internal standard working solution (50 ng/mL) was added. For total 
NNAL analysis, the urine aliquot fortified with internal standard was mixed with 5 mL of 
50 mM pH 6.4 ammonium dihydrogen phosphate buffer (NH4H2PO4.2H2O). To this, 0.5 
mL of 20,000 units/mL β-glucuronidase solution was added and the mixture was incubated 
at 37 ˚ C for 48 hours. For free NNAL analysis, the urine aliquot was adjusted to pH 6 -7 
using acetic acid. The samples were then centrifuged at 3000 r.p.m for 15 minutes. The 
solid phase extraction was performed in a centrifuge. The MIP cartridges were set onto 16 
x 125 mm culture tubes which were used to collect the eluted liquid components. The 
cartridge-tube combinations were then loaded onto the centrifuge. Table 4 shows the 
optimized centrifugation conditions for the various extraction steps. The MIP cartridges 
were primed by applying 1.0 mL aliquots of dichloromethane, methanol and water in that 
order. Urine samples were then loaded onto the cartridge taking care that the packing 
material does not dry prior to loading the sample. The wash step to elute potential 
interferences while retaining the analytes comprised of two 1.0 mL aliquots of deionized 
water. This was followed by a drying step by centrifugation at a relatively high centrifugal 
force to remove residual moisture from the cartridge. The rinsing was continued with 1.0 
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Total NNAL 
analysis 
5 mL urine aliquot 
Add 20 µL internal standard 
Add 5 mL pH 6.4 
ammonium dihydrogen 
phosphate buffer 
+ 
0.5 mL of 20,000 units/mL 
β-glucuronidase solution 
Free NNAL 
analysis 
Incubate for 48 hrs at 
37 oC 
Adjust pH to 7.0 
SPE carried out in centrifuge 
using MIP cartridges as per 
steps depicted in Table 4 
Evaporate samples to dryness 
Reconstitute with 100 µL 
mobile phase and inject 20 
µL on to the MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Scheme showing sample preparation steps of the modified method 
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Table 4: Centrifugation conditions for sample preparation 
Step Solvent Aliquot size 
(mL) 
RPM Time 
(mins) 
     
Priming Dichloromethane 1 200 3 
 Methanol 1 200 3 
 Water 1 200 3 
     
     
Loading Urine Sample 5 200 10 
     
     
Washing Water 1 200 3 
 Water 1 200 3 
                                                                            Drying 1500 10 
  Toluene 1 800 6 
 Toluene: dichloromethane (9:1 v/v) 1 700 3 
 Toluene: dichloromethane (4:1 v/v) 1 500 3 
                                                                            Drying 1500 2 
     
     
Elution Dichloromethane: methanol (9:1 v/v) 1 350 5 
 Dichloromethane: methanol (9:1 v/v) 1 200 5 
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mL aliquots of toluene, toluene: dichloromethane mixture (9:1 v/v) and toluene: 
dichloromethane (4:1 v/v), respectively.Low polarity solvents such as toluene and 
dichloromethane were used in order to suppress the nonspecific interactions without 
disrupting the selective interactions between the MIP cavity and the target analyte. Drying 
was repeated, and the collection tubes were appropriately replaced upon reaching volume 
capacity. Elution of the analytes was then performed using two 1 mL aliquots of 10% 
methanol in dichloromethane. The 16 x 125 mm culture tubes were replaced by 16 x 114 
mm conical centrifuge tubes to collect the eluted analytes. Samples were evaporated to 
dryness using a TurboVap evaporator at 48 ˚C for 17 minutes under a gentle stream of 
nitrogen at 20 psi. The residue was reconstituted in 100 μL of mobile phase A, and 
transferred to 150 μL silanized glass inserts for analysis. The injection volume was 20 μL. 
 
2.2.8. Matrix Effects Analysis 
In order to investigate matrix effects associated with the modified method, a post-
column infusion study was conducted as described by Bonfiglio et al., 1999. A 100 ng/mL 
solution of NNAL was prepared in mobile phase A. It was continuously infused at 10 
μL/min post HPLC column into the mass spectrometer using a “tee” connection. The post-
column infusion setup is depicted in Figure 7. Upon stabilization of the baseline response, 
a processed blank urine sample was injected. The matrix effect was investigated from the 
resulting profile for any change in the ESI response of NNAL. The absolute matrix effect 
for the current method was also assessed using the method suggested by Matuszewski et 
al., 2003. This was done by comparing the peak areas of processed blank urine samples  
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Figure 7: Schematic diagram of the post-column infusion experimental arrangement 
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post-spiked with low, medium and high QC concentrations of NNAL to the peak areas of 
dilutions of aqueous NNAL stock solution prepared at equivalent concentrations. 
 
2.2.9. Validation 
The method validation was performed according to FDA guidelines for 
Bioanalytical Method Validation (US Food and Drug Administration, 2001). Validation 
runs containing calibration standards in duplicate, blank samples, blank sample spiked with 
internal standard, and replicates of QC samples were run on three separate days. 
 
2.2.9.1. Linearity and LLOQ 
Seven calibration standards having concentrations of 20, 50, 100, 250, 500, 1000 
and 2500 pg/mL were prepared in duplicate in pooled blank human urine. For the 
determination of NNAL concentration, a 1/x weighing was employed for the linear 
regression of the ratio of the peak area response of NNAL and internal standard versus 
concentration. For each calibration curve, the back-calculated standard concentrations must 
be within 15% deviation from the nominal value (DFN) with RSD < 15% except at LOQ, 
where it can be within 20% DFN and RSD < 20%. The lower limit of quantitation (LLOQ) 
was the concentration of NNAL at which the analyte response was at least 5 times the 
signal to noise ratio of the blank response, with accuracy and precision as stated above.  
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2.2.9.2. Accuracy and Precision 
Accuracy and precision were determined from the QC samples for three different 
validation runs. The concentrations of the QC samples were calculated from the calibration 
curves analyzed in the same run. A criterion of ±15% of the nominal concentration was 
used to assess accuracy (±20% for LOQ), while precision expressed as %RSD should not 
exceed 15% (20% for LOQ). Both intra- and inter-assay accuracy and precision were 
determined. Dilution controls at a level of 10 ng/mL were prepared to evaluate the 
capability of accurately diluting a sample having a concentration above the upper limit of 
quantitation (2500 pg/mL). These controls were analyzed in triplicate in each run with a 
1:10 dilution in blank human urine to obtain an effective nominal concentration of 1000 
ng/mL.  
2.2.9.3. Selectivity 
 Six different lots of blank urine were used to assess selectivity. Each individual lot 
was processed and analyzed as per the procedure described earlier. For the method to be 
selective, areas of peaks co-eluting with NNAL should be less than 20% of the peak area 
of the LOQ sample of NNAL for all the six lots of blank urine. This would ensure that the 
endogenous urine components do not interfere with the assay. 
 
2.2.9.4. Recovery and Carryover 
             Recovery or the extraction efficiency of NNAL from the urine after the extraction 
procedure was determined as follows. Urine samples were spiked with NNAL at the three 
QC concentrations (60, 400, 2000 pg/mL). These samples were compared with urine 
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samples spiked post-extraction with equivalent final concentrations of NNAL. The ratio of 
the peak area response of the pre-spiked and the post-spiked samples would then determine 
the recovery of NNAL from urine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 Sample carryover was assessed by injecting a reconstitution blank immediately 
following a HQC sample (2000 pg/mL) injection at the end of the run. The acceptance 
criterion for carryover was ≤20% of the LLOQ. Sample carryover during the run was also 
assessed by injecting a HQC sample immediately followed by a LQC sample six times and 
was evaluated for any bias. Lack of carryover was considered acceptable if the bias was 
within 15% of the LQC concentration.  
 
2.2.9.5. Stability 
 The stock solution stability for NNAL was determined during storage and 
processing. The stock solutions were considered stable if the concentration of NNAL was 
within ±5% of the original concentration. Stability experiments in human urine were 
performed at least two QC concentrations (60 pg/mL and 2000 pg/mL) in triplicate. The 
stability in urine was assessed during storage and after three freeze-thaw cycles at -20 ˚C 
with at least 24 hours in between two cycles. These freeze-thaw QC samples were then run 
against freshly prepared calibration standards. The bench-top stability at room temperature 
was assessed in urine for 7 hours to cover for the processing time of the samples. The post 
preparative stability or the auto-sampler stability was assessed from re-injection 
reproducibility after storage of the samples in the auto sampler for 36 hours at 6 ˚C. The 
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samples were considered to be stable in urine if the concentration of NNAL was within 
±15% of the nominal concentration for the QC samples tested.  
 
2.2.9.6. Incurred Sample Analysis 
Incurred urine samples from smokers were purchased from BioChemed Services 
(Winchester, VA, USA). Samples were obtained from ten male African American 
smokers. The average number of cigarettes smoked per day as reported by the smokers 
ranged from 20 to 50. The 24 hour urine samples were used for analysis. 
 
2.3.   Results and Discussion 
 
2.3.1. LC-MS/MS 
Precursor and product ions were selected by infusing 500 ng/mL solutions of 
NNAL and internal standard into the mass spectrometer in the 5-500 m/z range. The best 
intensity for the [M+H]+ ions for NNAL at m/z 210.1 and [M+H]+ ions for NNAL-d3 at 
m/z 213.0 was found in the positive polarity mode using electrospray ionization. The 
analytical transitions at m/z 210.1  180.2 for NNAL and m/z 213.0  183.2 for NNAL-
d3 were selected since they were the most abundant transitions as also reported by a 
previous study (Byrd and Ogden, 2003). Optimization of the desolvation temperature and 
the API gas flow was critical in achieving maximum sensitivity. It was observed that the 
sensitivity decreased as the gas flow dropped below 600 L/hr. The desolvation temperature 
was adjusted to 450 ˚C. Minor changes in the ion spray voltage did not affect signal 
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intensity and was set at 0.32 kV. The dwell time was set at 0.2 seconds, and no cross-talk 
was found between the two MRM channels. 
 Chromatographic analysis of the analytes and internal standard was attempted on a 
variety of columns such as the XTerra MS C18 (used in the original method), Ascentix 
Express C18, Polaris C8 and C-18, and Gemini C18. A gradient using a combination of 
ammonium formate buffer and acetonitrile was optimized to produce the best sensitivity, 
efficiency and peak shape. Column life was one of the biggest challenges encountered. The 
accumulation of strongly retained material on an HPLC column can dramatically reduce its 
lifetime.  By modifying the packing surface, these retained materials can cause shifts in 
peak retention, loss of resolution, and efficiency, as well as degradation of peak shape. The 
Gemini C-18 analytical column (100 mm x 2.0 mm I.D., 3.0 μm) was found to have the 
best column life. It also provided good peak shape and response as seen in Figure 8. 
Whereas some of the other columns clogged leading to high back pressure with as few as 
35 to 40 injections, the Gemini C18 column was stable after more than 350 injections. A 
Phenomenex C18 guard column (4.0 mm x 2.0 mm) was employed to extend the life of the 
analytical column. A mobile phase comprised of 10 mM ammonium formate (pH 6.1) and 
acetonitrile with the gradient conditions as depicted in Table 3 was found to be most 
suitable. The analyte and internal standard eluted at 1.8 minutes, with a run-time of 6.5 
minutes. 
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(A)             (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) 
Figure 8: Representative chromatograms of (A) 
blank urine (B) blank urine spiked with IS at 250 
pg/mL and (C) Urine spiked with NNAL at LLOQ 
of 20 pg/mL and IS at 200 pg/mL. (MRM 
transitions 210.1180.2 and 213183.1 
corresponds to NNAL and d3-NNAL respectively). 
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2.3.2. Sample Preparation 
The sample preparation was adapted from the previously reported method by Xia et 
al., 2005 that employed molecularly imprinted polymer column extraction and LC/MS/MS. 
The method was modified and improved for analysis using a relatively low sensitivity 
mass spectrometer, the Waters Quattro LC as compared to the PE Sciex API 4000 mass 
spectrometer used in the published paper. Considering the urine aliquot of 5 mL, it was not 
possible to use common automated SPE systems which are limited by their low volume 
handling capacities and would require multiple transfers. A vacuum manifold was initially 
evaluated for sample extraction although the limited number of sample ports on a typical 
manifold and highly uneven elution rates led to impaired throughput. We therefore utilized 
a centrifuge which could accommodate as many as 76 samples for the solid phase 
extraction. All the steps for extraction on the centrifuge are summarized in Table 4. The 
revolutions per minute (RPM) and the centrifugation times were adjusted to obtain optimal 
elution flow rates. The column drying step between the water and toluene wash was very 
important and required a very high RPM (1500 RPM) to ensure a completely dry column 
in order to prevent clogging due to the water-toluene immiscibility.  
Xia et al., 2005 had used β-glucuronidase type IX-A from E.coli for conversion of 
the glucuronide conjugate to the free form. For the current assay, β-glucuronidase type H1 
from H.Pomatia was used. This is another common source of β-glucuronidase employed in 
enzyme hydrolysis reactions, and was preferred over the E.coli source due to its lower cost. 
In order to ensure complete conversion of the glucuronide using β-glucuronidase type H1, 
a time course of the NNAL-Gluc hydrolysis reaction at 37 ˚C was studied. The results of 
   
 74 
the study are shown in Figure 9. The x-axis represents the time in hours for the various 
sampling intervals for which the reaction was carried out. The y-axis represents the 
percentage of maximum conversion. Three different lots of urine from smokers were 
subjected to the enzymatic reaction. As can be seen from the graph, the reaction appears to 
be complete by 24 hours, but was carried on for 48 hours in order to ensure maximum 
yield. The error bars in this graph represent the standard error of the mean measurement. 
Some of the modifications in the extraction procedure are as listed in Table 4. An 
extra washing step comprised of toluene: dichloromethane (4:1) was introduced to yield 
cleaner extracts.   The final reconstitution volume reported in the original method by Xia et 
al., 2005 was 20 μL with an injection volume of 10 μL. Experiments with other 
reconstitution and injection volumes were performed for this method. One would expect 
response to decrease as the sample is diluted. However, the response was almost three 
times greater when the sample was reconstituted in 100 μL of mobile phase with a 20 μL 
injection volume. This increase in response may be due to a dilution of the matrix effect as 
the final reconstitution volume is increased. Thus, in the current method, the residue was 
reconstituted after evaporation with 100 μL of the mobile phase with an injection volume 
of 20 μL. This also has an added advantage of providing enough sample for multiple 
injections if necessary. 
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Figure 9: Time course of NNAL-Gluc hydrolysis reaction 
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2.3.3. Matrix Effects 
 The results of the post column infusion study for the original method when 
reproduced in our laboratory and the current modified method are shown in Figure 10A 
and Figure 10B, respectively. Figure 10A(i) and Figure 10B(i) show the ion profiles when 
a 100 ng/mL solution of NNAL is infused into the mass spectrometer. Figure 10A(ii) and 
Figure 10B(ii) show the ion profiles upon injecting a processed blank sample. Figure 
10A(iii) and Figure 10B(iii) show the retention time for the analytes (500 pg/mL NNAL 
spiked in urine). It can be observed that reproduction of the original method resulted in 
more than 30% ion suppression at the retention time of the analyte. The inherently more 
sensitive mass spectrometer used in the original publication allowed for the lower limits to 
be detectable despite the ion suppression. 
In order to overcome the ion suppression, chromatographic conditions were 
modified and the additional wash step was included. The post column infusion experiments 
for the current method (Figure 10B) resulted in a relatively low amount (approximately 
25%) of ionization enhancement at the retention time of the analyte. Comparison of the 
results for the two methods shows a 25 fold improvement in response for NNAL. This 25 
fold improvement in response resulted from overcoming ion suppression as well as a 
possibly improved analyte desolvation and ionization leading to an enhanced response in 
MS detection with the modified chromatographic conditions.   
Ionization enhancement was further confirmed using absolute matrix effect results 
by comparing the mean areas of post-extraction spiked samples to external solutions of the 
analyte. A positive matrix effect was observed at all three concentrations. The mean matrix  
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Figure 10: Results of post column infusion study for (A) method published by Xia et al., 2005 reproduced in the lab; (B) 
current modified method. (i) Ion profile when a 100 ng/mL solution of NNAL is infused into the mass spectrometer; (ii) Ion 
profile upon injecting a processed blank sample; (iii) Representative chromatograms showing the retention time for the 
analytes. 
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effects at the LQC, MQC and HQC were 123.3%, 124.8% and 119.3% with an overall 
mean of 122.5%. The ion enhancement did not affect the assay performance as seen in the 
validation results. The use of a stable isotope labeled internal standard compensated for 
any matrix effect variability.  
 
2.3.4. Validation Results  
2.3.4.1. Linearity 
 The peak area ratio of NNAL to internal standard in human urine was linear as a 
function of concentration over the range 20 to 2500 pg/mL. The calibration curves were 
well described with a mean correlation coefficient ≥ 0.998. A weighing factor of 1/x was 
used since the back-calculated residuals demonstrated heteroscedasticity with a 
proportional change in residuals as the concentration changed. The data are presented in 
Table 5. Accuracy calculated in terms of the percent deviation from nominal (% DFN) for 
the mean back-calculated values of the calibration standards ranged from -8.0% to 7.2%, 
while precision measured in terms of percent relative standard deviation ranged from 1.9% 
to 7.4%. The LLOQ was established at 20 pg/mL of NNAL in human urine. The LLOQ 
was reproducible with accuracy and precision within the FDA guidance acceptance criteria 
with a signal-to-noise ratio of 10. 
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Table 5: Reverse predicted residuals for NNAL standard concentrations 
NNAL concentration (pg/ml) 
 
intercept slope r2 
Run # 20.00 50.00 100.00 250.00 500.00 1000.00 2500.00         
            1 18.30 52.00 103.20 256.20 517.90 999.00 2473.50 
 
0.0055 0.00149 0.999 
 
20.10 51.10 105.70 263.50 510.90 997.20 2471.20 
    2 16.80 55.50 107.30 224.90 513.90 1009.40 2449.00 
 
0.0073 0.00146 0.998 
 
19.40 54.10 111.60 256.10 530.20 1096.30 2395.40 
    3 17.60 55.20 103.70 272.40 533.70 968.40 2599.60 
 
0.0083 0.00149 0.997 
 
18.20 49.50 107.80 279.80 559.90 944.50 2330.00 
    
            
            Mean 18.40 53.58 106.55 258.82 521.32 1014.06 2453.12 
 
0.0070 0.00148 
 SD 1.19 1.95 3.09 19.03 10.09 48.43 90.23 
  
0.00002 
 %RSD 6.49 3.64 2.90 7.35 1.94 4.78 3.68 
  
1.17030 
 %DFN -8.00 7.16 6.55 3.53 4.26 1.41 -1.88 
                            
Standard error of regression = 0.019 
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2.3.4.2. Accuracy and Precision 
 The intra- and inter-run precision and accuracy data are summarized in Table 6 and 
Table 7 respectively. The intra- and inter-run accuracies and precision were determined at 
LOQ QC, LQC, MQC and HQC.  The intra-run accuracy was within ± 5.2% (maximum 
RSD of 7.2%) for all the concentrations including the LLOQ. Also, the inter-run accuracy 
was within ±1.5% (maximum RSD of 7.2%) for all the concentrations. Thus, the method 
was both accurate and precise according to established acceptance criteria. Analysis of the 
dilution QC samples revealed that concentrations above the upper limit of quantification 
can be safely diluted up to 10 fold. The dilution QC prepared at a concentration of 10000 
pg/mL when diluted 10 fold demonstrated an intra-run accuracy of 0.11% DFN and a 
precision of 0.69% %RSD. 
 
2.3.4.3. Selectivity 
 The selectivity of the method with regard to endogenous urine components was 
evaluated in six different lots of blank human urine. No endogenous peaks at the retention 
time of NNAL and the internal standard were observed for any of the urine lots. Figure 8 
demonstrates the selectivity results with representative chromatograms of (A) blank urine 
sample, (B) blank urine lot spiked with internal standard, and (C) analyte at the LLOQ 
level (20 pg/mL). 
  
   
 81 
 
 
Table 6: Intra-run accuracy and precision data for NNAL 
 
NNAL Concentration (pg/mL) 
Run#  2000.00 400.00 60.00 20.00 
  
   
  
1 1959.40 413.00 62.10 22.90 
  1972.90 393.20 62.80 19.50 
  1960.40 403.00 64.50 21.30 
  1951.60 397.50 65.00 n.a. 
  1964.40 400.70 62.00 20.70 
  1820.20 398.10 62.30 19.20 
  
   
  
  
   
  
Mean 1938.15 400.92 63.12 20.72 
SD 58.20 6.78 1.30 1.49 
%RSD 3.00 1.69 2.07 7.19 
%DFN -3.09 0.23 5.19 3.60 
     n.a. – not available since sample was lost due to vial breakage 
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Table 7: Inter-run accuracy and precision data for NNAL 
 
NNAL Concentration (pg/mL) 
 Run# 2000.00 400.00 60.00 20.00 
  
   
  
1 1959.40 413.00 62.10 22.90 
  1972.90 393.20 62.80 19.50 
  1960.40 403.00 64.50 21.30 
  1951.60 397.50 65.00 na 
  1964.40 400.70 62.00 20.70 
  1820.20 398.10 62.30 19.20 
  
   
  
  
   
  
2 2024.10 366.30 60.50 19.20 
  2254.10 403.60 55.60 21.80 
  1869.80 431.10 55.50 20.80 
  
   
  
  
   
  
3 2006.30 396.80 61.20 20.10 
  2024.10 380.20 61.50 18.70 
  2098.00 374.60 57.90 18.00 
  
   
  
  
   
  
MEAN 1992.11 396.51 60.91 20.20 
SD 109.32 17.19 3.09 1.46 
%RSD 5.49 4.34 5.07 7.22 
%DFN -0.39 -0.87 1.51 1.00 
     n.a. – not available since sample was lost due to vial breakage 
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2.3.4.4. Recovery and Carryover 
The mean recoveries of NNAL from human urine determined at the LQC, MQC 
and HQC concentrations were 32.7%, 30.14% and 43.09% respectively. The mean 
extraction recovery is 35.33% for the current extraction protocol. No detectable carryover 
in the analysis of NNAL was observed. 
  
2.3.4.5. Stability 
 The stock solution of the analyte prepared in methanol and stored at -20˚C was 
stable over a period of four months. The mean difference between the concentrations of 
NNAL analyzed over this time period was 4.73%. The stability tests performed indicated 
no significant degradation under the conditions of freeze-thaw test, bench-top stability and 
post-preparative stability. The results of stability analysis are provided in Table 8. This 
confirmed the overall stability of NNAL in the urine matrix under frozen conditions, assay 
processing and freeze-thaw conditions. The long term storage stability experiments were 
not performed as it is reported in the literature that NNAL is stable in frozen urine samples 
stored at -20 ˚C for up to four years as demonstrated by Yuan et al., 2009.  
 
2.3.4.6. Incurred Sample Analysis 
 The results of the smoker’s urine analysis are summarized in Table 9. Two subjects 
had unconjugated NNAL concentrations below the LOQ while one subject had a total-
NNAL level below the LOQ. The mean concentrations of NNAL and total-NNAL for the 
remaining subjects were 89.5 pg/mL and 101.2 pg/mL respectively. The ratio of total-
NNAL to free NNAL ranged from 1.7 to 3.1 for these smokers. This outcome is 
comparable to values reported in the literature (Hecht et al., 1999).  
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Table 8: Post-preparative, freeze-thaw and bench-top stability data for NNAL 
Stability NNAL Concentration (pg/mL) 
(n=3) 2000.00 400.00 60.00 
Post-Preparative – 36 hours       
   
 
Mean 2032.93 407.87 64.33 
SD 23.57 16.34 0.15 
%RSD 1.16 4.01 0.24 
%DFN 1.65 1.97 7.22 
  
  
(n=6) 2000.00 60.00  
Freeze Thaw – 3 Cycles     
 
  
  
Mean 1826.00 53.10  
SD  28.81 2.44  
%RSD 1.60 4.60  
%DFN 8.70 11.60  
  
  
(n=6) 2000.00 60.00  
Bench-Top  - 7 hours     
 
  
  
Mean 1910.42 59.73  
SD 39.69 6.65  
%RSD 2.08 11.13  
%DFN -4.48 -0.44  
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Table 9: NNAL and NNAL-Gluc measured in Smoker’s urine 
Subject Self-reported 
Cig/Day 
Age (years) NNAL 
(pg/mL) 
Total NNAL 
(pg/mL) 
     
1 20 48 160.4 392.2 
2 20 42 101.8 193.1 
3 28 44 48.3 89.1 
4 28 31 110.8 186.8 
5 30 32 123 222.8 
6 30 39 <LOQ <LOQ 
7 30 35 64 200.3 
8 40 45 <LOQ 39.8 
9 50 48 54.6 141.8 
10 50 54 53.1 99.4 
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2.4. Summary: 
 The method published by Xia et al., 2005 described the first use of molecularly 
imprinted polymers for sample preparation in the analysis of urinary NNAL using LC/MS-
MS. However, this method did not investigate the effect of matrix effects which can 
constitute a major concern in the analysis of biological samples using ESI MS. In the 
current work, we reproduced the original assay and concluded the presence of ion 
suppression matrix effect affected the sensitivity and likely the reproducibility of responses 
of the assay. The extraction steps and chromatographic separation were modified from the 
original publication to yield a 25 fold improvement in sensitivity. This allowed 
achievement of low pg/mL detection levels of urinary NNAL on the inherently low 
sensitivity Waters Quattro LC mass spectrometer available in our lab. The analysis in the 
original publication was carried out on a more sensitive PE Sciex API 4000 triple 
quadrupole mass spectrometer. Additionally, the Gemini C18 column used in the current 
method was stable even after as many as 350 injections as opposed to the XTerra MS C18 
column described in the original publication which could not maintain a stable back 
pressure for more than 60 injections before clogging. The sample preparation time was cut 
down by almost half when the solid phase extraction was carried out by centrifugation, 
which also resulted in uniform elution rates. The selectivity of the method with regard to 
endogenous urine components was not evaluated in the original publication. Our modified 
method was demonstrated to be selective. Finally, the overall extraction efficiency 
(absolute recovery) was not reported in the original publication. Our results show that the 
recovery was 35%. 
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2.5. Conclusion 
 The determination of NNAL in human urine using MIPS coupled with LC-MS/MS 
has been accomplished using an extraction protocol and LC conditions that provided a 
more robust and sensitive method. Issues related to matrix effects and throughput have also 
been addressed and improved in the current method. This method can be used for 
quantitative analysis of low concentrations of free and total urinary NNAL in smokers. The 
validation data demonstrated excellent precision, accuracy and stability.  
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CHAPTER 3 Microfluidic Extraction of NNAL Using Molecularly Imprinted 
Polymers by Direct Injection of Urine Coupled On-Line with LC-MS/MS 
 
3.1. Introduction  
There is a constant need for reducing development and analysis times of 
bioanalytical assays. Ability to monitor biomarker concentrations is very important in 
understanding disease progression and drug development. In this sense, a large number of 
clinical trials are conducted, thereby increasing the number of samples requiring 
bioanalysis per unit time. Moreover, not only is the number of samples increasing, but also 
the time available for method development is decreasing. Apart from throughput 
requirements, most bioanalytical investigations also require analysis of biological samples 
at very low quantification levels (Evans, 2004). An important component of bioanalytical 
assays is sample extraction prior to analysis. Solid phase extraction (SPE) techniques have 
turned out to be the most preferred techniques for extraction of analytes of interest from 
biological fluids prior to quantitative analysis. SPE has many advantages compared to 
traditional liquid/liquid extraction methods, the most important being the availability of a 
wide range of sorbents which makes this technique applicable to most classes of 
compounds (Venn, 2000). Recently molecularly imprinted polymers (MIPs) have attracted 
much attention as SPE sorbents because they show promise as compound-selective or 
group-selective media (Lasakova and Jandera, 2009). Xia et al., 2005 have developed 
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MIPs for offline solid phase extraction of tobacco specific nitrosamine NNAL followed by 
LC-MS/MS analysis.  
A drawback of off-line SPE procedures is that they can be time consuming and 
cumbersome to perform, often requiring several steps prior to reaching a concentrated 
extract suitable for instrumental analysis (Bones et al., 2006). The use of on-line SPE 
techniques can enable faster method development by reducing the sample preparation time 
and thus increasing the sample throughput. Conditioning, washing and elution steps can be 
automated and performed online. The need for high throughput can be met to a great extent 
by application of an automated integrated analytical system which also includes the sample 
extraction step. Other important advantages of online sample extraction include decreased 
risk of contamination of the sample, elimination of analyte degradation in evaporation 
steps, and improved precision and accuracy (Watabe et al., 2006). Higher sensitivity is 
achievable by concentrating the sample on-column. The analysis of the whole sample leads 
to lower detection limits, and consequently smaller sample volumes may be sufficient to 
obtain enough sensitivity. Additionally, the on-line sample extraction configuration has 
been shown to reduce solvent consumption, and is thereby environmentally friendly 
(Quintana et al., 2006). The SPE sorbent can be regenerated and can be used multiple times 
unlike the single use offline SPE cartridge format (Rodriguez-Mozaz et al., 2007). Thus, 
online SPE procedures are particularly attractive for high-throughput, low-cost, low 
sample volume automated analysis. Method development for determining drug or 
metabolite concentrations from urine samples can be substantially simplified with the 
implementation of online SPE. Because of its aqueous nature and lack of protein content, 
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urine samples can be directly injected and extracted online. Barrett et al., 2005 have 
developed a sensitive method for quantitation of urinary 6β-hydroxycortisol and cortisol by 
direct injection using online SPE and LC–MS/MS. The simplest configuration for online 
sample extraction coupled to LC-MS/MS, involves a single column approach in which the 
column plays a dual role: the extraction support as well as the analytical column (Veuthey 
et al., 2004). In this configuration the column is connected to the MS detector by means of 
a switching valve. The biological sample can be directly injected onto the extraction 
support with an aqueous mobile phase. After the extraction step, the valve is switched, and 
analytes are transferred to the detector with the eluting mobile phase. Finally, the 
extraction sorbent is re-equilibrated. Different extraction sorbents allowing direct injection 
of biological fluids can be used in the online sample extraction format. These extraction 
supports or sorbents include restricted access media (RAM), large-size particle, monolithic 
material, and disposable SPE cartridges (Xu et al., 2007). These sorbents are used by 
themselves, or in conjunction with other sorbents. 
Recently, MIPs have been utilized as extraction supports for online sample 
extraction. Columns packed with MIPs have been directly coupled to liquid 
chromatography for analysis of 4-nitrophenol from river water. At least 70 river water 
samples of 10 mL volume were pre-concentrated online using the MIP column without any 
loss in performance (Masque et al., 2000). By coupling a MIP-SPE column online with a 
C18 column, triazine was separated from humic acid, reaching an enrichment factor up to 
100-fold with satisfactory recoveries (Bjarnason et al., 1999). A similar online 
configuration of a MIP coupled with HPLC and electrochemical detection has been used 
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for the analysis of bisphenol A providing concentration factors up to 1000-fold (Ou et al., 
2006). There is a significant challenge for the extraction of analytes using MIPs from 
aqueous matrices, however. When the analyte of interest is presented in an aqueous 
medium (e.g. urine), the analyte and other matrix compounds are retained nonspecifically 
on the polymer since the contribution of hydrophobic interactions increases (Qiao et al., 
2006). Consequently, to achieve a selective extraction, a washing step with a non-polar 
solvent is introduced prior to the elution step. This will enhance the analyte binding to the 
MIP cavity while washing out the matrix components. Such an effective washing step can 
easily be incorporated when the extraction is to be performed in an off-line mode using 
non- to moderately polar solvents such as toluene or dichloromethane. However, when the 
extraction of aqueous samples is to be performed in an on-line format, incorporation of 
wash solvents such as toluene or dichloromethane may pose problems, since these may not 
always be compatible with the detector (e.g. mass spectrometer). Extraction of analytes 
using MIPs in an online mode may presents considerable challenge. 
 There is a also a substantial interest in the development of miniaturized sample 
preparation methods for pre-treatment of complex biological samples. An online coupling 
of miniaturized sample preparation and micro-column separation enables the researcher to 
take advantage of features of the combined system such as high speed analysis with high 
efficiency, low cost of operation due to lower solvent consumption, and development of 
highly selective analysis through tailored systems designed for specific applications. MIPs 
are highly selective media, and present an excellent opportunity for development of 
miniaturized sample extraction in an online format. Because MIPs are man-made mimics 
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of antibodies (Sellergren, 2001) many of the principles applicable to immunoaffinity 
separation may be applicable to molecularly imprinted separations. Bead based immuno-
assays using immobilized antibodies packed in separation capillaries have been used for 
qualitative and quantitative bioanalysis. Peoples et al., 2008 have developed a capillary 
based microfluidic system to demonstrate direct capture immunoaffinity separation for C-
Reactive protein. Peoples and Karnes, 2008 were able to use microfluidic capillaries 
packed with antibody coated silica beads to capture C-Reactive protein in human serum 
and cerebrospinal fluid. Microfluidic systems typically describe movement of liquids 
through chips or capillaries with internal dimensions smaller than 1.0 mm. Microchips, 
capillary columns and connecting tubing for microfluidic devices are often made of 
polymers, fused-silica or polyetheretherketone (PEEK). Analogous to immunoaffinity 
separations, the technology of packing microfluidic capillaries can potentially be extended 
to molecularly imprinted beads. According to Buranda et al., 2002 and Verpoorte, 2003, 
separation capillaries packed with beads offer the advantage of reduced diffusion distances 
for mass transport resulting in much shorter analysis times and the ability to concentrate 
samples online in a fluidic system. Alternative technologies using monolithic molecularly 
imprinted polymers (Huang et al., 2003) or in-situ polymerization (Matsui et al., 2000) 
may have potential for miniaturization in a microfluidic format, although these might 
suffer from problems of high back pressures and low efficiencies. 
The aim of this work was to design a capillary microfluidic system employing MIP 
beads specific to the tobacco specific nitrosamine NNAL. The system was developed for 
online sample extraction combined with mass spectrometric detection to enable fast online 
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extraction and small volume injection with ability to detect low pg/mL concentrations of 
NNAL and its glucuronide conjugate metabolite in human urine. The system was 
optimized and evaluated with respect to matrix effects. The method was validated as per 
the FDA bioanalytical method validation guidance (US Food and Drug Administration, 
2001) and used for analysis of urine samples from smokers. The measured concentrations 
of NNAL and NNAL-Glucuronide were used to develop a cancer risk assessment tool.   
 
3.2. Experimental 
3.2.1. Chemicals and Reagents 
NNAL (C10H15N3O2, MW =209.25) (Figure 5) and 4-(methyl-d3-nitrosamino)-1-(3-
pyridyl)-1-butanol (i.e. d3-NNAL) (C10H12D3N3O2, MW=212.16) (Figure 5) were purchased 
from Toronto Research Chemicals (Toronto, ON, Canada). High purity water was obtained 
in-house using a Nanopure Diamond water system from Barnstead International (Dubuque, 
IA, USA). High purity methanol was obtained from Burdick and Jackson (Muskegon, MI, 
USA). Acetic acid was procured from Curtin Matheson Scientific Inc. (Houston, TX, 
USA). Formic acid was obtained from EMD Chemicals Inc. (Gibbstown, NJ, USA). Blank 
as well as smokers human urine were purchased from BioChemed Services (Winchester, 
VA, USA), Type H1 β-glucuronidase and ammonium dihydrogen phosphate was obtained 
from Sigma Aldrich (St.Louis, MO, USA). 
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3.2.2. Materials 
Urine samples were aliquoted into 15 mL flip-top plastic centrifuge tubes obtained 
from Nalge Nunc International (Rochester, NY, USA). SupelMIP – SPE NNAL 
molecularly imprinted polymeric cartridges were obtained from Supelco (Bellefonte, PA, 
USA).  
 
3.2.3. Instrument and Analytical Conditions 
A basic schematic diagram of the instrumentation is displayed in Figure 11. A 
Shimadzu (Shimadzu, Kyoto, Japan) chromatographic system was used in the study. The 
HPLC system consisted of a Shimadzu system controller SCL-10A VP, pumps LC-10AD 
VP, solvent degasser DGU14A. The auto-sampler HTS PAL from CTC Analytics 
(Zwingen, Switzerland) and a CH-30 column heater from Eppendorf (Westbury, NY, 
USA) were used. Sample extraction was performed online on a capillary micro-column 
packed with molecularly imprinted polymeric beads specific to NNAL (description about 
the construction of the MIP micro-column will be discussed in a later section). A multi-
port Cheminert switching valve and a microelectric actuator obtained from Valco 
Instruments Co. Inc. (Houston, TX, USA) was used to divert the effluent from the micro-
column during washing and elution steps. Mobile phase A was comprised of water which 
was used as the loading and wash solvent. Mobile phase B was comprised of methanol 
which was used as the elution solvent. The time-table for the mobile phase is shown in 
Table 10. The injection port and sample loop were washed in between runs three times 
with water containing 1% formic acid followed by three times with a 1:1 mixture of 
methanol and acetonitrile.   
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Switching Valve Position A 
 
 
Switching Valve Position B 
 
Figure 11: Schematic diagram of on-line sample extraction 
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Table 10: Time-table for mobile phase with on-line sample extraction 
Time 
(min) 
Mobile Phase A 
mL/min 
Mobile Phase B 
mL/min 
Valve Position 
    
0.01 0.25 0.75 A 
3.20 0.25 0.75 B 
4.51 0.25 0.75 A 
6.00 0.25 0.75 A 
Mobile phase A: Water 
Mobile phase B: Methanol   
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Initial method development was performed on a Micromass QuattroMicro triple 
quadrupole mass spectrometer from Waters Corporation (Milford, MA, USA) with data 
acquisition software MassLynx version 4.1 installed on an IBM Lenovo ThinkCenter 
computer. The data analysis was performed using the QuanLynx processing software that 
accompanies MassLynx. Later method development, validation and real sample analysis 
was performed on a 4000 QTrap hybrid triple quadrupole/ linear ion trap mass 
spectrometer from Applied Biosystems (Foster City, CA, USA) with data acquisition and 
quantitation software Analyst version 1.5 installed on an Dell Precision T3400 computer. 
 
3.2.4. Mass Spectrometric Conditions 
The mass spectrometric conditions for Waters QuattroMicro mass spectrometer are 
as follows. It was operated in the positive electrospray ionization (ESI) mode with multiple 
reaction monitoring (MRM). The mass spectrometer parameters were tuned and optimized 
to achieve maximum sensitivity. The desolvation temperature was maintained at 500 ˚C, 
and the source block temperature was maintained at 135 ˚C. The capillary voltage and 
multiplier voltage were fixed at 0.25 kV and 650 V, respectively. The cone, extractor and 
RF lens voltages were optimized at 17.0 V, 3.0 V and 0.1 V respectively. The entrance 
potential, collision energy and exit potentials were set at values of 0, 10 and 1 respectively. 
The mass spectrometer was equipped with an Edwards E2M30 two stage rotary vacuum 
pump (Edwards, UK). Liquid nitrogen from Airgas National Welders (Charlotte, NC, 
USA) was used as nebulizer and desolvation gas source with flow rates of 90 L/hr and 700 
L/hr, respectively.  
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The mass spectrometric conditions for Applied Biosystems 4000 QTrap mass 
spectrometer are as follows. It was also operated in the positive electrospray ionization 
(ESI) mode with multiple reaction monitoring (MRM). The mass spectrometer parameters 
were tuned and optimized to achieve maximum sensitivity. The desolvation temperature 
was maintained at 450 ˚C. The ion spray voltage and CEM multiplier voltage were fixed at 
5.5 kV and 2.3 kV, respectively. The de-clustering, entrance and exit potentials were set at 
values of 49, 10 and 18 respectively. The collision gas was set at high. The mass 
spectrometer was equipped with a Varian MS40+ single stage rotary vane vacuum pump 
from Varian Vacuum Technologies (Lexington, MA, UK). Nitrogen was generated using 
LCMS-5000NA TriGas generator obtained from Parker Balston (Haverhill, MA, USA). 
The curtain gas was set at 15, while the ion source gas 1 and gas 2 flow rates were set at 62 
and 20 respectively. 
NNAL and NNAL-d3 were assayed by quantifying the MRM transition of [M + H]+ 
ion of NNAL at m/z 210.1  180.2 and d3-NNAL at m/z 213.0  183.2.  
 
3.2.5. Stock Solution Preparation and Stock Dilution 
A standard stock solution of 10 mg/mL of NNAL was prepared in methanol and 
stored at -20 ˚C. A series of standard working solutions was then obtained by appropriately 
diluting the standard stock solution of NNAL with water. An internal standard stock 
solution at 1 mg/mL was prepared in methanol and stored at -20 ˚C. An internal standard 
working solution was prepared at a concentration of 10 ng/mL by appropriately diluting 
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the internal standard stock solution in water. Both NNAL and internal standard working 
solutions were prepared immediately prior to spiking into the urine. 
 
3.2.6. Preparation of Calibration Standards and Quality Control Samples  
Six lots of analyte-free human urine (obtained from non-smokers) were thawed and 
pooled to provide the matrix for the study. Appropriate volumes of the working solutions 
of NNAL were spiked into the urine to obtain calibration curve standards spanning a range 
of 20 to 2500 pg/mL. Calibration standards were prepared freshly before each analytical 
run. In a similar fashion, quality control (QC) samples representing limit of quantitation 
(LOQ) QC, low (LQC), medium (MQC) and high (HQC) quality controls were prepared at 
20, 60, 400 and 2000 pg/mL, respectively. A dilution QC sample above the upper limit of 
quantitation was prepared at a concentration of 10 ng/mL. All of the calibration standards, 
as well as the QC samples contained less than or equal to 5% (v/v) of the working solution 
in order to simulate a real sample as much as possible. For total NNAL analysis, standards 
and QC samples were subjected to enzyme hydrolysis prior to analysis using β-
glucuronidase enzyme as described later in section 0. 
 
3.2.7. Micro-column Design 
The micro-column design and construction procedure was based on a previously 
published method developed in our laboratory (Peoples et al., 2007). Micro-columns were 
constructed from polyetheretherketone (PEEK) capillary tubing of 500 μm inner diameter 
(ID) and 1/16 in outer diameter (OD) purchased from Upchurch Scientific (Oak Harbor, 
WA, USA). The choice of the PEEK tubing with 500 μm ID was governed by the 20-90 
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μm particle size distribution of the packing material. Also, 1/16 in OD is the most 
commonly used tubing size for standard, analytical LC and related techniques. The PEEK 
tubing has a pressure and temperature rating of 7000 psi and 100 ˚ C respectively. Stainless 
steel external column end-fittings and ferrules were purchased from Valco Instrument Co. 
Inc. (Houston, TX). A stainless steel 0.5 μm frit in a polymer ring (Upchurch) with 
dimensions 0.038 in x 0.030 in x 0.062 in was used to retain stationary phase material.  
The PEEK tubing ends were cut and leveled with a PEEK tubing cutter to make 
them suitable for use with a HPLC system. After installing the frit, ferrule and fittings on 
the PEEK tubing, it was wrench-tightened. One set of end-fittings and frit was then 
removed, and the other open end of the micro-column was subjected to slurry packing 
under negative pressure (approximately 600 psi maximum) using a vacuum pump. The 
slurry consisted of a 10 mg/mL suspension of molecularly imprinted polymeric beads 
obtained from the commercially available SupelMIP – SPE NNAL molecularly imprinted 
polymeric cartridges in a 1:1 mixture of water and methanol. Approximately 5 to 10 μL 
drops were added each time using a microlitre pipette. To maintain the homogeneity of the 
slurry, it was continuously rotated on a suspension mixer. A jeweler engraver was 
intermittently tapped on the sides of the microcolumn to eliminate air voids and enable 
efficient packing. The procedure was continued till beads were seen at the top of the 
column. After leveling off the beads, the frit and end-fittings were reassembled by wrench 
tightening. The micro-column was then subjected to a 0.3 mL/min flow of a 1:1 mixture of 
methanol and water using the HPLC pump. This further compressed the packing material 
and ensured packing uniformity. Next, the fittings and frit at the end of the micro-column 
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Figure 12: Components of the packed micro-column and diagram of the packing procedure 
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originally used for packing were again de-assembled. More slurry was added at the top of 
the column under vacuum to fill up any drop in packing level. Finally, the column fittings 
and frit were reinstated. Column lengths of 19 mm (smallest possible size considering end-
fitting dimensions) were packed using this procedure. Approximately 100 μL of slurry 
added drop-wise was sufficient to pack the micro-column. This corresponded to 
approximately 1 mg of packing material (based on 10 mg/mL suspension of molecularly 
imprinted polymeric beads as stated above). Thus, a 19 mm micro-column was able to 
accommodate approximately 1 mg of the packing material and could be packed in 
approximately 15 minutes. Figure 12 shows a diagram of the components of the PEEK 
micro-column packed with MIP beads specific to NNAL and the packing procedure for the 
same. 
 
3.2.8. Sample Extraction 
Sample extraction was performed on-line by direct injection of urine sample on the 
molecularly imprinted polymer micro-column followed by LC-MS/MS analysis. Urine 
samples were thawed at room temperature. The pH of the urine was checked with pH 
paper, and adjusted between pH 5 and pH 7 using 10% v/v acetic acid solution. To a 1 mL 
urine aliquot, 20 μL of internal standard working solution (10 ng/mL) was added. For total 
NNAL analysis, the urine aliquot fortified with internal standard was mixed with 1 mL of 
50 mM pH 6.4 ammonium dihydrogen phosphate buffer (NH4H2PO4.2H2O). To this, 0.1 
mL of 20,000 units/mL β-glucuronidase solution was added and the mixture was incubated 
at 37 ˚C for 48 hours. The samples were then centrifuged at 3000 r.p.m for 15 minutes, and 
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the clear supernatant was transferred to HPLC vials for direct injection. The injection 
volume was 20 μL.     
 
3.2.9. Method Optimization and Evaluation 
Studies were performed to optimize and evaluate the system in order to obtain 
maximum recovery of NNAL on the MIP micro-column. These studies included wash time 
optimization, wash step flow rate optimization, sample pH optimization, evaluation of 
column loadability and injection volume optimization. 
 
3.2.9.1. Wash Time Optimization 
To ensure that NNAL is not lost in the wash step, a wash time optimization study 
was performed. The matrix components were washed on the MIP micro-column by 
flowing water through the MIP micro-column for different time intervals at 1.2, 2.2, and 
3.2 minutes respectively. The wash time was optimized to allow maximum removal of 
matrix components without any loss of NNAL in the wash step. 
 
3.2.9.2. Wash Step Flow Rate Optimization 
To ensure that NNAL is not lost in the wash step, a wash step flow rate 
optimization study was performed. Molecularly imprinted polymers are by nature artificial 
immunosorbents. Thus, flow rate may have an effect on the retention of the analytes on the 
MIP stationary phase just as shown for immunoaffinity separations by Phillips and 
Dickens, 2000. Thus, a wash step flow rate optimization study was performed in order to 
ensure balance between adequate recoveries of NNAL while allowing maximum removal 
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of matrix components. A 30 ng/mL urine sample spiked with NNAL was injected on to the 
MIP micro-column. The MS response for different wash step flow rates studied (0.05, 0.1, 
0.25, 0.3, 0.4, 0.5 and 0.75 mL/min) was studied.   
 
3.2.9.3. pH Optimization 
Recognition of NNAL molecules on a MIP column depends on interactions based 
on hydrogen bonding and ionic and hydrophobic effects (Haginaka, 2009). Thus, the 
influence of pH on recovery of NNAL from the MIP columns was studied over a pH range 
of 2-10. The urine sample pH was adjusted with either 10% v/v acetic acid or 10% w/v 
sodium hydroxide. 
 
3.2.9.4. Column Loadability Evaluation 
The MIP micro-column loadability was evaluated in order to assess the maximum 
saturation binding. If the maximum saturation binding is reached before sufficient 
enrichment of NNAL on the MIP micro-column, the capacity of the column can be 
increased by packing longer columns. In order to evaluate maximum saturation binding, 
increasing concentrations of NNAL spiked in urine were injected on to the MIP micro-
column. A 20 μL injection volume was used. The column loadability was investigated for a 
concentration range of 10 pg/mL to 100000000 pg/mL. 
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3.2.9.5. Injection Volume Study 
In order to provide for low detection limits, the sample can be concentrated on-
column. This can be achieved by increasing the injection volume. Initial studies on the 
recovery of NNAL with increasing injection volumes were evaluated at injection volumes 
of 20, 50, 100, 140 and 190 μL.  
 
3.2.10. Evaluation of Matrix Effects  
In order to investigate matrix effects, a post-column infusion study was conducted 
as described by Bonfiglio et al., 1999. A syringe pump (pump # 17) from Harvard 
Apparatus (Holliston, MA, USA) was used for infusing NNAL for post-column infusion 
studies. A 500 ng/mL solution of NNAL was prepared in methanol. It was continuously 
infused at 10 μL/min post HPLC column into the mass spectrometer using a “tee” 
connection. Upon stabilization of the baseline response, a blank urine sample was injected 
which was subjected to extraction in the on-line format on the MIP micro-column. The 
matrix effect was investigated from the resulting profile for any change in the ESI response 
of NNAL. A 100 ng/mL solution of NNAL in urine was injected as a reference. 
 
3.2.11. Validation 
The method validation was performed according to FDA guidelines for 
Bioanalytical Method Validation (US Food and Drug Administration, 2001). Validation 
runs containing calibration standards in duplicate, blank samples, blank sample spiked with 
internal standard, and replicates of QC samples were run on three separate days. 
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3.2.11.1. Linearity and LLOQ 
Seven calibration standards having concentrations of 20, 50, 100, 250, 500, 1000 
and 2500 pg/mL were prepared in duplicate in pooled blank human urine. For the 
determination of NNAL concentration, a 1/x weighing was employed for linear regression 
of the ratios of the peak area responses of NNAL and internal standard versus 
concentration. For each calibration curve, the back-calculated standard concentrations must 
be within 15% deviation from the nominal value (DFN) with RSD < 15% except at the 
LOQ, where it can be within 20% DFN with RSD < 15%. The lower limit of quantitation 
(LLOQ) was the lowest calibration standard concentration of NNAL at which the analyte 
response was at least 5 times the signal to noise ratio of the blank response, with accuracy 
and precision as stated above.  
 
3.2.11.2. Accuracy and Precision 
Accuracy and precision were determined from the QC samples for three different 
validation runs. The concentrations of the QC samples were calculated from the calibration 
curves analyzed in the same run. An acceptance criterion of ±15% of the nominal 
concentration was used to assess accuracy (±20% for LOQ). This describes the closeness 
of results obtained by the analytical method to the true concentration of the analyte. 
Precision expressed as %RSD should not exceed 15% (20% for LOQ). This describes the 
closeness of individual measures of the analyte when the method is applied repeatedly to 
multiple aliquots of the same sample. These acceptance criteria were selected based on the 
based on the guidance for bioanalytical method validation as prescribed by the FDA (US 
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Food and Drug Administration, 2001). Both intra- and inter-assay accuracy and precision 
were determined. Dilution controls at a level of 10 ng/mL were prepared to evaluate the 
capability of accurately diluting a sample having a concentration above the upper limit of 
quantitation (2500 pg/mL). These controls were analyzed in triplicate in each run with a 
1:10 dilution in blank human urine to obtain an effective concentration of 1000 ng/mL.  
 
3.2.11.3. Selectivity 
 Six different lots of blank urine were used to assess selectivity. Each individual lot 
was processed and analyzed as per the procedure described earlier. In order to establish 
selectivity for urine samples subjected to enzymatic hydrolysis to measure total NNAL, six 
individual lots of blank urine samples were incubated with β-glucuronidase enzyme and 
processed as described in section 0. For the method to be selective, areas of peaks co-
eluting with NNAL should be less than 20% of the peak area of the LOQ sample of NNAL 
for all the six lots of blank urine. This would ensure that the endogenous urine components 
do not interfere with the assay. 
 
3.2.11.4. Recovery and Carryover 
             Recovery or the extraction efficiency of NNAL from the urine after the online 
extraction procedure was determined as follows. Urine samples were spiked with NNAL at 
the two QC concentrations (400, 2000 pg/mL) and analyzed using online extraction. These 
samples were compared with urine samples that were spiked with equivalent final 
concentrations of NNAL post extraction on a MIP cartridge in an offline format. The 
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washing and elution steps in the offline extraction were mimicked as in the online format. 
The ratio of the peak area response of the pre-spiked and the post-spiked samples were 
then compared to determine the recovery of NNAL from urine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 Sample carryover was assessed by injecting a reconstituted blank immediately 
following a HQC sample (2000 pg/mL) injection at the end of the run. The acceptance 
criterion for carryover was ≤20% of the LLOQ. Sample carryover during the run was also 
assessed by injecting a HQC sample immediately followed by a LQC sample six times and 
was evaluated for any bias. Lack of carryover was confirmed if the bias was within 15% of 
the LQC concentration.  
 
3.2.11.5. Stability 
 The stock solution stability for NNAL was determined during storage and 
processing. The stock solutions were considered stable if the concentration of NNAL was 
within ±5% of the original concentration. Stability experiments in human urine were 
performed at least two QC concentrations (60 pg/mL and 2000 pg/mL) in triplicate. The 
stability in urine was assessed during storage and after three freeze-thaw cycles at -20 ˚C 
with at least 24 hours in between two cycles. These freeze-thaw QC samples were then run 
against freshly prepared calibration standards. The bench-top stability at room temperature 
was assessed in urine for 7 hours to cover for the processing time of the samples. The post 
preparative stability or the auto-sampler stability was assessed from re-injection 
reproducibility after storage of the samples in the auto sampler for 24 hours at 6 ˚C. The 
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samples were considered to be stable in urine if concentration of NNAL was within ±15% 
of the nominal concentration for the QC samples tested.  
 
3.2.12. Real Sample Analysis 
This method was applied to the analysis of free and total NNAL in urine samples 
from 43 smokers. The smoker’s urine samples were purchased from BioChemed Services 
(Winchester, VA, USA). These were informed consent 24 hour urine samples donated by 
healthy smoking volunteers. A product data sheet accompanied the urine samples citing 
demographic information such as age, gender, race, and cigarettes smoked per day (See 
appendix for copy). These demographic details are described in Error! Reference source 
not found.. 
Because these urine samples may be subject to differences in dilution resulting 
from each individual’s state of hydration, all results were normalized by expressing 
concentrations per milligram of urinary creatinine levels. Creatinine analyses were 
performed at the Department of Internal Medicine, Division of Nephrology, Virginia 
Commonwealth University Medical Center (Richmond, VA, USA) using the Nova 
Biomedical 16 + Electrolyte/Chemistry Analyzer obtained from Nova Biomedical Corp. 
(Waltham, MA, USA). This analyzer provided a rapid and simple method based on ion 
selective electrode technology for the measurement of urinary creatinine.  
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3.2.13. Real Sample Data Analysis – Pattern Recognition and Classification 
Glucuronidation by the UDP-glucuronosyltransferase (UGT) superfamily of 
enzymes is a major mode of detoxification of NNAL in vivo (Ren et al., 2000; Wiener et 
al., 2004). Genetic variants have been identified in coding and non-coding sequences of 
 
Table 11: Demographic data for the smokers' urine samples  
Subject 
 
Gender Race Age 
 
Cig/day Subject 
 
Gender Race Age 
 
Cig/day 
          
1 Male Black 48 28 23 Male Black 49 25 
2 Male Black 42 50 24 Male Black 23 25 
3 Male Black 44 20 25 Male Black 19 25 
4 Male White 31 20 26 Male Black 35 25 
5 Male White 32 30 27 Female Black 43 25 
6 Male White 39 28 28 Male Black 21 25 
7 Male Black 35 30 29 Male Black 55 25 
8 Male Black 45 30 30 Female White 42 25 
9 Male Black 48 40 31 Male Black 45 25 
10 Male Black 54 50 32 Female White 21 25 
11 Male Black 40 25 33 Female Black 29 25 
12 Male Black 25 25 34 Female White 46 25 
13 Male Black 47 25 35 Female Black 18 25 
14 Female Black 42 25 36 Female White 26 25 
15 Male Black 32 25 37 Female White 52 25 
16 Male Black 57 25 38 Female Black 31 25 
17 Male Black 46 25 39 Female Black 19 25 
18 Male Black 33 25 40 Female Black 24 25 
19 Male Black 55 25 41 Female Black 30 25 
20 Male Black 27 25 42 Female Black 45 25 
21 Male Black 46 25 43 Female Black 32 25 
22 Male Black 56 25      
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several UGT genes, and similar observations should be anticipated for all UGTs. As 
glucuronidation plays a critical part in the inactivation or elimination of NNK-NNAL 
pathway, genetic variants in this enzyme family can lead to altered expression or activity 
of UGTs and may likely have some impact on the cancer risk of an individual (Desai et al., 
2003). In a study by Lazarus et al., 2005 it was shown that the polymorphic UGT2B17 
gene deletion was associated with significant reductions in the rate of NNAL 
detoxification in vivo. This may likely increase an individuals’ susceptibility to tobacco 
related cancers. In another study, Chen et al., 2008a studied the association between 
UGT2B10 genotypes and NNAL-glucuronidation activity in human liver microsomes. 
They found that the UGT2B1067Tyr variant corresponding to the UGT2B10 haplotype C is 
a functional single nucleotide polymorphism. This polymorphism may be responsible for 
inter-individual variation in NNAL-N-glucuronidation activity and may increase 
susceptibility to smoking related cancers. Wiener et al., 2004 characterized NNAL-N-
glucuronide formation in human liver and identified UGT1A4 as the major UGT 
responsible for this metabolic pathway. The authors speculate that variations in UGT1A4 
expression or the presence of activity-altering UGT1A4 gene polymorphisms may be a 
reason for significant inter-individual variations in the formation of NNAL glucuronide. 
As described earlier, glucuronide conjugates of NNAL have been identified in the 
urine of tobacco smokers (Carmella et al., 2002). The concentrations of free NNAL and 
NNAL-Gluc measured in the urine of smokers can be evaluated for the possible existence 
of patterns corresponding to the extent of metabolism for the NNK pathway. The existence 
of differences in the extent of NNK metabolism rates may in turn be potentially related to 
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an individuals’ susceptibility to lung cancer. In fact, findings of a recent study by Yuan et 
al., 2009 directly link NNK exposure to lung cancer development in humans. Ability of an 
individual to extensively metabolize NNK and NNAL to its glucuronide detoxification 
product may be correlated to a potentially reduced lung cancer risk. Conversely, the slight 
metabolism of NNK and NNAL to the glucuronide conjugate may possibly be related to a 
higher lung cancer risk of an individual. In other words, the higher the ratio of NNAL-Gluc 
concentrations to free NNAL concentrations, the lower may be an individuals’ 
vulnerability to lung cancer and vice versa. The most important benefit of knowing 
whether a smoker is at increased risk for lung cancer is that his or her doctor can screen the 
person regularly for abnormalities, in the hopes of diagnosing the cancer early. Lung 
cancer is, however, just one consequence of smoking. So this type of cancer susceptibility 
information may not be applicable to all forms of cancer. But as far as lung cancer goes, it 
may give people a better idea of when and how often to get screened. Even if the test 
outcome results in a low risk of developing lung cancer, an individual may be vulnerable 
to other forms of cancer caused by smoking.        
The method of principal component analysis (PCA) which is one of the most 
widely used technique in chemometrics for the transformation and classification of multi-
dimensional data sets in multivariate data analysis was used for the current data analysis 
(Otto, 1999; Massart, 1988). The main idea of PCA involves approximation of the original 
data matrix comprised of features and objects into a product of two smaller matrices – the 
score and loading matrices. The urine samples collected from the 43 smokers comprised 
the objects. The 3 features selected for the PCA were free NNAL concentrations, NNAL-
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Gluc concentrations and ratio of NNAL-Gluc concentrations to free NNAL concentrations. 
The classification of the data was then done on the basis of the scores plot and the 
characteristics of each species were evaluated by the interpretation of loadings plots. 
Scores plots describe the relative position of each object in the principal component space. 
Each original feature has loadings that describe its contribution to each principal 
component. The corresponding loadings plots display relationships between features and 
can be used to identify which features contribute to the positioning of the objects on the 
scores plot and hence influence any observed separation in the dataset. PCA is an 
unsupervised classification method and any prior knowledge relating to the class 
membership is not used. 
In order to further understand and improve the outcome of results of the PCA, a 
cluster analysis tool was used. The hierarchical cluster analysis is a commonly used 
exploratory data analysis tool used to solve classification problems (Azevedo et al., 2008, 
Wiedemann et al., 2005, Gonçalves et al., 2006). The principle of hierarchical cluster 
analysis is based on sorting of objects into groups or clusters in such a manner that the 
degree of association is strong between objects of the same cluster and weak between 
objects of different clusters. It is a statistical method for finding relatively homogeneous 
clusters of cases based on measured characteristics. It starts with each case in a separate 
cluster and then combines the clusters sequentially, reducing the number of clusters at each 
step until only one cluster is left (Massart, 1988).   
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The relationships between other demographic variables (age, cigarettes per day, 
gender and race) and each of the three features selected for PCA were also evaluated. This 
investigation was done by calculating the correlation matrices.  
Computations for principal component analysis, correlation matrices and 
hierarchical cluster analysis were performed using the MATLAB software from 
MathWorks Inc. (version 7.7) (see appendix for MATLAB commands). Euclidean distance 
was used in the calculations for hierarchical cluster analysis. The features used in PCA as 
well as the demographic variables were normalized by autoscaling the data in order to 
eliminate the potential distortion of data that may be caused by different absolute values as 
well as different variances.   
 
3.3. Results and Discussion 
3.3.1. Sample Extraction 
The initial results with online sample extraction demonstrated good selectivity with 
respect to interferences. Figure 13A shows chromatogram for a 500 ng/mL urine sample 
spiked with NNAL. Figure 13B shows the chromatogram for blank urine. The MS 
response of a 100% matrix sample spiked with NNAL was three orders of magnitude 
lower than a neat solution at a similar concentration, however. Also, based on the S/N ratio 
of a matrix sample, the sensitivity needed almost a 1000 fold improvement in order to 
determine low urinary concentrations of NNAL. The system thus needed optimization. The 
influence of matrix effects needed to be assessed. 
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(A) 
 
 
(B) 
Figure 13: Sample chromatograms after online sample extraction on a MIP micro-column 
of (A) Urine sample spiked with 500 ng/mL NNAL and, (B) Blank urine sample 
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3.3.2. Optimization Studies 
3.3.2.1. Wash Time Optimization 
Figure 14 shows the results of the wash time optimization study. The MS response 
was measured as a function of changing wash times. No significant decrease in response 
was observed with increasing wash times. Thus, a wash time of approximately 3.2 minutes 
was selected as an appropriate balance between an acceptable run time, and an opportunity 
to wash off the maximum amount of matrix components without loss of NNAL recovery. 
 
3.3.2.2. Wash Step Flow Rate Optimization 
Figure 15 shows the results of the wash step flow rate optimization study. The MS 
response was measured as a function of changing wash step flow rates. At lower flow-
rates, the NNAL recovery was higher. This is possibly due to a slower mass transfer of 
NNAL on the molecularly imprinted polymer at lower flow rates, resulting in a better 
retention of NNAL. Thus, the molecularly imprinted polymer micro-column performance 
can be improved by decreasing the wash step flow rate. However, at very low flow rates, 
the variability in response was higher as seen in the graph. This may be possibly due to the 
limitations of the HPLC pump to perform accurately at lower flow rates. It was also 
observed that the response dropped as the flow rate was increased. These observations 
were in line with other published results employing molecularly imprinted polymers 
(Haginaka and Kagawa, 2002). Thus, a wash step flow rate of 0.25 mL/min was selected to 
maintain an adequate balance between sufficient recovery and consistency of results. 
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Figure 14: Results of wash-time optimization study  
 
 
  
n=3 replicates 
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Figure 15: Results of wash step flow rate optimization study 
  
n=3 replicates 
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3.3.2.3. pH Optimization 
Figure 16 shows the results of the pH optimization study. The MS response was 
measured as a function of changing pH. Optimum recoveries were obtained between pH 
ranges of 5 to 7. These results suggest development of electrostatic interaction between 
NNAL and the functional groups on the molecularly imprinted polymer in this pH range. 
The molecularly imprinted polymer for NNAL has acidic nature due to the presence of 
carboxylic acid functional group arising from the use of methacrylic acid as the functional 
monomer (Xia et al., 2005) during the synthesis process. The pKa of this acid functions in 
the polymeric complex is estimated to be about 6.5 according to previously published 
studies (Baggiani et al., 1997). NNAL is a basic compound having pKa = 4.9 (calculated 
using pKa prediction software developed by Tetko et al., 2005), suggesting that it ionizable 
in the pH range of 5 to 7. Consequently, an ion exchange mechanism can take place 
between the hydrogen of carboxylic acid functions of the molecularly imprinted polymer 
and the basic function of NNAL. The maximum recovery between pH 5 to 7 suggests that 
this is the domain where both NNAL and the carboxylic acid functional groups are 
simultaneously ionized leading to the development of electrostatic interaction favoring 
NNAL rebinding to the molecularly imprinted polymer cavities. Thus, prior to analysis, the 
urine samples were checked to see if they lie within the pH ranges of 5 to 7 using a pH 
paper. If the measured pH was outside this range, buffered urine was adjusted 
appropriately using either 10% v/v acetic acid or 10% w/v aqueous solution of sodium 
hydroxide.  
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Figure 16: Results of pH optimization study 
 
  
n=3 replicates 
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3.3.2.4. Column Loadability 
A three parameter curve characterizing saturation binding was used to determine 
the binding capacity of the column based on neat solutions. The model followed the 
equation Y=[Bmax x Xh/(Kdh + Xh)] and is sigmoidal in nature. The model used a 
logarithmic x-axis scale as shown in Figure 17A. In the above equation, X corresponds to 
the logarithmic concentration of free NNAL measured in ng/mL and Y represents the 
corresponding response. ‘Bmax’ is the maximum specific binding (i.e. maximum number of 
binding sites), ‘kd’ is the concentration required to achieve half-maximum binding and ‘h’ 
is the slope. A weighting factor of (1/Y2) was used to fit the data. The parameter estimates 
with standard error are: Bmax = (1.75±0.05) x 106, kd = 695±48, h=0.939±0.007. The 
percent relative error (%RE) of each calibration point was plotted against the NNAL 
concentration as shown in Figure 17B. The difference between back-calculated values and 
nominal values was divided by the nominal values and multiplied by 100% to give %RE. 
The % RE data was less that 5% at all concentrations except at the lowest concentration of 
10 pg/mL where it was less than 30%. 
Based on the parameter estimates, the concentration required to achieve 90% 
binding is ~76000 ng/mL which corresponds to an on-column capacity of 1.52 μg of 
NNAL/mg of the packing material based on a 20 μL injection volume. Thus, the on-
column capacity was more than five orders of magnitude greater than the expected levels 
of NNAL in urine indicating a great potential to concentrate the sample on-column without 
saturating the micro-column. 
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(A) 
 
(B) 
Figure 17: (A) Saturation binding study and, (B) Relative error plot of NNAL spiked in 
urine 
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3.3.2.5.Injection Volume Study 
The results of the injection volume study are depicted in Figure 18A. The y-axis 
depicts the % increase or decrease in MS response as a function of increasing volumes 
plotted on the x-axis. The experiment was carried out with urine samples spiked with 
NNAL at a concentration of 100 ng/mL NNAL, and was repeated with a similar 
concentration of NNAL spiked in deionized water. It was observed that while the response 
increased proportionally with increasing injection volume for neat solutions, a similar 
situation is not observed in the case of urine matrix samples and it remained almost 
constant. In the presence of excess matrix, two situations might occur. Either NNAL does 
not bind as the binding sites might be depleted in the presence of matrix, or ionization 
suppression due to matrix effects is taking place.  
In order to evaluate the possibility of matrix effects, a separate experiment was 
conducted. The change in MS response as a function of changing matrix/water 
compositions was evaluated. The injection volume was held constant at 20 μL for all 
matrix/water compositions. The results of this study are depicted in Figure 18B. Possible 
matrix effects due to ionization suppression may be indicated as depicted by the decreasing 
response for matrix samples for a same injection volume. 
 
3.3.3. Evaluation of Matrix Effects  
The results of the post column infusion study are shown in Figure 19. Figure 19A 
show the ion profiles when a 500 ng/mL methanolic solution of NNAL is infused into the 
mass spectrometer. Figure 19B shows the ion profiles upon injecting a blank urine sample.  
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 (A) 
 
 
 (B) 
Figure 18: (A) Percentage increase or decrease in MS response as a function of injection 
volume, (B) MS response as a function of varying percentage of urine matrix in a 
matrix/water mixture  
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Figure 19: Results of post-column infusion study for online extraction of NNAL on a MIP 
micro-column. (i) Ion profile when a 500 ng/mL solution of NNAL is infused into the 
mass spectrometer; (ii) Ion profile upon injecting a processed blank sample; (iii) 
Representative chromatogram showing retention time of the analyte 
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Apart from injecting a blank urine sample in the latter case, no other experimental 
parameters were changed for the ion profiles represented by Figure 19A and Figure 19B. 
This ensured that a constant solvent background was being maintained for both the 
situations. Figure 19C shows a reference chromatogram for 100 ng/mL NNAL in urine. 
The results of the post column infusion study reveal the presence of ion suppression at the 
retention time of the analyte. Ion suppression occurred immediately as the multi-port valve 
was switched from the washing state to the elution state. This resulted in more than 90% 
drop in analyte response.  
 
3.3.4. Addressing Matrix Effects  
The two most prominent ways to eliminate or minimize matrix effects are either 
modification in the sample extraction procedure and/or chromatographically resolving the 
peak of interest from the region of suppression (Taylor, 2005; Van Eeckhaut et al., 2009). 
Matrix effects are generally related to an insufficient sample cleanup of the biological 
sample. Although molecularly imprinted polymers are highly selective sample extraction 
sorbents, optimization of the wash and elution step in the sample extraction procedure is 
very important, especially because non-specific binding of matrix components to the 
molecularly imprinted polymer cavities can be a potential problem. Analytes can also be 
retained chromatographically in such a manner that the impact of matrix effects can be 
minimized. In this regards, information obtained from a post column infusion experiment 
can be very useful. This data provides an idea where matrix effects are occurring in a 
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chromatographic run, and the analyte can be chromatographically resolved from the 
affected region in order to provide a more robust method. 
 
3.3.4.1. Wash and Elution Step Evaluation 
The wash step and the elution step were evaluated for their effects on ion 
suppression. The percentage of methanol, which is a stronger solvent, was increased in the 
wash step in a bid to remove matrix components in order to minimize matrix effects, while 
still providing adequate recovery for NNAL. The changing methanol composition in the 
wash step was studied as a function of: (a) Its effect on the ion suppression measured in 
terms of absolute matrix effects (Matuszewski et al., 2003), and (b) NNAL recovery 
measured in terms of the MS response. The composition of methanol which yields the 
biggest difference between the minimum matrix effects and maximum NNAL recovery can 
then be selected for the wash step. In order to calculate absolute matrix effects, 100 ng/mL 
solutions of NNAL in urine and water were used. Absolute matrix effect was calculated as 
B/A x 100% where, B corresponds to peak area obtained in matrix and A corresponds to 
peak area obtained in neat solution.  
The results of the wash step evaluation are shown in Figure 20A. Methanol 
concentration is plotted on the x-axis. The left y-axis represents NNAL recovery measured 
in terms of MS response as the methanol composition in the wash step is changed. The 
right y-axis represents absolute matrix effects as the methanol composition in the wash 
step is changed. For non-covalent MIPS, if the analyte is present in an aqueous medium, 
the contribution of non-specific hydrophobic interactions increases in the retention of the 
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analyte as well as other matrix components on the polymer (Qiao et al., 2006). To achieve 
selective extraction non-polar to moderately polar organic solvents are typically introduced 
in the wash step. The wash solvent should disrupt the non-specific interactions without 
disrupting the selective interactions between MIPs and the target molecule. Solvents such 
toluene and dichloromethane are most widely used wash solvents in order to retain the 
target molecules (Haginaka, 2009). However, because of incompatibility with ESI-MS, 
these solvents were not selected.  Consequently, changing concentrations of methanol were 
tested in the wash step. It was observed that an increasing percentage of methanol in the 
wash step resulted in a rapid decrease in the MS response indicating loss in NNAL 
recovery on the MIP micro-column. However, the changing methanol concentration did 
not affect absolute matrix effects. In other words, selective disruption of non-specific 
hydrophobic interactions was likely not achieved using this approach. Thus, the next step 
was to try and evaluate the elution step. 
The percentage of methanol, which is a stronger solvent, was decreased in the 
elution step in a bid to retain back maximum matrix components on the MIP micro-
column, yet still providing adequate recovery for NNAL. Similar to the previous case, the 
changing methanol composition in the elution step was studied as a function of: (a) Its 
effect on the ion suppression measured in terms of absolute matrix effects and (b) NNAL 
recovery measured in terms of the MS response. The composition of methanol which 
yields the biggest difference between the minimum matrix effects and maximum NNAL 
recovery can then be selected for the elution step.  
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The results of the elution step evaluation are shown in Figure 20B. Again, methanol 
concentration is plotted on the x-axis. The right y-axis represents the NNAL recovery 
measured in terms of MS response as the methanol composition in the elution step is 
decreased. The right y-axis represents the absolute matrix effects as the methanol 
composition in the wash step is decreased. It was observed that the MS response remained 
almost constant with decreasing concentration of methanol in the elution step, and 
decreased rapidly with less than 20% methanol. However, the changing methanol 
concentration did not affect absolute matrix effects. In other words, both the non-specific 
interactions between the matrix components and the polymer as well as the selective 
interactions between the analyte and the polymer were likely being disrupted using this 
approach. Consequently, the matrix effects did not improve as the methanol concentration 
in the wash step decreased. 
 
3.3.4.2. Resolving Ion Suppression by Integration of an Analytical Column 
As a next approach to address the ion suppression problem, a reverse phase HPLC 
column was introduced in-line after the MIP micro-column to separate matrix components 
from co-eluting with the analyte of interest. NNAL is a moderately polar organic 
compound. The relatively moderate polarity of NNAL would allow it to be more retained 
on a reverse phase HPLC column compared to the more polar interfering matrix species. 
This would be the mechanism for separation of NNAL from the matrix components which 
would potentially result in a reduced impact of ion suppression matrix effects commonly 
encountered in electrospray ionization of biological extracts.   
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(A) 
 
 
(B)Figure 20: NNAL recovery and matrix effects as a function of changing methanol 
concentration in (A) Wash Step and, (B) Elution step 
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The schematic diagram of on-line sample extraction with the incorporation of 
analytical HPLC column is shown in Figure 21. The HPLC column was a Phenomenox 
Gemini C-18 column (100 mm x 2.0 mm I.D., 5.0 μm) with incorporation of an isocratic 
elution mode as shown in Table 12. A Phenomenex C18 guard column (4.0 mm x 2.0 mm) 
was used for extending life of the analytical column. The column temperature was 
maintained at 60 ˚C. The wash solvent on the MIP micro -column comprised of water. 
Considering that NNAL recovery was not affected by decreasing methanol concentration 
in the elution step (see Figure 20B), the elution solvent was comprised of a 1:1 mixture of 
methanol water. This enabled retention of NNAL on the reverse phase HPLC column. A 
third solvent line comprised of 10 mM ammonium formate buffer (pH 6.1) was introduced 
via a tee connection in order to chromatographically separate the NNAL peak from the 
region of ion suppression. This was also necessary to ensure a relatively constant 
proportion of mobile phase introduced into the mass spectrometer and prevent any base-
line shifts due sudden changes in solvent composition arising from switching of the valve 
going from the wash step to elution step. 
A post column infusion study was repeated in order to evaluate the presence of 
matrix effect. Results of the post column infusion study after integration of the analytical 
HPLC column are shown in Figure 22. It can be observed that the region of ion 
suppression is now chromatographically resolved from the NNAL retention time. 
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Switching Valve Position A 
 
 
Switching Valve Position B 
 
Figure 21: Schematic diagram of on-line sample extraction with the incorporation of 
analytical HPLC column 
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Table 12: Time-table for mobile phase with on-line sample extraction after incorporation 
of analytical column 
Time 
(min) 
Mobile Phase A 
mL/min 
Mobile Phase B 
mL/min 
Mobile Phase C 
mL/min 
Valve Position 
     
0.01 0.24 0.18 0.18 A 
3.50 0.24 0.18 0.18 B 
3.70 0.24 0.18 0.18 A 
7.00 0.24 0.18 0.18 A 
Mobile phase A: Water 
Mobile phase B: Methanol:Water (1:1) 
Mobile phase C: 10 mM Ammonium formate buffer (pH 6.1) 
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Figure 22: Results of post-column infusion study for online extraction of NNAL on a MIP 
micro-column after integration of analytical column. (i) Ion profile when a 500 ng/mL 
solution of NNAL is infused into the mass spectrometer; (ii) Ion profile upon injecting a 
processed blank sample; (iii) Representative chromatogram showing retention time of the 
analyte. 
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3.3.4.3. Optimization of Injection Volume after Resolution of Ion Suppression 
Region: 
After integrating the analytical column in line with the MIP micro-column, the 
region of ion suppression was chromatographically resolved from the analyte. On-column 
concentration can now potentially be accomplished by increasing injection volumes in 
order to detect low concentration of urinary NNAL. However, the effectiveness of 
increasing injection volume will be limited because of an expected decrease in the 
resolution of NNAL from the ion suppression region due to the increased amount of matrix 
components injected. Lack of adequate resolution from the region of ion suppression may 
in turn compromise the assay precision. Thus, maintenance of an adequate balance 
between resolution of NNAL from the region of ion suppression (baseline resolution of at 
least 1.2) and the optimum injection volume required to achieve the necessary on-column 
concentration (target concentration of at least 20 pg/mL) is essential. On-column 
concentration is measured in terms of NNAL response. The graph in Figure 23 shows the 
relationship between the change in injection volume as a function of analyte response 
(measured in terms of signal-to-noise ratio) and the resolution of the analyte from the ion 
suppression region. It is observed that as the injection volume is increased, the s/n 
increases up to about 300 μL injection volume, and then begins to drop. Similarly, 
sufficient resolution of about 1.4 is observed between the region of ion suppression and the 
peak of interest up to about 200 μL injection volume. Further increases in injection volume 
compromises resolution drastically. So, to maintain sufficient balance between the two 
parameters, an injection volume of 200 μL was chosen. 
   
 136 
 
 
Figure 23: Injection Volume as a function of a) s/n and b) resolution from region of ion 
suppression after integration of HPLC column in line with the MIP micro-column 
  
   
 137 
3.3.5. Validation Results  
3.3.5.1. Linearity 
 The peak area ratio of NNAL to internal standard in human urine was linear as a 
function of concentration over the range 20 to 2500 pg/mL. The calibration curves were 
well described with a mean correlation coefficient ≥ 0.999. A weighing factor  of 1/x was 
used since the back-calculated residuals demonstrated heteroscedasticity with a 
proportional change in residuals as the concentration changed. The data are presented in 
Table 13. Accuracy calculated in terms of the percent deviation from nominal (% DFN) for 
the mean back-calculated values of the calibration standards ranged from -3.5% to 5.9%, 
while precision measured in terms of percent relative standard deviation ranged from 
0.95% to 7.39%. The LLOQ was established at 20 pg/mL of NNAL in human urine. The 
LLOQ was reproducible with accuracy and precision within the FDA guidance acceptance 
criteria with a s/n ratio of 10. 
 
3.3.5.2. Accuracy and Precision 
 The intra- and inter-run precision and accuracy data are summarized in Table 14 
and Table 15 respectively. The intra- and inter-run accuracies and precision were 
determined at LOQ QC, LQC, MQC and HQC.  The intra-run accuracy was within ± 
14.8% (maximum RSD of 11.3%) for all the concentrations including the LLOQ. Also, the 
inter-run accuracy was within ±9.6% (maximum RSD of 11.4%) for all concentrations. 
The method was both accurate and precise according to established acceptance criteria. 
Analysis of the dilution QC samples revealed that concentrations above the upper limit of  
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Table 13: Reverse predicted residuals for NNAL standard concentrations 
NNAL concentration (pg/ml) 
 
intercept slope r2 
Run # 20.00 50.00 100.00 250.00 500.00 1000.00 2500.00         
            1 20.80 52.00 101.00 247.00 473.00 1030.00 2470.00 
 
-0.0102 0.00320 0.999 
 
20.80 48.90 95.50 248.00 481.00 1020.00 2540.00 
    2 23.60 50.20 98.90 247.00 477.00 1010.00 2490.00 
 
-0.0108 0.00316 0.999 
 
19.40 44.70 n.a. 262.00 474.00 1000.00 2550.00 
    3 20.50 48.50 93.10 251.00 497.00 962.00 2510.00 
 
-0.0091 0.00313 0.999 
 
21.60 51.00 99.90 255.00 483.00 1020.00 2530.00 
    
            
            Mean 21.18 48.66 96.85 252.60 482.40 1002.40 2524.00 
 
0.0100 0.00316 0.999 
SD 1.57 2.43 3.13 6.11 8.88 24.06 24.08 
  
0.00004 
 %RSD 7.39 4.99 3.23 2.42 1.84 2.40 0.95 
  
1.11018 
 %DFN 5.90 -2.68 -3.15 1.04 -3.52 0.24 0.96 
                     
Standard error of regression = 0.028 
n.a. – not available because of broken vial 
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Table 14: Intra-run accuracy and precision data for NNAL 
 
NNAL Concentration (pg/mL) 
Run#  2000.00 400.00 60.00 20.00 
      
1 1800.00 415.00 58.80 15.30 
  1790.00 335.00 54.30 21.20 
  1780.00 366.00 49.90 20.00 
  1830.00 322.00 52.50 22.30 
  1880.00 348.00 53.70 19.40 
  1800.00 328.00 52.30 16.90 
      
      
Mean 1822.50 341.00 52.10 19.65 
SD 43.49 20.03 1.59 2.22 
%RSD 2.39 5.87 3.05 11.29 
%DFN 8.88 14.75 13.17 1.75 
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Table 15: Inter-run accuracy and precision data for NNAL 
 
NNAL Concentration (pg/mL) 
 Run# 2000.00 400.00 60.00 20.00 
      
1 1800.00 415.00 58.80 15.30 
  1790.00 335.00 54.30 21.20 
  1780.00 366.00 49.90 20.00 
  1830.00 322.00 52.50 22.30 
  1880.00 318.00 53.70 19.40 
  1800.00 328.00 52.30 16.90 
      
      
2 1790.00 411.00 56.90 21.00 
  1820.00 420.00 54.10 19.20 
  1760.00 421.00 59.50 20.00 
      
      
3 1850.00 406.00 53.80 20.80 
  1780.00 405.00 56.50 19.50 
  1810.00 405.00 55.20 17.60 
      
      
MEAN 1807.50 379.33 54.79 19.43 
SD 34.95 43.36 2.90 1.99 
%RSD 1.93 11.43 5.29 10.23 
%DFN 9.63 5.17 8.68 2.83 
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quantitation can be accurately and precisely diluted up to 10 fold. The dilution QC 
prepared at a concentration of 10000 pg/mL when diluted 10 fold demonstrated an intra-
run accuracy of -0.24% DFN and a precision of 3.47% %RSD. 
 
3.3.5.3.Selectivity 
 The selectivity of the method with regard to endogenous urine components was 
evaluated in six different lots of blank human urine. No endogenous peaks at the retention 
time of NNAL and the internal standard were observed for any of the urine lots. Figure 24 
demonstrates the selectivity results with representative chromatograms of (A) blank urine 
sample, (B) blank urine lot spiked with internal standard, and (C) analyte at the LLOQ 
level (20 pg/mL). The method also showed adequate selectivity for urine samples spiked 
with β-glucuronidase enzyme. 
 
3.3.5.4. Recovery and Carryover 
The mean recoveries of NNAL from human urine determined at the MQC and 
HQC concentrations were 30.3%, and 31.7% respectively. The mean extraction recovery is 
31.0% for the current extraction protocol. No detectable carryover in the analysis of NNAL 
was observed. 
 
3.3.5.5. Stability 
 The stability tests performed indicated no significant degradation under the 
conditions of freeze-thaw test, bench-top stability and post-preparative stability. The 
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accuracy was within ±11.6% (maximum RSD of 10.1%) for all conditions which was 
within the FDA prescribed limits for accuracy and precision. The results of stability 
analysis are provided in Table 16. This confirmed the overall stability of NNAL in the 
urine matrix under frozen conditions, assay processing and freeze-thaw conditions. The 
long term storage stability experiments were not performed as it is reported in the literature 
that NNAL is stable in frozen urine samples stored at -20 ˚C for up to four year s as 
demonstrated by Yuan et al., 2009.  
 
3.3.6. Capillary Micro-column Ruggedness 
After validating the method, the capillary micro-column packing reproducibility 
was evaluated. Three capillary micro-columns were packed on separate occasions and 
tested at low, medium and high QC concentrations. Additionally, three different lots of 
MIP beads were packed in capillary micro-columns and evaluated at similar 
concentrations. Results of column packing uniformity as well as lot-to-lot uniformity study 
are shown in Figure 25. Excellent column packing reproducibility was obtained at all QC 
concentrations as seen in Figure 25A. The lot-to-lot recovery was slightly lower for one lot 
of MIPs at high QC concentration as seen in Figure 25B. This may potentially be due to 
reduced number of binding sites for that particular lot. A significant advantage of the 
online capillary micro-column was the ability to re-use the micro-column for multiple 
injections. More than 300 injections were obtained on a single micro-column without loss 
of performance. 
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(A)                                                                                                               (B) 
 
      (C) 
Figure 24: Representative chromatograms of (A) 
blank urine (B) blank urine spiked with IS at 250 
pg/mL and (C) Urine spiked with NNAL at LLOQ of 
20 pg/mL and IS at 200 pg/mL. (MRM transitions 
210.1180.2 (upper channel) and 213183.1 (lower 
channel) corresponds to NNAL and NNAL-d3 
respectively. 
 144 
Table 16: Post-preparative, freeze-thaw and bench-top stability data for NNAL 
Stability NNAL Concentration (pg/mL) 
(n=3) 2000.00 400.00 60.00 
Post-Preparative – 24 hours       
   
 
Mean 1850.00 416.33 57.80 
SD 17.32 4.73 5.81 
%RSD 0.94 1.14 10.06 
%DFN -7.50 4.08 -3.67 
  
  
(n=6) 2000.00 60.00  
Freeze Thaw – 3 Cycles     
 
  
  
Mean 1826.00 53.06  
SD  28.81 2.44  
%RSD 1.58 4.60  
%DFN 8.70 11.57  
  
  
(n=6) 2000.00 60.00  
Bench-Top  - 7 hours     
 
  
  
Mean 1816.67 54.17  
SD 32.15 1.37  
%RSD 1.77 2.52  
%DFN 9.17 9.72  
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(A) 
 
 
(B) 
Figure 25: Capillary micro-column reproducibility study - (A) Column packing 
reproducibility study. (B) Lot-to-lot reproducibility study. 
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3.3.7. Real Sample Analysis 
The mean age of smokers whose urine samples were analyzed in the study was 37.9 
years (median age = 40 years). The self-reported average number of cigarettes smoked per 
day was 26.8 cigarettes (median cigarettes per day = 25). The ratio of males to females in 
the study was 65:35, while the ratio of black smokers to white smokers was 77:23. Urine 
samples were stored at -20 ˚C until analysis. The concentrations of free NNAL measured 
ranged from BLOQ to 1.26 pmol/mg creatinine while NNAL-Gluc concentrations ranged 
from BLOQ to 0.50 pmol/mg creatinine. 
Table 17 shows the concentrations of NNAL and NNAL-Gluc measured in 
smokers. The ratios of NNAL-Gluc concentrations to NNAL concentrations are also 
depicted in Table 17. 
 
3.3.8. Subject Sample Data Analysis – Pattern Recognition and Classification 
Before carrying out the multivariate analysis, the relationship between the 
demographic variables (gender, age, race and cigarettes/day) and the feature variables 
(NNAL concentrations, NNAL-Gluc concentrations and ratio of NNAL-Gluc to NNAL 
concentrations) was studied. Each feature variable (x) was compared with the demographic 
variable (y), and the corresponding correlation matrix (r) was calculated to decide if a 
correlation existed between these two variables. This was is an important preliminary study 
to identify if the feature variables selected for the multivariate analysis showed any 
systematic dependence to the demographic variables. Maximal absolute correlation exists 
when the absolute value of the correlation coefficient |r(x,y)| = 1, and it can be concluded  
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Table 17: Concentrations of NNAL and NNAL-Gluc measured in urine of smokers 
Subject  
ID 
NNAL 
concentrations 
NNAL-Gluc 
concentrations 
Ratio 
 
Subject 
 ID 
NNAL 
concentrations 
NNAL-Gluc 
concentrations 
Ratio 
 
        
1 0.194 0.080 0.412 23 0.378 0.353 0.934 
2 0.153 0.096 0.630 24 0.311 0.187 0.603 
3 0.120 0.176 1.466 25 0.319 0.155 0.485 
4 0.389 0.229 0.589 26 0.574 0.399 0.695 
5 0.350 0.166 0.474 27 1.259 0.165 0.131 
6 0.235 0.054 0.229 28 0.310 0.113 0.363 
7 0.000 0.221 0.000 29 0.326 0.188 0.576 
8 0.205 0.344 1.682 30 0.465 0.291 0.626 
9 0.000 0.113 0.000 31 0.289 0.275 0.952 
10 0.230 0.157 0.684 32 0.386 0.207 0.536 
11 0.112 0.233 2.091 33 0.694 0.501 0.722 
12 0.236 0.148 0.626 34 0.000 0.000 0.000 
13 0.000 0.125 0.000 35 0.360 0.132 0.368 
14 0.243 0.100 0.410 36 0.327 0.300 0.917 
15 0.445 0.213 0.479 37 0.000 0.000 0.000 
16 0.396 0.198 0.500 38 0.210 0.113 0.540 
17 0.307 0.283 0.921 39 0.000 0.000 0.000 
18 0.472 0.401 0.849 40 0.000 0.000 0.000 
19 0.384 0.192 0.501 41 0.250 0.414 1.651 
20 0.168 0.072 0.429 42 0.379 0.355 0.935 
21 0.234 0.411 1.754 43 1.054 0.234 0.222 
22 0.000 0.000 0.000     
Note: NNAL and NNAL-Gluc concentrations are reported as pmol/mg creatinine 
          NNAL-Gluc concentrations determined from difference between free and total NNAL concentrations  
          Ratio is the Ratio of NNAL-Gluc to NNAL concentrations  
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that the feature variables are perfectly co-related with the corresponding demographic 
variable. When the two variables are not correlated, the value of |r(x,y)| approaches close to 
zero. The results of the correlation matrices of the data are depicted in  as correlation 
coefficients. A 95% confidence interval for the correlation coefficient was calculated. As 
seen from the Table 18, all the 95% confidence intervals included zero indicating that none 
of the feature variables bear any significant correlation to the demographic variables. This 
conclusion is important in the interpretation of the pattern recognition discussed below, 
confirming that any difference in classification may not be attributable to demographic 
variables.  
Multivariate data analysis was carried out after normalization of the feature data 
that were preprocessed by autoscaling before PCA transformation. Autoscaling is a scaling 
method used to eliminate differences in the metric properties of the feature variables. It is 
used to give equal weighting to all portions of experimentally measured data. The resulting 
columns of the variables are said to be scaled to unit variance. Autoscaling is performed as 
shown in the equation below: 
zij = (xij – xmj)/sj 
where xij is the value of object i of feature variable j, xm is the mean for feature variable j, 
and sj is the standard deviation of feature variable j (Massart, 1988; Otto, 1999). The zij 
values were then used for PCA transformation. 
A new system of co-ordinates corresponding to principal components was used to study 
the relationship between objects and features in a more efficient way. The percentage of 
explained variance approach was applied in calculating the number of principal 
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components used to represent the data (Otto, 1999). According to this, each subsequent 
principal component describes a maximum of variance that is not modeled by the earlier 
components.  The use of all principal components is usually not justified in order to 
separate the pure components from the noise components. Table 19 shows the percentage 
of explained variance of the autoscaled data. More than 92% of the explained variance of 
the autoscaled data can be explained by the first two principal components which were 
used for analysis. Accordingly, sample patterns were detected using the first two principal 
components (PC1 and PC2 with 60.66% and 32.06% of explained variance respectively). 
Interpretation of the PCA outcome to evaluate the existence of patterns was carried out by 
visual inspection (Otto, 2007). As seen in the scores plot (Figure 26), the data revealed a 
visual differentiation among the objects and offered valuable evidence for potential 
classification. Two classes of smokers were adequately separated.  
Class 1: Positioned at the upper right quartile (pink ellipse). These were subjects with 
measured with high concentrations of free NNAL and having low NNAL-Gluc to NNAL 
ratios indicating poor metabolic deactivation, and consequently may be at a higher lung 
cancer risk. 
Class 2: Positioned at the bottom right quartile (purple ellipse). These were subjects with 
having high NNAL-Gluc to NNAL ratios indicating strong metabolic deactivation, and 
consequently may be at a lower lung cancer risk. 
The majority of the objects (non-classified) were positioned between classes 1 and 2, near 
the center of the PCA axes (green ellipse). The discrimination of more classes within the 
non-classified group seemed difficult indicating similarities in the extent of metabolism of  
   
 150 
 
Table 18: Correlation coefficients obtained for feature variables w.r.t. demographic 
variables as calculated from the correlation matrices using MATLAB software (ver. 7.7) 
Variables (x, y) Age Gender Race Cigarettes/day 
     
NNAL 
Concentrations 
-0.1141 
[-0.40, 0.19] 
0.2276 
[-0.08, 0.49] 
-0.0529 
[-0.35, 0.25] 
-0.1803 
[-0.46, 0.13] 
     
NNAL-Gluc 
Concentrations 
-0.0088 
[-0.31, 0.29] 
-0.0451 
[-0.34, 0.26] 
-0.1497 
[-0.43, 0.16] 
-0.1508 
[-0.43, 0.16] 
     
Ratio (NNAL-
Gluc: NNAL 
Concentrations) 
0.0707 
[-0.23, 0.36] 
-0.1945 
[-0.47, 0.11] 
-0.1737 
[-0.45, 0.13] 
-0.0837 
[-0.37, 0.22] 
Note: Numbers in the parentheses show the 95% confidence interval of the respective correlation coefficient   
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Table 19: Percentage of explained variance to calculate the number of principal 
components [Computed using MATLAB Software (ver. 7.7)] 
Component Eigenvalue  
(autoscaled) 
Explained variance % Cumulative variance % 
    
    
1 76.43 60.66 60.66 
2 40.4 32.06 92.72 
3 9.17 7.28 100.00 
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Figure 26: Scores plot from the PCA for the first and second principal components 
(Numbers on the scores plot correspond to the subject I.D.)  
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these subjects, although having different concentrations of free and conjugated NNAL. A 
closer examination of the non-classified class revealed a small sub-class positioned at the 
extreme right along the PCA axis where the concentrations of NNAL and/or total NNAL 
were BLOQ (orange ellipse).  
Correlation and the importance of feature variables are decided from the loading 
plots. Figure 27 shows the loading plots for the first two components of the nitrosamine 
data. As seen in the plot, there is mild correlation between the NNAL-Gluc concentrations 
with NNAL concentrations and the ratio of NNAL-Gluc to NNAL concentrations 
(described by the cosine of angles between these vectors). On the other hand, correlation 
between NNAL concentrations and the ratio of NNAL-Gluc to NNAL concentrations is 
less. Also, all features are important in describing the first principal component. The 
second component is mainly characterized by NNAL concentrations and the ratio of 
NNAL-Gluc to NNAL concentrations, with almost not contribution from NNAL-Gluc 
concentrations.  
In order to better understand and verify discrimination among the objects by PCA, 
a statistical approach consisting of cluster analysis was performed. This approach sorts a 
set of objects described by several features, into ‘homogeneous’ clusters. Similarity index 
values are then calculated by the following equation: similarityab = 1- dab/dmax, where dab is 
the Euclidian distance of objects a and b and dmax the largest Euclidian distance in the data 
set (Wiedemann et al., 2005). The resultant dendrogram is shown in Figure 28. The links 
between objects in the dendrogram are represented as upside-down U-shaped lines. The 
height of the U indicates the Euclidian distance between the objects. Upon examination of  
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Figure 27: Loading plot from the PCA for the first and second principal components 
(Numbers on the loading plot correspond to the features – 1: NNAL concentrations; 2: 
NNAL-Gluc concentrations; 3: Ratio of NNAL-Gluc to NNAL concentrations) 
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Figure 28: Dendrogram showing results of hierarchical cluster analysis 
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the dendrogram, the data set can be classified into three clusters when the similarity index 
was fixed at about 0.45. The clusters observed in the dendrogram correspond well with the 
PCA classification of objects as seen in the scores plot. 
The characteristics of the three clusters were as follows: 
First cluster (purple): Corresponds to class 1 from PCA analysis 
Second cluster (pink): Corresponds to class 2 from PCA analysis 
Third cluster (green+orange): Corresponds to the non-classified class from PCA 
The sub-group obtained in the PCA scores plot can be observed as a sub-cluster in the third 
cluster of the dendrogram obtained from hierarchical cluster analysis. This sub-cluster 
(orange color) can be observed in the third cluster when the similarity index is fixed at 
about 0.65. This sub-group corresponded to NNAL and/or NNAL-Gluc concentrations that 
were BLOQ.    
Thus, measurement of urinary NNAL and its glucuronide conjugate might provide 
a valuable tool to assess the cancer risk of an individual subject. In order to validate this 
tool, individual subjects should be monitored for possible progression towards disease. 
Correlation of the actual disease outcome should then be performed with the outcome from 
the NNAL data analysis. In order to make the cancer risk-assessment tool more robust, real 
sample analysis should be performed under controlled conditions and on increased number 
of subjects. Lack of important information and no control on variables such as type of diet, 
brand and type of cigarette smoked, active years of smoking, other disease conditions or 
impairments, concurrent medication, etc. are all important factors that can affect an 
individuals’ susceptibility to cancer. Nevertheless, under controlled conditions, 
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measurement of NNAL and its glucuronide metabolite in human urine can be used to 
investigate the extent of NNK metabolism, thus giving potential insights in the assessment 
of lung cancer risk. 
 
3.4. Conclusions 
The determination of NNAL in human urine using on-line extraction on a microfluidic 
capillary column packed with MIPs coupled with LC-MS/MS has been accomplished. The 
method was optimized to achieve maximum analyte recovery. Issues related to matrix 
effects were addressed in the current method, and the method was validated as per the FDA 
bioanalytical method validation recommendations. The validation data demonstrated 
excellent precision, accuracy and stability. This method can be used for routine assay of 
low concentrations of free and total urinary NNAL in smokers. A distinct advantage of the 
on-line format compared with the off-line format (discussed in Chapter 2) in the extraction 
of urinary NNAL is the micro-column re-usability. While the MIP cartridges used for off-
line extraction are only single-use cartridges, as many as 300 urine samples were 
successfully analyzed on a single MIP capillary micro-column in the on-line format. The 
capillary micro-column contains approximately 1 mg of the MIP sorbent beads compared 
to a 25 mg MIP bed-weight for the off-line cartridges. Considering this, a cost saving of 
approximately 7500 fold is perceivable just by substituting the cartridge format with the 
capillary micro-column format and performing the extraction in the on-line mode. This 
cost saving becomes all the more significant when one takes into account that a single non-
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reusable MIP cartridge used in the off-line format costs approximately $11.50. However, it 
should also be realized that an extra HPLC pump would be required to perform the 
extraction in the on-line format format which may potentially add to the cost. Finally, 
chemometric methods were employed to analyze the low concentrations of NNAL and 
NNAL-Glucuronide measured in smokers, and a possible cancer risk assessment tool was 
developed based on the ratio of the concentrations of these compounds in human urine. 
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CHAPTER 4 A Proposed Fixed Range Decision Criteria for Bioanalytical Method 
Transfers and Comparison 
Drawn from manuscript published in J. Chromatogr. B (2009) 877: 2270-2274 
 
 
4.1. Introduction  
Quantitative bioanalytical methods are used for the analysis of drugs and their 
metabolites in biological matrices such as blood, plasma, serum or urine. Procedures such 
as gas chromatography (GC), high-pressure liquid chromatography (LC), combined GC 
and LC mass spectrometric (MS) procedures such as LC-MS, LC-MS-MS, GC-MS, and 
GC-MS-MS are routinely performed for determination of small and large molecules. After 
development, the method is validated to establish that it is shown to provide accurate, 
precise, and reproducible data. Bioanalytical method validation plays a significant role in 
the evaluation and interpretation of bioavailability, bioequivalence, pharmacokinetics, and 
toxicokinetics studies involving bioanalytical data. Bioanalytical methods are also 
routinely transferred and redeveloped for a number of reasons including: a change in 
analytical technology (e.g., changes in detection system), change in the relevant 
concentration range (e.g., need for more sensitivity), transfer to new laboratories to 
improve capacity, addition of metabolites, new species or matrices, etc. (US Food and 
Drug Administration, 2001). In the current work, an offline sample extraction method for 
the analysis of urinary tobacco specific nitrosamine NNAL was developed using 
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molecularly imprinted polymer combined with LC-MS/MS. Subsequently, the method was 
redeveloped by adapting a capillary microfluidic extraction system coupled online with 
mass spectrometric detection for analysis of urinary NNAL using molecularly imprinted 
polymers. Apart from physically transferring or redeveloping a validated procedure, 
transfer or redevelopment of the method requires assurance that the “test” laboratory or 
method can obtain reliable and equivalent results as the “reference” laboratory or method. 
In the current case, the original validated off-line sample extraction method serves as the 
reference method, while the revised on-line microfluidic sample extraction method will 
serve as the test method. Comparability of between-study data is helpful to ensure proper 
interpretations of bioavailability, bioequivalence, pharmacokinetics, and toxicokinetics 
data. Cross validation and/or transfer of bioanalytical methods encompasses comparison of 
control data for two or more bioanalytical circumstances used to generate data within the 
same studies or across different studies (US Food and Drug Administration, 2001). Inter-
laboratory and cross validation studies as well as incurred sample reanalysis are generally 
evaluated using spiked matrix controls.   
In order to evaluate whether the on-line microfluidic sample extraction approach 
for the analysis of NNAL using molecularly imprinted polymers (chapter 3) is capable of 
producing comparable results as the off-line sample extraction approach (chapter 2), the 
standard of practice is to cross-validate the method. Cross validation of bioanalytical 
methods is an area that requires consideration of method transfers concepts. These 
concepts include (a) an ability to demonstrate that two laboratories or methods are capable 
of producing equivalent results through appropriate experimental design, (b) to identify the 
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source of any differences and (c) to resolve the differences. At present, however, several 
approaches have been used for method comparisons and there is no clear consensus on the 
most appropriate acceptance criteria or study design in such bioanalytical method data 
comparisons.  
Relatively complex “true” statistical approaches are not easily carried out and/or 
understood in many bioanalytical laboratories.  The standard of practice has been use of 
fixed criteria established by the FDA. However FDA has not as yet established any 
regulatory guidance on transfer of bioanalytical methods. Several approaches have been 
described for the evaluation of method transfer (International Society for Pharmaceutical 
Engineering, 2003; Dewé et al., 2007; Hartmann et al., 2002; Feng et al., 2006; Vial et al., 
1998; de Fontenay, 2008; DeStefano, 2006). Some groups which are active within the 
pharmaceutical industry have also proposed their own transfer methodologies (Schepers 
and Watzig, 2005; International Society for Pharmaceutical Engineering, 2003) for 
different circumstances. Use of multiple approaches in different laboratories can often 
make it difficult to determine whether the test laboratory meets the needs of a particular 
project. More recently, Dewé et al., 2007 have proposed the use of total error as a decision 
criteria in analytical method transfer, and Rozet et al., 2008 have used these criteria in 
bioanalytical applications. The total error approach is based on a complete consideration of 
statistics and is more robust. However, this approach may not be readily applicable in 
laboratories lacking knowledge in statistics. In these cases, it may be useful to investigate 
“fixed” criteria that are based in part on statistical science.  Although not completely 
correct statistically, fixed criteria based on statistical concepts are more appropriate than 
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fixed criteria which do not consider statistics. Such criteria would be effective for 
evaluation of the major risks associated with the transfer of methods and, at the same time, 
would be more acceptable among non-statistician bioanalysts.  
In the present chapter, the predominant approaches used for method transfer 
evaluation will be discussed addressing the advantages and limitations in each case. A 
fixed range decision criteria based on standard error of the mean will be proposed. 
Computer simulations will be evaluated in order to gauge the probability of successful 
transfers for various experimental designs using the proposed criteria. The on-line and the 
off-line sample extraction methods for NNAL analysis will be then evaluated for method 
comparability using the proposed criteria. 
 
4.2. Predominant Approaches used in Bioanalytical Method Transfers 
One of the most important questions that need to be addressed when transferring a 
method is whether or not one can assure comparability of data. There is generally a trade-
off between the following two situations. Acceptance criteria that are not very restrictive 
might fail to adequately demonstrate the equivalence of two methods. In this case, the 
acceptance criteria are too wide and can lead to acceptance of non-equivalent results from 
the two participating laboratories (also referred to as β-error or false negative error). 
Conversely, a criterion that is too narrow might lead to generation of unnecessary data and 
may lead to rejection of equivalent results from the two participating laboratories (also 
referred to as α-error or false positive error). The definitions of false positive and false 
negative errors are summarized in Table 20. The goal of a bioanalytical method transfer 
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should be to limit the number of false positive as well as false negative errors and ensure 
that the method performs equivalently at each site. Currently, the predominant approaches 
used for evaluation of control data for bioanalytical method transfer include i) The 
independent validation approach, ii) Statistical difference testing using a Student’s t-test 
and iii) Statistical equivalence testing, iv) The total error based approach 
 
4.2.1. Independent Validation Approach 
According to the independent validation approach, both the reference and the test 
method must be shown to meet the validation criteria for accuracy (± 15% of the nominal 
concentration) and precision (≤ 15% coefficient of variation) as prescribed by the US Food 
and Drug Administration, 2001. The means of the two methods (e.g. x1 and x2 
respectively) are compared against the true reference value (μ) which is taken as the 
nominal spiked concentration. As depicted in Figure 29, the maximum allowable 
difference between the means of the two laboratories would be 30% (i.e. ± 15% of the 
nominal value for each mean) and the maximum allowable imprecision would be ≤ 15% 
coefficient of variation (%CV) in order to fulfill the current FDA criteria on bioanalytical 
method validation. The school of thought with this approach is that if both methods are 
valid to within FDA criteria using the same control, then the methods are also comparable 
within FDA established criteria. 
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Table 20: α- and β-errors in bioanalytical method transfer 
 
 
Actual equivalence of reference and transferred method 
Bias present No bias present 
Statistical 
test results 
Test shows 
bias present 
Truly non-equivalent methods False positive (α-error) 
Test shows no 
bias present 
False negative (β-error) Truly equivalent methods 
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Figure 29: Normal distributions around means measured at the extremes of the maximum 
acceptable difference of ±30% based on the existing FDA criteria for independent 
validation. 
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It has been very well established that such acceptance criteria based on ad-hoc rules 
are subject to unknown and uncontrolled risks of accepting unsuitable bioanalytical 
methods and rejecting suitable bioanalytical methods (Kringle and Khan-Malek, 1994). 
The non-statistical approach of simply comparing the observed bias and precision between 
two laboratories to pre-set acceptance limits can result in both, rejection of results that are 
truly equivalent, and acceptance of results that are truly non-equivalent. For example, 
Kringle et al., 2001 have discussed that when the true relative bias is at the extreme of the 
acceptance criteria, there is a 50% chance of falsely concluding that the relative bias is 
acceptable. This is evident in Figure 29 where half of the area of the distribution around 
each mean measurement is inside of the acceptance region. This independent validation 
approach based on FDA acceptance limits might lead to a relatively high acceptance of 
bioanalytical method transfers when the maximum allowable difference between two 
laboratories is close to 30% as depicted in Figure 29. This is because such an approach 
fails to control both, the risk of accepting transfers when they are not truly acceptable, and 
the risk of rejecting transfers when they are truly acceptable. Such a situation is not 
desirable and should be avoided. 
 
4.2.2. Difference Approach using Student’s t-test 
A common statistical approach used within bioanalytical laboratories is the 
“difference approach” using the Student’s t-test. A t-test is applied to test the hypothesis 
that the transferred method yields identical results as the reference method. The t-test asks 
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the question: “Are the means the same?” The null and alternate hypotheses for a t-test can 
be stated as: 
H0: X1 = X2 
H1: X1≠ X2 
The t-test controls the risk of false positives, i.e. the risk of concluding that there is 
bias when there is none (α-error). Figure 30A depicts the distribution of measurements 
around the means of the reference and the test methods (one mean is inside the acceptance 
range - x1, and one is outside - x2). The FDA allows a ±15% acceptance range for 
accuracy. A pre-selected  t-test α value therefore allows control of the probability of 
concluding there is a clinically significant bias between the  two methods, when in fact 
they are equivalent (note: only positive bias is shown in the figure.  The risk of committing 
a false positive or a false negative error can be minimized in the following way. The most 
obvious approach is to suitably modify the test method (e.g. change technology) so that the 
means are closer together or the variance around the mean is reduced. This might not be 
the most efficient approach since many bioanalytical methods are very complex and  
modification can be a hit or miss proposition..  A second approach would be to adjust the 
acceptance range for a successful transfer. This would allow control over the risk of 
committing a false positive or a false negative error. However, there is an inverse 
relationship between these two types of errors. As shown in Figure 30B for example, when 
one tries to control the risk of falsely concluding that there is a bias (false positive) by 
increasing the acceptance range, the risk of wrongly concluding the absence of bias 
increases correspondingly (false negative). Narrowing the spread of observations around 
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the means of the reference and the test method can also be accomplished by increasing the 
number of replicate analyses, and thus improving the estimate of the means. Figure 31A 
and Figure 31B show that an increase in the sample size will reduce the variance of the 
mean, thus reducing both, the risk of false positives and false negative errors. Kringle et 
al., 2001 have demonstrated in the case of analytical method transfers, when the true bias 
between the reference and the test laboratory is exactly equal to the acceptance limit, the 
chance of a false negative conclusion (β-error) can be as high as 38% for a three day 
sampling period. As the sampling period increases to five days, the false negative error 
reduces to 12%. In both sampling situations, the false positive conclusion is constant at 
50% because the true relative bias is exactly at the acceptance boundary. However, when 
the true relative bias is small and within acceptance limits, the authors were able to show 
that the probability of correctly concluding that the two methods are equivalent decreases 
with increasing sample size. This phenomenon is a result of the way the null and 
alternative hypothesis are set up, and makes the difference test a scientifically illogical 
approach when the objective is to demonstrate that two methods are sufficiently similar. 
Such a situation is undesirable and based on these limitations, there is a need to modify the 
t-test approach so that bias and precision can be combined as total error, which is the sum 
of the systemic and random errors.  
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(A)                                                                                                 (B) 
 
Figure 30: Normal distribution of measurements around the means of hypothetical reference and the test methods (x1, x2 
respectively).  Figures A and B show that decreasing the risk of false positives increases the risk of false negatives 
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(A)                                                                                                    (B) 
 
 
Figure 31: Normal distribution of measurements around the means of hypothetical reference and the test methods (x1, x2 
respectively).  Figures A (high variance) and B (low variance) show that the risk of false positives and false negatives are 
reduced by increasing sample size. 
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4.2.3. Statistical Equivalence Test 
The statistical equivalence test is based on reversing the null (H0) and the alternate 
(H1) hypotheses as follows: H0: | μT – μR | ≥ δ and H1: | μT – μR | < δ where μT and μR are 
the mean results of the test and reference formulations, and δ is the acceptance limit pre-
specified by the analyst. If the null hypotheses is rejected, the test and reference methods 
will be considered comparable (i.e. μT = μR).  This statistical test is rigorous and 
scientifically correct. It was originally proposed for bioequivalence studies by Schuirmann, 
1987 and has also been extended to analytical method comparisons by Hartmann et al., 
2002. In the case of bioanalytical method transfers, a two-sided (1-2α)100% confidence 
interval will be constructed for μT – μR that will then be compared to the FDA acceptance 
criteria of -15% to +15%.  
Considering this, the test method can be considered equivalent to the reference 
method at a 95% confidence level if the entire two sided 90% confidence interval is 
completely included in the acceptance range. Figure shows the normal distributions (± 
15% CV) of the difference (d) between the reference and test method  means around the 
extremes of the FDA guidance accuracy criterion ( ± 15%) to yield an acceptance criterion 
of 30%. Applying the reverse hypothesis t-test, as shown in Figure 32, situation 1 would 
lead to a conclusion that there is no significant difference since the estimated mean 
difference along with the 90% CI is entirely within the acceptance criteria. Situation 2 
would lead to a conclusion that there is a significant difference and in the case of situation 
3, the transferred method is out of specification when compared with the reference method. 
By stating the hypothesis in such a manner, we gain control over the risk of falsely 
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concluding that the test method is equivalent to the reference method, when in fact they are 
not. In this case, the probability of accepting a method that shows a relevant bias of 30% is 
limited to a fixed β-error. 
The statistical equivalence test is especially appropriate when the objective is to 
demonstrate sufficient equivalence beyond a reasonable doubt. This test asks the question 
“Do the means differ more than a certain amount?” Although the statistical equivalence 
test controls the false negative error at a fixed level a limitation of this test is that the false 
positive error may be unacceptably high, and like the Student’s t-test, is controlled only 
with a sufficiently large number of replicates.  
 
4.2.4. Total Error Based Approach 
In order to avoid limitations observed with the above described approaches, it has 
been proposed to combine the estimates of systematic and random errors into one single 
decision criterion – the total error defined as the sum of the systematic and random errors. 
The concept of total error is shown in Figure 33 (Westgard and Barry, 1986). The total 
error is the sum of random and systematic errors. The random error can either be positive 
or negative. It can thus potentially add to systematic errors. Combination of accuracy and 
precision criteria allows acceptance of situations where there is no bias but a random 
variation higher than the acceptance limit. In such a case, the absence of systematic error 
may compensate for random error and one can still guarantee that the results will be close 
enough to their true value. The opposite situation also exists when a systematic difference 
is not acceptable by the systematic error criterion but the total error criterion is met 
because the random variation is small. The total error approach simultaneously controls the  
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Figure 32: Normal distributions (± 15% CV) of the difference between the reference and 
test method means (d) around the extremes of the FDA guidance accuracy criterion ( ± 
15%) to yield a total error criterion of 30%. Solid lines across the measured situational 
mean represent a 90% confidence interval, which correspond to a one-sided 95% 
confidence interval. For the test method to be acceptable the entire CI should be within the 
acceptance limits. (Situation 1: No significant difference; Situation 2: Significant 
difference; Situation 3: Cannot conclude with confidence that there is no significant 
difference) 
 
 
 
 
 
 
 
  
   
 174 
 
 
Figure 33: Total error concept 
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risk of both false positive and false negative errors, and is statistically the most correct 
approach (Dewé et al., 2007).   
 Dewé et al., 2007 have developed the statistical method based on total error 
concepts applicable for analytical method transfers. The principle of this method is to 
calculate a tolerance interval [LR, UR] from the experimental results for the test laboratories 
(or receiver laboratory as per the authors’ nomenclature), in which we expect to find a 
large proportion (β) of the measurement results. This interval is then compared with 
respect to the acceptance limit interval [µL(1-λ), µU(1+λ)], where µL and µU are the upper 
and lower limits of a confidence interval (usually a 95% confidence interval) for the 
reference laboratory mean measurement, and λ is the is a tolerance value chosen in 
accordance with the performance of the measurement method of interest (λ is selected as 
15% in case of bioanalytical method transfers). The transfer is accepted if the β-
expectation tolerance interval for the test laboratory falls within this acceptance limit. 
The β-expectation tolerance interval for the test (receiver) laboratory [LR, UR] to 
estimate the interval in which a proportion β of the measured population is expected to 
belong can be calculated as: 
 
where L and U are the lower and upper limits of the tolerance interval, sub-script R 
indicates test (receiver) laboratory, µ is the mean concentration value, σ is the standard 
deviation, sub-script I indicates the inter-run precision estimate, and k is calculated as 
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follows in order to have an expected proportion β of the population within the tolerance 
interval: 
 
where t(f,γ) is the γth percentile of a student t(f) distribution and R is the ratio between the 
run-to-run variance and the within-run variance. I indicates the number of runs with J 
replicates. 
This is a sophisticated statistical approach to judge method transfers which 
considers a full risk analysis. However, such a sophisticated approach may not always be 
easily applicable within laboratories lacking statisticians. Thus, there may be some benefit 
in a compromise between a completely statistically derived approach, and a fixed range 
approach derived from statistical considerations. 
 
4.3.Proposed Fixed Criterion 
As described earlier, bioanalysts have been historically more prepared to accept 
criteria which are fixed and easy to use. The “4/6/15” rule is one such example in method 
validation. According to this rule as defined in FDA Bioanalytical Method Validation 
guidance, “at least four of every six QC samples should be within 15% of their respective 
nominal value. Two of the six QC samples may be outside the 15% of their respective 
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nominal value, but not both at the same concentration” (US Food and Drug 
Administration, 2001). A criticism of this criterion is that it lacks a consistent statistical 
foundation. In the absence of an accepted guidance criterion for method transfer, many 
laboratories choose to use the fixed accuracy criteria of ±15%  to compare the difference 
between means of the reference and the test method (DeStefano, 2006). Since this involves 
a comparison of the means, it is logical to allow for random variation although no 
allowance is generally made. Failure to account for imprecision in such a comparison 
would lead to method transfers being judged unsuccessful, when the method is truly valid 
under both conditions. At the same time, failure to evaluate imprecision could also lead to 
the acceptability of method transfer when the transfer is truly not acceptable. 
It would be desirable to employ approaches based on statistical considerations to 
establish fixed criteria rather than using fixed criteria based on a consensus opinion 
without statistical considerations. Such a proposal, like any other “fixed” criterion, may 
have some drawbacks and not be entirely correct statistically, but can have practical and 
conceptual advantages over a straight comparison of means approach. 
 If μT is defined as the test method mean result, and μR as the reference method 
mean result, the proposed acceptance criterion would be more accurately comprised of the 
sum of the FDA guidance accuracy limit of ±15% and the standard error of the mean of 
μT. The standard error of the mean is defined as the ratio of the standard deviation “s” of 
the test method to the square root of the number of replicate measurements ‘n’ (i.e., s/√n). 
The standard error of the mean provides a gauge for how variable the mean can be 
expected to be when performing n replicate analyses (Massart, 1988). Considering the 
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FDA guidance on precision of 15% CV (US Food and Drug Administration, 2001), fixed 
acceptance limits for bioanalytical method transfer based on the FDA guidance acceptance 
limit maxima can be set as ± (15% + 15%/√n). Figure 34 depicts the proposed acceptance 
criterion that takes into account method imprecision. In this context, the x-axis shows the 
estimated mean difference (d) between the two methods. A risk analysis can then be 
employed to determine the probability that the test laboratory would observe results 
outside the stated acceptance limits of ± (15% + 15%/√n). This provides a tool to 
determine a reasonable fixed criterion for bioanalytical method transfer. Such a tool would 
depend on the number of samples, the number of times the samples are run, number of 
quality control samples, etc.  
 
4.4.Experimental  
4.4.1. Computer Simulations 
Computer simulations were performed in order to evaluate the probability of a 
successful transfer for different experimental designs. The probability of success for the 
proposed fixed range total error approach was compared with the independent validation 
criteria. The transfer simulations were performed using Crystal Ball (ver. 7.3.1) software 
developed by Oracle (www.crystalball.com). The software uses Monte Carlo simulations 
to forecast a range of results possible for a given situation. It also shows confidence 
intervals to gauge the probability of a given event taking place. A one-way random effects 
(ANOVA I) model described in the equation below was used to generate data for the 
reference and test laboratories.  
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Figure 34: Normal distributions (± 15% CV) of the difference between the reference and 
test method means (d) around the extremes of the FDA guidance accuracy criterion (± 
15%), the broadness of which is determined by the standard error of the means. The 
acceptable difference (d) between reference and test method is based on the maximum 
allowable error of the mean 
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YijR  =  μ + εBR + εWR     and     YijT  =  μT + εBT + εWT    
where Yij is the jth (j = 1, 2….J) replicate observation from the ith (i = 1, 2,….I) run, μ is 
the true analytical mean,  εB and εW are the errors associated with between- and within-run 
variability. The super-scripts R and T represent the reference and the test laboratories 
respectively. The random errors εB and εW are assumed to be normally and independently 
distributed with means zero, and variances σ2B and σ2W respectively. The total analytical 
variance σ2TOT = σ2B + σ2W. The variance estimates used in the data simulations are shown 
in Table 21. The data were simulated in a manner so that the total analytical variance of the 
reference method would not exceed the FDA criterion of 15% CV. 
The variance of the reference and the test method were assumed to be the same for 
the various simulations performed. Parameters used for data simulation are depicted in 
Table 22. Various combinations of experimental designs were simulated. The number of 
replicates simulated were J = 3 and 6, and the number of runs simulated were I = 3 and 6. 
In each case, 10000 simulations were run. The limits of acceptance based on the proposed 
fixed range approach were set as ± (15% + 15%/√n) where n is the number of samples 
evaluated. Since an actual experiment would involve comparing mean values between the 
results of the two laboratories, a standard error can be expected when performing n 
replicate analyses of the same sample. This acceptance criterion is logically more correct, 
since it provides an estimate of the confidence in the mean value. The quality of the mean 
results would be expected to improve as the number of replicates increases, and 
consequently the acceptance limits would become narrower. For various combinations of 
these simulations, the probability of the test method results falling within acceptance limits  
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Table 21: Estimate of variances for one-way random effects model 
Variance component Estimate 
σ2W 
 
σ2B 
 
σ2TOT σ
2
W  +  σ2B 
 
  
I
∑
i=1
J
∑
j=1
(Yij – Yi)2/ I (J-1)
I
J ∑
i=1
(Yi – Y)2 / (I-1) - σ2W / J
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Table 22: Parameters used for computer simulations 
Variance component Estimate 
Concentration (ng/mL) 0.5, 4, 80 
Within-run %RSD 4, 7, 10 
Variance Ratio (R) = σ2B/ σ
2
W 0.5, 1 
Bias (%) between the averages of reference and test 
laboratories 
14, 15, 16, 18, 20, 22, 25, 30 
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was evaluated. The probability of a successful transfer for the proposed fixed range 
acceptance criterion was then compared with the ±15% difference between the means 
criterion without any allowance for imprecision.   
 
4.4.2. Application of Criteria to Real Data for comparison of Offline and Online 
Sample Extraction Procedure for the analysis of NNAL 
The proposed fixed range acceptance criterion for method comparison was 
evaluated through application to data for the offline and an online sample extraction 
method for the extraction of tobacco specific nitrosamine NNAL in human urine. Initially, 
an offline sample extraction method using molecularly imprinted polymers specific to 
NNAL in SPE format was developed. The sample extraction method was based on offline 
SPE due to commercially available molecularly imprinted polymer cartridges for NNAL in 
SPE format. Subsequently, a capillary microfluidic system developed in our laboratory for 
immunoaffinity separations (Peoples and Karnes, 2008; Peoples et al., 2007; Peoples et al., 
2008) was adapted to extraction of NNAL from human urine using molecularly imprinted 
polymers. This method was developed in an online format in order to improve the assay. 
Both the methods were based on LC-MS/MS detection operated in the positive ESI mode 
suitable for analysis of free and total NNAL as described in Chapter 2 and Chapter 3. 
Some of the other advantages of the online sample extraction method included low sample 
volume, high throughput, reusable microfluidic columns, elimination of the evaporation 
step for sample concentration and low cost per sample. 
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This was a typical example of method transfer in which a validated offline sample 
extraction method for analysis of NNAL is adapted to an online format. Method 
comparison was indicated such that the modified method generates “equivalent” results to 
the reference method. For both the offline and online method, the inter- and intra-assay 
precision and accuracy were calculated from quality control samples at four concentration 
levels (LOQ quality control – 20 pg/mL, low quality control 60 pg/mL, medium quality 
control 400 pg/mL and high quality control 2000 pg/mL) over three validation days. The 
means of the test online method were then compared with the reference offline method. 
The success or failure of the transfer was then evaluated using the proposed fixed range 
decision criteria based on a consideration of standard error of the means. At the same time, 
success or failure of the transfer was also evaluated by the comparison of the means 
approach employing an acceptance limit of ±15 %, without accounting for imprecision and 
the total error approach suggested by Dewé et al., 2007. The β-expectation tolerance 
interval calculations for the total error based approach were performed using the E-Noval 
Software (ver. 3.0) designed by Arlenda Laboratory Solutions (Liege, Belgium).  
 
4.5. Results and Discussion 
4.5.1. Computer Simulations 
Figure 35 to Figure 38 shows the probability of successful transfer for the test 
method based on the two separate decision criteria for simulated results involving various 
experimental scenarios. As seen in these figures and as expected, there is a clear difference 
in the probabilities of a successful transfer for the two criteria. For example, considering 
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Figure 35, if the true relative bias between the means of the two methods is 15%, the ±15% 
criterion without accounting for imprecision demonstrates a probability of rejecting a 
transfer of 50% for all combinations of runs and replicates. Such a large probability of 
rejection for a level of imprecision that is acceptable according to the FDA criterion may 
not be reasonable. Conversely, if the limits of acceptance are established to be ± (15% + 
15%/√n) we can conclude from the simulation that the probability of an unsuccessful 
transfer is less than or equal to 5% for all experimental designs, thereby saving the labor 
and cost of generating unnecessary data.  
If one compares the results represented by Figure 35 and Figure 36, it can be 
observed that for both criteria, when the relative bias is within the acceptance criterion, the 
probability of accepting a transfer is greater with more precise methods. Conversely, when 
the relative bias is outside the acceptance criteria, the probability of rejecting a transfer 
increases with more precise methods. There is a better correlation for the proposed fixed 
range acceptance criteria in this regard as seen by the steeper slopes of the probabilities of 
successful transfer for simulations with a 4% RSD as compared to simulations with a 10% 
RSD.  Thus, as the precision of a method improves, the chance that a correct decision is 
made is better controlled with the ± (15% + 15%/√n) criteria as compared to the ±15% 
criteria. 
Another interesting observation is seen when the true bias between the means of the 
two methods is exactly at the boundary of the FDA acceptance limit for accuracy (±15%) 
(US Food and Drug Administration, 2001). Looking at Figure 35, a node is observed when 
one views the probability of successful transfer for various experimental designs. This 
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indicates that at the boundary of acceptance, the probability of a successful transfer does 
not change even as the experiments become more rigorous. The failure rate of a 3-replicate 
3-run design is about 50% and is the same for a 6-replicate 6-run simulation. Such an 
outcome negates the benefit of rigorous experimental designs in their ability to more 
accurately assess transfers. No such node is observed in the case of the proposed fixed 
criteria. In fact, the acceptance limits changes in this case as the experimental design 
changes. For instance, the probability of accepting a transfer with a 3 run 3 replicate design 
is about 50% at the acceptance boundary of ± 20% [i.e. ± (15% + 15%/√9)]; however, the 
probability of accepting a transfer increases to approximately 75% with a 6 run 6 replicate 
design at the acceptance boundary of 17.5% [i.e. ± (15% + 15%/√36) as observed in Figure 
35.   
Figure 37 shows simulations for a concentration of 0.5 ng/mL with an RSD of 10% 
and a variance ratio R = 0.5. When comparing Figure 36 and Figure 37, the probabilities of 
accepting a comparison are almost constant over a broad range of concentrations using 
both the criteria for the various experimental designs. Figure 38 shows simulations for 0.5 
ng/mL with an RSD of 10% and a variance ratio (R) = 1. When comparing Figure 37 and 
Figure 38, it can be observed that the difference in variance ratio did not affect the 
outcome of accepting a transfer for both criteria. In other words, the probability of 
accepting a comparison is  constant for varying values of R (i.e. σ2B/ σ
2
W ) using both 
criteria for the various experimental designs. 
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Figure 35: Probability of successful transfer as a function of % relative bias between test 
and reference methods for simulated results and various experimental scenarios 
(Concentration = 80 ng/mL; within-run RSD = 4%; R = 0.5). Dotted lines represent the 
±15% criterion without accounting for imprecision. Continuous lines represent the 
proposed ±(15%+15%/√n) criterion. 
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Figure 36: Probability of successful transfer as a function of % relative bias between test 
and reference methods for simulated results and various experimental scenarios 
(Concentration = 80 ng/mL; within-run RSD = 10%; R = 0.5). Dotted lines represent the 
±15% criterion without accounting for imprecision. Continuous lines represent the 
proposed ±(15%+15%/√n) criterion. 
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Figure 37: Probability of successful transfer as a function of % relative bias between test 
and reference methods for simulated results and various experimental scenarios 
(Concentration = 0.5 ng/mL; within-run RSD = 4%; R = 0.5). Dotted lines represent the 
±15% criterion without accounting for imprecision. Continuous lines represent the 
proposed ±(15%+15%/√n) criterion. 
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Figure 38: Probability of successful transfer as a function of % relative bias between test 
and reference methods for simulated results and various experimental scenarios 
(Concentration = 80 ng/mL; within-run RSD = 4%; R = 0.5). Dotted lines represent the 
±15% criterion without accounting for imprecision. Continuous lines represent the 
proposed ±(15%+15%/√n) criterion. 
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Based on the simulations, the simplest experimental design of 3-runs and 3-
replicates provide reasonable results using the proposed fixed range criterion. 
Experimental designs that employ a greater number of runs and/or replicates provide an 
increased probability of success for systematic error differences of 15% or less. It is more 
efficient in terms of throughput, however, to use experimental design with fewer replicates 
and runs in order to detect differences.  Similarly, for systemic errors outside the 
acceptance range, the results can be made more reliable with an increase in the number of 
replicates and runs, resulting in an increased rejection rate.  
Based on a 3-replicates and 3-runs experimental design, a fixed range acceptance 
criterion can be proposed as ±(15% + 15%/√9) = ±20%. Since the criterion is derived 
based on a consideration of one standard deviation, the probability that the true mean 
would be expected to be within the defined range would be 67%.  Each concentration 
would require individual evaluation and must conform to the acceptance criterion for a 
method to be considered equivalent. A 3 run, 3 replicates design would thus result in a 
consistent, reliable and easy to remember rule of thumb which we will refer to as the 
3/3/20 rule based on the number of runs (3), the number of replicates (3) with a maximum 
allowable relative bias of the mean test result of ±20%. Similarly, for a 3 run 6 replicate 
experimental design, the fixed range acceptance criteria can be proposed as ± (15% + 
15%/√18) = ±18.5% (= 18% approximately) of the reference method mean. A 3/6/18 rule 
can be suggested in this case resulting in a more rigorous experimental design and an 
improved ability to detect differences at the expense of requiring a larger number of 
experiments. 
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Although the proposed acceptance criteria controls the risk of α errors more 
efficiently when compared to the ±15% criterion without an allowance for precision, it 
increases the risk of committing a β error. This is evident from the results of simulations 
depicted in Figure 35 to Figure 38. The proposed criterion is a “fixed range criterion” 
however, and a drawback of any fixed criteria is that it is not possible to simultaneously 
control both α and β errors. Individual laboratories might require tighter control of β errors 
and rigorous statistical approaches are acknowledged to be more correct in providing this. 
Fixed criteria are universally used and accepted in regulated environments however, and a 
fixed criterion which better controls β errors can be proposed as follows.  
An alternative approach to limit β error, would be to reduce the accuracy criteria of 
±15% prescribed by the FDA by a factor equal to 15%/√n. In this alternate approach, the 
proposed fixed criterion would then be a maximum allowable acceptance limit of ±15% 
and would still account for imprecision. The proposed acceptance limit would then be a 
sum of the more conservative accuracy criterion of ± (15% - 15%/√n) and the maximum 
allowable standard error of the mean of the test method i.e., 15%/√n. This would result in a 
maximum acceptance limit of ± 15% for method comparison that would depend on the 
experimental design. Figure 39 and Figure 40 show representative simulation results for 
the modified criterion. The parameters simulated were similar to those previously 
described. The systematic bias simulated was in the range of 9% to 30%. It can be 
observed from these results that the probabilities have been reversed when compared with 
the earlier described ±(15% + 15%/√n) criterion. For example, when the proposed criterion 
was fixed at ±(15% + 15%/√n), the risk of making a false negative error for a 6 run 6 
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replicate design at the acceptance boundary of 17.5% was approximately 70%. This is 
evident from Figure 35. This risk of committing a false negative error at the boundary of 
acceptance, however, reduces to about 50% for the same experimental design when the 
acceptance criterion is fixed at ±15% as seen in Figure 39. Figure 39 shows simulation 
results for a RSD of 4%, while Figure 40 shows simulation results for a RSD of 10%. 
Comparing the simulation results of Figure 39 and Figure 40, it can be observed that more 
precise methods have better control over falsely rejecting truly comparable methods as 
well as falsely accepting truly non-equivalent methods. Simulation outcomes based solely 
on the accuracy criterion (shown by dotted lines in Figure 39 and Figure 40) would result 
in a greater incidence of rejecting truly comparable methods. Thus, a trade-off exists 
between the type of error that needs a more stringent control, and the proposed acceptance 
criteria present a good compromise. Based on the simulation results, an experimental 
design of 6 runs and 6 replicates provides greater control over the β-error when compared 
to an experimental design with lesser number of runs or replicates. Based on a 6-replicates 
and 6-runs experimental design, a fixed range acceptance criterion can be proposed as 
±(15% - 15%/√36 + 15%/√36) = ±15%. A 6/6/15 rule can be suggested in this case. 
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Figure 39: Probability of successful transfer using a more conservative accuracy criterion 
as a function of % relative bias between test and reference methods for simulated results 
and various experimental scenarios. (Concentration = 80 ng/mL; within-run RSD = 4%; R 
= 0.5). Dotted lines represent the ±15% criterion without accounting for imprecision. 
Continuous lines represent the proposed ±(15%+15%/√n) criterion. 
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Figure 40: Probability of successful transfer using a more conservative accuracy criterion 
as a function of % relative bias between test and reference methods for simulated results 
and various experimental scenarios. (Concentration = 80 ng/mL; within-run RSD = 10%; R 
= 0.5). Dotted lines represent the ±15% criterion without accounting for imprecision. 
Continuous lines represent the proposed ±(15%+15%/√n) criterion. 
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4.5.2. Application of Criteria to Real Data for comparison of Offline and Online 
Sample Extraction Procedure for the analysis of NNAL 
Table 23 represents a summary of the results obtained for the offline and the online 
sample extraction methods for the analysis of NNAL. Precision (measured as the percent 
relative standard deviation based on the pooled variance, %RSD) and accuracy (measured 
as the percent difference from nominal, %DFN) were calculated from quality control 
samples at four quality control concentrations over three validation days. The overall inter 
and intra-assay precision was ≤  7.8% and 7.2% respectively for the offline mode. The 
inter- and intra-assay accuracy for the offline method was ≤ 1.3% and 5.2% respectively. 
Similarly, in the case of the online sample extraction method, the overall inter and intra-
assay precision was ≤  11.7% and 11.3% respectively, while the inter- and intra-assay 
accuracy was ≤ 9.3% and 14.8%, respectively. Comparing the difference between the 
means of the two methods (Table 23), the method transfer is successful according to the 
±15% criteria as shown in the table. 
Table 23 also represents the transfer outcome using the proposed fixed range 
acceptance criteria based on standard error of the mean. The acceptance criteria in this case 
as discussed earlier was fixed at ±20% of the reference method mean when 3 independent 
runs with 3 replicates were used. As we can observe from the outcome of the results, using 
the proposed criteria, the transfer is successful in this case also.  
 Table 24 represents the transfer outcome using the total error based tolerance 
interval approach suggested by Dewé et al., 2007 (see appendix for software output used in 
the generation of results). The tolerance value λ was set as 15% keeping in mind the FDA 
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regulations (US Food and Drug Administration, 2001). A 95% confidence interval was 
calculated around the reference method mean, results of which are depicted in Table 24. 
The upper and lower limits of this confidence interval were multiplied by (1-λ) and (1+λ) 
respectively, in order to set the acceptance interval. A tolerance interval for the test method 
was then calculated. The maximum risk tolerated 1−β was fixed at 20%. The lower and 
upper limits of this tolerance interval are shown in Table 24. It is observed that the 
tolerance interval is included in the acceptance limits and the effective risk is smaller than 
the maximum tolerated risk (1−β). In other words, it can be said with 95% confidence that 
at least 80% of the future results of NNAL obtained with the test method will be within 
15% of the reference method mean. This implies that the total error based total error 
approach resulted in a successful transfer of the method under the specified conditions. 
Although the transfers were successful using all the three approaches, these 
examples do not imply that the three approaches are equivalent. They only imply that all 
the three approaches result in judging the example comparison to be successful in this case. 
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Table 23: Summary of results obtained for the offline method and the online method for analysis of NNAL. The transfer 
outcomes are shown for (i) ±15% difference between the means acceptance criteria without accounting for precision and (ii) 
±(15% + 15%/√n) total error based fixed acceptance criteria. The results are based on an outcome for 3 runs and 3 replicates 
 Offline Method 
(Reference Method) 
Online Method 
(Test Method) 
% Difference between 
Means 
Transfer Outcome 
             ±15% criteria 
without 
accounting for 
precision 
±20% fixed 
range 
criteria 
Spiked 
QC conc. 
(pg/mL) 
20 60 400 2000 20 60 400 2000 20 60 400 2000   
               
Mean  20.26 60.18 395.76 2018.79 19.63 54.94 381.78 1813.33 3.07 8.70 3.53 10.18 Successful Successful 
SD 1.58 3.17 20.08 107.88 1.67 2.33 44.79 36.74       
%RSD 7.80 5.26 5.07 5.34 8.51 4.25 11.73 2.03       
%DFN 1.28 0.30 -1.06 0.94 -1.83 -8.43 -4.56 -9.33       
 
SD – Standard deviation 
RSD – Relative standard deviation based on pooled variance 
DFN – Deviation from nominal 
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Table 24: Summary of results obtained for the offline method and the online method for analysis of NNAL. The transfer 
outcomes are shown for the total error based tolerance interval approach. The results are based on an outcome for 3 runs and 
3 replicates (See appendix for software output used in the generation of results). 
 
Offline Method (Reference Method) 
Conc. 
(pg/mL) 
Lower limit 
95% CI* 
Upper limit 
95% CI* 
Lower Acceptance Limit 
= (Lower limit 95% CI)*(1-λ) 
Upper Acceptance Limit 
= (Upper limit 95% CI)*(1+λ) 
  
       20 17.38 20.06 14.77 23.07 
  60 56.23 61.50 47.80 70.73 
  400 379.64 410.80 322.69 472.42 
  2000 1939.02 2106.01 1648.15 2421.90 
  
       
       
 
Online Method (Test Method) 
   
Lower limit β tolerance interval Upper limit β tolerance interval 
 
Transfer 
Outcome 
       20 
  
16.59 22.23 
 
Successful 
60 
  
51.18 59.79 
 
Successful 
400 
  
349.30 447.90 
 
Successful 
2000 
  
1662.01 1885.00 
 
Successful 
       *CI – Confidence Interval 
(1-β) = 20% 
λ=15% 
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4.6. Conclusion 
Several approaches have been suggested in the literature to address the issue of 
analytical method transfer and method comparisons. The statistically rigorous total error 
approach proposed by Dewé et al., 2007 is perhaps the most robust and scientifically 
correct. However, this may require adequate knowledge of statistics as well and an 
evaluation of the variability of the methods being tested. A ±15% difference between the 
means criteria, without allowance for precision, does not provide a reasonable approach to 
address the risk of false conclusions regarding method comparisons. A user-friendly 
“fixed” range acceptance criteria has been proposed based on a consideration of method 
accuracy and precision. This approach combines a consideration of the maximum 
allowable FDA bioanalytical guidance limits on precision and accuracy and the ease of 
application of a fixed range approach.  Various experimental designs were evaluated and 
although there are many options, an experiment with 3 runs with 3 replicates each at 3 
concentrations with an acceptance range of ±20% is proposed. This general approach could 
be applied to individual dosed subject samples or prepared controls. A 3/3/20 criterion for 
method comparisons turns out to be reasonable in terms of its ease of use, the number of 
required experiments and the control of false positive results.  In instances where a greater 
control over false negative results is required, a reduced accuracy based fixed criterion has 
been suggested. The proposed fixed range approach could also be extended to other 
validation situations in which data comparisons are involved.  For example, in the case of 
incurred sample reanalysis, an experimental design could be anticipated that would involve 
comparing observations with n=1 for each comparison. An acceptance criterion consistent 
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with this approach and the established guidance would then be ± (15% + 15%/√1) or 
±30%.   
 The off-line and the on-line sample extraction methods for NNAL analysis 
discussed in chapters 2 and 3 respectively were deemed comparable using the proposed 
fixed range acceptance criteria.  
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CHAPTER 5 Overall Summary 
 
 
Tobacco products have been estimated to cause approximately 30% of deaths in 
developed countries (American Cancer Society, 2009). Cancers of the  lung, larynx, oral 
cavity, esophagus, pancreas, kidney, liver, bladder, stomach and colon are all associated 
with tobacco use (Hecht, 2003). Several types of tobacco carcinogen related biomarkers 
have been studied extensively. Although measurement of DNA and protein adducts may 
provide a direct link to cancer risk, there have been significant analytical challenges in the 
measurement of these compounds (Poirier et al., 2000).   
Urinary metabolites are probably the most practical biomarkers for cancer risk and 
provide important information about carcinogen dose and metabolism (Hecht, 2002; 
Hecht, 2003). Tobacco specific nitrosamines (TSNA) are a prominent class of carcinogens 
found only in tobacco products that play an important role in cancer induction (Hecht, 
1999). Of the several TSNAs that have been identified in tobacco products, NNK is one of 
only two carcinogens considered to be carcinogenic to humans. It is a systemic lung 
carcinogen (International Agency for Research on Cancer, 2007). 
The three main routes of NNK metabolism in humans include carbonyl reduction, 
pyridine oxidation and α-hydroxylation (Hecht, 2002). NNK undergoes extensive carbonyl 
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reduction to form NNAL, which is also a potent lung carcinogen having similar 
carcinogenicity and a similar metabolic pathway to NNK. One feature of NNAL 
metabolism is the formation of NNAL-Gluc, which is an important detoxification pathway 
for NNK and NNAL (Chen et al., 2008b). Both NNAL and its glucuronides are excreted in 
human urine, although unchanged NNK has not been detected in human urine. The half-
lives of NNAL and NNAL-Gluc are long as compared to other urinary metabolites making 
them ideal candidates as biomarkers (Stepanov et al., 2008). The pyridine-N-oxidation 
pathway results in the formation of NNK-N-oxide and NNAL-N-oxide (Hecht et al., 
1993b). This is, however, a minor metabolic pathway for NNK. Metabolic activation of 
NNK and NNAL to DNA adducts proceeds via the α-hydroxylation pathways. The end 
products of this pathway are keto acid and hydroxy acid. Both of these compounds can be 
measured in human urine. However, these cannot be used to measure the extent of α-
hydroxylation because they are formed from nicotine as well (Hecht, 2002). This renders 
measurement of the end-products of the α-hydroxylation pathways non-specific as markers 
and suggests that measurement of urinary NNAL and its glucuronide conjugate may 
provide the best biomarker of tobacco smoke lung carcinogen metabolism.  
In chapter 1 of the thesis, a listing of the literature compiling the issues and 
developments in the analysis of tobacco specific nitrosamines in human biological matrices 
is provided. The two most commonly used approaches for TSNA analysis in biological 
matrices are based on GC-thermal energy analysis (TEA) and LC-ESI-MS/MS. The 
advantages as well as the limitations for both approaches have been discussed. The 
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nitrosamine selective GC-TEA technique had been the method of choice for bioanalysis of 
TSNAs until the early 2000’s. However, due to the extensive and complex sample 
preparation steps for GC-TEA methods, recently there has been a shift to development of 
methods for TSNA bioanalysis using the more widely available LC-MS/MS technique. 
LC-MS/MS based methods are also more amenable to thorough validation. Addressing ion 
suppression matrix effects remains an important challenge for hyphenated mass 
spectrometry based methods, however. 
Recently, molecularly imprinted polymers have been developed with applications 
in the area of bioanalysis to provide high selectivity and molecular recognition ability 
(Haginaka, 2009). The application of these synthetic polymers as sorbents allows pre-
concentration and selective as well as selective extraction of target analytes. Xia et al., 
2005 had published a method for the off-line analysis of NNAL in human urine by 
extraction on a molecularly imprinted polymeric (MIP) cartridge  followed by LC-MS/MS 
analysis. Chapter 2 of this thesis investigated the presence of matrix effects and related 
problems with sensitivity for modification of the method by Xia et al., 2005. Issues related 
to throughput were also addressed and improved in the modified method. In this method, 
urinary NNAL was analyzed based on an “off-line” sample extraction using MIPs 
combined with LC/MS-MS. The method was validated and the validation data 
demonstrated excellent precision, accuracy and stability complying with the FDA 
bioanalytical method validation guidance. This method was used for quantitative analysis 
of free and total urinary NNAL concentrations in incurred samples obtained from smokers. 
   
 205 
With the goal of further addressing throughput and efficiency, chapter 3 of this 
dissertation involved development of a high-throughput “on-line microfluidic” sample 
extraction method using capillary micro-columns packed with MIP beads hyphenated with 
tandem MS for the analysis of urinary NNAL. The method was optimized and matrix 
effects were evaluated and resolved. The method enabled low volume, rapid analysis of 
urinary NNAL by direct injection on the microfluidic column packed with molecularly 
imprinted beads specific to NNAL. The method was validated as per the FDA 
bioanalytical method validation guidance. It was used for the analysis of NNAL and 
NNAL-Gluc concentrations in smokers’ urine. The ratio of NNAL-Gluc to NNAL was 
used to investigate the extent of NNAL metabolism. Chemometric methods were examined 
to develop a potential cancer risk assessment tool based on pattern recognition in the 
measured concentrations of these compounds.  
In chapter 4 of this dissertation, method comparison approaches for the on-line and 
the off-line sample extraction techniques were investigated for generating comparable 
results. Currently there is no clear consensus on the most appropriate acceptance criteria or 
study design for transfer or comparison of bioanalytical methods. In this part of the 
dissertation, a ‘fixed’ range acceptance criterion based on a combined consideration of 
method precision and accuracy, and the FDA bioanalytical guidance limits on precision 
and accuracy was proposed. Considering the FDA guidance on precision and accuracy, 
fixed acceptance limits for bioanalytical method transfer based on the FDA guidance 
acceptance limit maxima were set as ±(15% + 15%/√n). Data simulations to evaluate the 
probabilities of a successful transfer using the proposed criterion were performed. 
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Alternate fixed range criterion providing better control over false negative errors (β-error) 
was also proposed. The advantages and disadvantages of the proposed fixed range criteria 
have also been discussed. 
In conclusion, the high-throughput, sensitive, selective and reliable methods 
developed in the current work for the measurement of free and total urinary NNAL will 
provide improved tools and approaches that will continue to provide understanding of the 
mechanisms by which tobacco carcinogens cause cancer and may enable the prediction of 
cancer risk. This ultimately would lead to advances and improvements in chemoprevention 
strategies. 
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Commands Used in MATLAB: 
 
 
[n,p]=size(TSNA); 
meanx=mean(TSNA); 
stdevx=std(TSNA); 
xas=(TSNA-ones(n,1)*meanx)./(ones(n,1)*stdevx); 
covariance_matrix = cov(TSNA) 
correlation_matrix = corrcoef(TSNA) 
[u, s, v] = svd(covariance_matrix,0) 
eigen_val_covariance_matrix = s*s 
[u1, s1, v1] = svd(xas,0) 
plot(u1(:,1)*s1(1,1),u1(:,2)*s1(2,2),'.') 
for m=1:n;text((u1(m,1)*s1(1,1)),(u1(m,2)*s1(2,2)),num2str(m));end; 
title('SVD-mode Scores Plot'); 
xlabel('PC #1'); 
ylabel('PC #2'); 
plot(v1(:,1),v1(:,2),'*m') 
for m=1:p;text(v1(m,1),v1(m,2),num2str(m));end; 
title('SVD-mode Loadings Plot'); 
xlabel('PC #1'); 
ylabel('PC #2'); 
 
 
X = xas; 
Y = pdist(X); 
Z = linkage(Y); 
dendrogram(Z); 
dendrogram(Z,43); 
set(H,'LineWidth',2); 
ylabel('Distance between Objects'); 
xlabel('Objects (Smokers)'); 
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Product Data Sheet for Urine Samples: 
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Software output [E-Noval (ver. 3.0)] used in the generation of results for the total error 
approach for method comparison: 
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